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Abstract 
 
Obesity and insulin resistance are associated with a constellation of features 
including hypertension, dyslipidaemia, type 2 diabetes, and premature cardiovascular 
disease, collectively termed the metabolic syndrome. Non-alcoholic fatty liver 
disease (NAFLD) represents the hepatic component of this syndrome, incorporating 
a spectrum of liver disease with increasing morbidity and mortality, from simple 
steatosis, to non-alcoholic steatohepatitis (or NASH), fibrosis, cirrhosis and 
ultimately hepatocellular carcinoma. However, factors influencing this progression 
are incompletely understood.  
 
In this thesis I sought to investigate pathways which promote hepatic inflammation 
and fibrosis by studying two contrasting dietary models of NAFLD in mice in which 
the risk of hepatic inflammation, insulin resistance and fibrosis differ; namely the 
methionine and choline deficient diet (MCDD) which induces steatohepatitis, hepatic 
insulin resistance, and weight loss, and the choline deficient diet (CDD) which may 
be protected from insulin resistance, and leads to steatosis without inflammation or 
weight loss. I investigated the possible molecular mechanisms underlying these 
differences, and whether they influenced progression to hepatic fibrosis induced by 
carbon tetrachloride (CCl4).  
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1 Chapter 1-Introduction 
 
1.1 NON-ALCOHOLIC FATTY LIVER DISEASE 
 
This thesis concerns the mechanisms underpinning non-alcoholic fatty liver disease 
(NAFLD) and its progression to non-alcohoic steatohepatitis (NASH). In this chapter, 
I will provide a summary of the clinical problems encompassed by NAFLD, 
followed by a detailed discussion of what is currently known about underlying 
mechanisms. Much of this has been learned from animal models, and these are 
reviewed, with a particular focus on the dietary models used in this thesis involving 
methionine and/or choline deficiency. One of the potentially modifiable mechanisms 
influencing liver fat accumulation and subsequent injury involves glucocorticoid 
signaling. The chapter therefore also includes a review of glucocorticoid biology and 
its influence on features of NAFLD. 
 
1.1.1 NAFLD: Background and terminology 
 
The association of obesity with intrahepatic triglyceride accumulation and 
inflammation has been known since the 1950s (Zelman 1952). However, it was not 
until several cases of liver failure were reported following intestinal (jejuno-ileal) 
bypass surgery for morbid obesity that interest in the condition began to develop 
(Peters et al. 1975), with the term non-alcoholic steatohepatitis or NASH being 
introduced by Ludwig in 1980 (Ludwig et al. 1980). The broader term non-alcoholic 
fatty liver disease (NAFLD or fatty liver) has subsequently been adopted to 
incorporate a wider spectrum of fatty liver disease, and is often used when 
histological information is unavailable. NAFLD is classically associated with 
features of the so-called metabolic syndrome, but other secondary causes of fatty 
liver disease, including alcohol, should be excluded (see Table 1.1) (Adams et al. 
2005). 
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No longer considered a benign condition, NAFLD represents a spectrum of disease 
with the potential to progress from uncomplicated intracellular triglyceride (TG) 
accumulation or simple steatosis (with or without elevated aminotransferases), to 
steatohepatitis, liver fibrosis, cirrhosis and ultimately hepatocellular carcinoma, with 
associated increases in morbidity and mortality (Matteoni et al. 1999). 
 
Table 1.1 Secondary causes of intrahepatic triglyceride accumulation 
Cause Examples 
Drugs Tamoxifen, amiodarone 
Rapid weight loss Following ileo-jejunal bypass 
Pregnancy  
Cushing’s syndrome  
Burns patients  
Rare syndromes Lipodystrophies, abetalipoproteinaemia 
 
1.1.2 NAFLD and the metabolic syndrome 
 
Insulin resistance is characterised by reduced peripheral (predominantly muscle) 
glucose uptake in response to insulin, and/or increased hepatic glucose output 
secondary to reduced hepatic insulin sensitivity, although effects on other metabolic 
pathways such as fatty acid and triglyceride metabolism may also be a feature. 
Insulin resistance is associated with a constellation of features including obesity 
(especially visceral obesity), hypertension, dyslipidaemia, abnormal glucose 
metabolism, and low birth weight, known as the metabolic syndrome and increases 
the risk of cardiovascular disease (Marchesini et al. 2001). NAFLD is now widely 
regarded as the hepatic component of the metabolic syndrome (Marchesini et al. 
2001). Hepatic triglyceride accumulation correlates with measures of peripheral 
(Marchesini et al. 1999), adipose and hepatic insulin resistance (Seppala-Lindroos et 
al. 2002). However, it is not clear whether insulin resistance is a contributing factor 
or a consequence of fatty liver and the mechanisms will be discussed later in this 
chapter. 
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1.1.3 Epidemiology 
 
In parallel with the epidemic of obesity and type 2 diabetes the prevalence and 
awareness of NAFLD are increasing, so much so that it is now a major public health 
concern. NAFLD is now the commonest reason for referral to a liver clinic for 
investigation of deranged liver function tests, and is thought to underlie the majority 
of cases of cryptogenic cirrhosis resulting in end stage liver failure (Clark et al. 2003). 
Indeed, fatty liver may recur in these patients following transplant (Ong et al. 2001).  
 
The true prevalence of NAFLD is difficult to determine as patients are often 
asymptomatic and liver function tests are often normal (Adams et al. 2005). 
Estimates therefore depend on a number of factors e.g. the population studied, the 
screening investigation, and diagnostic criteria used. In an urban population in the 
United States 33.6% of individuals were found to have elevated liver fat using 
magnetic resonance proton spectroscopy, the most sensitive screening investigation, 
performed in over two thousand participants in the Dallas Heart Study (Browning et 
al. 2004). In this study certain ethnic subgroups (Hispanics in particular) had a higher 
risk of NAFLD, whereas African Americans were relatively protected. Increased 
liver fat was also more common in males than females. Other estimates suggest up to 
75% of patients with type 2 diabetes and almost 100% of patients with both type 2 
diabetes and morbid obesity have fatty liver (Luyckx et al. 1998;Tolman et al. 2007). 
 
1.1.4 Histological Classification 
 
The liver acinus incorporates a functional zonation, with each zone differing in 
susceptibility to toxic and ischaemic damage, as well as fat accumulation (Brunt et al. 
1999). 
 
Zone 1: closest to the portal tracts is the first to receive toxic insult 
Zone 2: intermediate region between zones 1 and 3 
Zone 3: adjacent to the central venule, most prone to ischaemia (centrilobular 
necrosis) and fat accumulation 
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NAFLD is characterised histologically by macrovesicular steatosis, with intracellular 
lipid accumulation displacing the hepatocyte nucleus to the periphery of the cell, 
causing a “chicken wire” appearance. Classically, this begins in zone 3, before 
overflowing to the rest of the acinus, with greater than 5% steatosis by weight 
required to confirm the diagnosis (Adams et al. 2005). In contrast to imaging studies, 
only a liver biopsy can provide information on the presence of inflammation or the 
stage of fibrosis, which may alter patient monitoring and surveillance. Biopsy also 
excludes other causes of liver disease when the diagnosis is uncertain. 
 
Additional histological features in NAFLD may include Mallory bodies (eosinophilic 
intracellular inclusions composed mainly of ubiquinated keratin), ballooning 
degeneration of hepatocytes (possibly indicating necrotic cell death), and 
perisinusoidal fibrosis, although these changes can regress if cirrhosis ensues 
(Matteoni et al. 1999). Hence the diagnosis can be obscured in those with very 
advanced disease and a liver biopsy is required to differentiate between simple 
steatosis and more advanced NAFLD. Other findings include lipogranulomas 
composed of chronic inflammatory cells and Kupffer cells. 
 
Lobular inflammation, consisting of polymorponuclear leucocytes and monocytes, is 
usually mild and localised to the sinusoids in steatosis. NAFLD activity scoring 
systems have been introduced to classify the severity of NASH which is usually 
associated with necrosis and more widespread inflammation (Kleiner et al. 2005). 
Histological scoring systems also measure the extent of associated fibrosis (Kleiner 
et al. 2005). Perisinusoidal fibrosis usually begins in zone 3, although can progress to 
periportal fibrosis and bridging fibrosis may ensue. Differing patterns of fibrosis 
(periportal) have also been described in overweight NASH patients suggesting a 
different pathogenesis (Ratziu et al. 2000). A number of classification systems 
grading the degree of steatosis and necroinflammation, as well as the stage of fibrosis 
have been proposed (Brunt et al. 1999;Kleiner et al. 2005).  
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1.1.5 NAFLD and liver fibrosis 
 
Liver fibrosis, and its end stage cirrhosis, can be considered a chronic healing 
response to repeated liver injury. Worldwide, hepatitis B and C, and alcohol 
predominate as causes of liver injury (Bataller and Brenner 2005), but liver fibrosis 
secondary to NAFLD is increasingly recognised, and causative factors may co-exist 
e.g. fatty liver exacerbates hepatitis C induced liver injury (Vidali et al. 2008). 
Fibrotic liver disease is a major burden on health care systems globally. It is 
estimated that 1% of the population may have cirrhosis (Schuppan and Afdhal 2008), 
although the prevalence of lesser degrees of fibrosis will be greater. Given the 
increasing prevalence of obesity and type 2 diabetes, it is likely that we will see an 
increasing burden of liver disease secondary to NAFLD.   
 
Liver fibrosis is characterised by scarring, as normal liver tissue is replaced with the 
deposition of extracellular matrix (ECM) rich in fibrillar collagens (predominantly 
type 1 and type 3) (Schuppan et al. 2001). This disrupts the normal liver architecture, 
with loss of sinusoidal fenestrations, as the space of Disse becomes filled with scar 
tissue preventing sinusoidal functioning. Fibrosis may progress to classical nodular 
cirrhosis, with islands of hepatocytes surrounded by collagenous fibrous septae, 
ultimately producing liver dysfunction associated with portal hypertension, liver 
failure, and increased risk of hepatic carcinoma (Schuppan and Afdhal 2008).  
 
Cirrhosis is classically described as a diffuse, irreversible process, for which no cure 
exists except liver transplant. However, there is increasing evidence of histological 
improvement if the underlying fibrogenic factor is eliminated e.g. with antiviral 
drugs in cases of viral hepatitis, and removal of the toxic insult in animal models 
(Dienstag et al. 2003;Iredale 2007). Given this potential for improvement, it is 
essential we increase our understanding of the pathogenesis of liver fibrosis, 
including in NAFLD, to develop effective and targeted treatments.  
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1.1.6 Natural History of NAFLD 
 
Due to the invasive nature of liver biopsy, and the likely high proportion of the 
population with uncomplicated steatosis, only limited information is available on the 
natural history of NAFLD. Nevertheless, it is now accepted that individuals can 
progress from simple steatosis, to steatohepatitis, steatohepatitis with fibrosis and 
cirrhosis (Sanyal 2002). The progression from steatosis to steatohepatitis is thought 
to be rare, with one small study of 40 patients finding no progression over a 10 year 
period, although one patient did develop fibrosis (Teli et al. 1995). However, reports 
of patients with steatosis progressing to steatohepatitis do exist, especially following 
gastric bypass surgery (Luyckx et al. 1998), and more recent estimates suggest 
somewhere between 12-40% of patients with steatosis will progress to NASH with 
early fibrosis over an 8-13 year interval (de Alwis and Day 2008).  
 
Progression to liver fibrosis is more likely once NASH has developed. In one 
prospective study of 26 patients with biopsy proven NASH, followed for up to nine 
years, 27% progressed to fibrosis and 19% to cirrhosis, with the remainder not 
demonstrating progressive histology (Younossi et al. 2002). Other series have shown 
that up to 50% of NASH patients develop progressive fibrosis (Hui et al. 2005), 
although the interpretation of these results is limited due to study design including a 
selected patient population, with limited follow up. Once cirrhosis has developed 
there is a 10 year risk of liver related mortality of 30-40% (Edmison and 
McCullough 2007), and a 7% risk of hepatocellular carcinoma (de Alwis and Day 
2008).  
 
 - 25 - 
1.2 FATTY ACID AND TRIGLYCERIDE METABOLISM 
 
Abnormalities of free (or non-esterified) fatty acid (FFA) and triglyceride (TG) 
metabolism are likely to influence the pathogenesis of NAFLD. I will therefore 
provide an overview of FFA and TG metabolism and their hormonal regulation, 
followed by a discussion on how alterations in their metabolism could contribute to 
the pathogenesis of NAFLD and insulin resistance. 
 
Along with glucose, FFAs are a major source of fuel for oxidative metabolism 
(Coppack et al. 1994). FFA trafficking and metabolism is summarised in Figure 1.1. 
FFAs are insoluble in plasma and therefore require to be either complexed to 
albumin or esterified with glycerol to form TGs for packaging in lipoprotein particles 
before transport in the circulation (Spector 1975). The majority of fatty acids in 
humans are derived from dietary sources and stored as TGs in adipose tissue, or in 
small amounts in liver and muscle. De novo lipogenesis (DNL) is an additional 
source of FFAs (Hellerstein 1999). Circulating chylomicron and very low density 
lipoprotein (VLDL) TGs, delivered from the gut and liver respectively, are 
hydrolysed by lipoprotein lipase (LPL) located on the luminal surface of the capillary 
endothelium (Linder et al. 1976). This allows FFAs to be taken up into cells, either 
by a passive or facilitated process (Garfinkel et al. 1976;Kalant and Cianflone 2004), 
and then re-esterified to TGs within tissues. However, FFAs released from 
circulating TGs can also spillover into the plasma FFA pool without prior 
transportation into tissues (Coppack et al. 1992), and recent data suggests that direct 
uptake of circulating FFAs from plasma may also occur (Kratky et al. 2005).  
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Figure 1.1 Summary of free or non-esterifed fatty acid (FFA) metabolism and 
sources of intra-hepatic fatty acids and triglycerides (TG)  
Overview of fatty acid and triglyceride metabolism. FFAs reach the liver from a number of 
sources including hydrolysis of circulating TGs, or adipose stores. Within the liver de novo 
lipogenesis is another source of fatty acids. TG is exported from the liver in the form of 
VLDL which transports TG to tissues. FFAs are an important fuel for oxidative metabolism 
e.g. in muscles. DNL; de novo lipogenesis, LPL; lipoprotein lipase, VLDL; very low density 


























TGs form an efficient energy store, containing more than twice as many calories as 
glycogen or protein per gram, with less water content (Hillgartner et al. 1995), and 
are hydrolysed to release FFAs and glycerol (plus di- and mono-acylglyceride 
intermediates), a process known as lipolysis. Complete lipolysis of TGs yields three 
FFAs and one glycerol molecule. There are two fates for FFAs mobilised from stored 
TGs: one is β-oxidation within the mitochondria to generate ATP, and the second is 
re-esterification to TGs. As FFA release generally exceeds their oxidation, re-
esterification to TGs is a key factor regulating local FFA levels, e.g. in the liver, 
where FFAs can be incorporated into VLDL TG or the TG storage pool (Coppack et 
al. 1994).  
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Until recently, hormone sensitive lipase (HSL) was believed to be the main enzyme 
responsible for adipose tissue lipolysis (Miyoshi et al. 1988). However, it is now 
apparent that HSL acts to hydrolyse diacylglycerides released following prior 
hydrolysis of the first TG ester bond by adipose triacylglyceride lipase (ATGL) 
(Zimmermann et al. 2004). Single nucleotide polymorphisms in the gene encoding 
ATGL are associated with increased risk of type 2 diabetes, providing support for a 
role of abnormalities of lipolysis in the pathogenesis of insulin resistance 
(Schoenborn et al. 2006). 
 
1.2.1 Acute regulation of fatty acid metabolism 
 
Given their central role in the crucial process of cellular energy provision, it is not 
surprising that fatty acid metabolism is tightly regulated. The processes controlling 
the switch between predominant lipolysis/fatty acid oxidation during fasting and 
predominant lipid storage/glucose oxidation following feeding are determined 
principally by insulin and catecholamines, as follows.  
 
1.2.1.1 Adipose and intravascular lipolysis 
Lipolysis is closely regulated in a reciprocal, tissue specific manner such that 
following a meal, when glucose and chylomicrons are in abundant supply, adipose 
tissue LPL is upregulated, whereas its activity in muscle is suppressed (Fielding and 
Frayn 1998). Insulin is the major hormone encouraging lipolysis of circulating TG 
rich lipoproteins, whilst also suppressing release of FFAs from adipose tissue 
(Coppack et al. 1994) and promoting re-esterification of FFAs within adipocytes 
(Campbell et al. 1992). In contrast, during the post-absorptive period, when insulin 
levels are low, circulating adrenaline and locally produced nor-adrenaline are the 
main stimulators of adipose tissue lipolysis (Coppack et al. 1994). 
 
Additional paracrine, autocrine and hormonal factors may be important in regulating 
lipolysis but their significance in vivo is less clear. In vitro studies suggest that the 
regulation of LPL expression and activity is complex (reviewed in (Mead et al. 
2002)), and occurs in part by post-translational modification (Ong and Kern 1989). 
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Furthermore, local conditions including blood flow may influence the efficiency of 
lipoprotein metabolism by LPL (Coppack et al. 1994), and hence the degree of 
spillover of FFAs into the circulation (Samra et al. 1996b). 
 
1.2.1.2 De novo lipogenesis  
Acetyl CoA derived from glycolysis, via pyruvate, can be utilised to synthesise FFAs 
under the regulation of insulin dependent SREBP1c and glucose responsive ChREBP 
transcription factors (Postic and Girard 2008). Acetyl CoA carboxylase and fatty acid 
synthase are two key enzymes catalysing DNL, and require an ample supply of 
substrates including acetyl CoA, NADPH and ATP to allow the synthesis of FFAs 
(Berdanier 1989). Both liver and adipose tissue are capable of synthesising fatty 
acids de novo. However, although the biosynthetic pathways of DNL are well 
characterised, and rodent studies suggest that a large number of regulatory dietary 
and hormonal factors may be important (reviewed by (Hillgartner et al. 1995)), the 
physiological significance of factors influencing DNL in humans is less clear. Indeed, 
except during embryogenesis and lactation, the importance of DNL as a source of 
lipids is a matter of debate (Hellerstein 1999). Broadly speaking, however, insulin 
promotes DNL, whereas adrenaline, glucagon and FFAs themselves inhibit DNL 
(Hillgartner et al. 1995).  
 
1.2.1.3 Mitochondrial β-oxidation 
Mitochondrial β-oxidation is essentially the reverse process of lipogenesis, producing 
acetyl CoA and ATP from the oxidation of FFAs. However, whereas lipogenesis is a 
cytosolic process, FFAs first require to be converted to acyl CoA intermediates for 
transfer into mitochondria for oxidation (McGarry and Brown 1997). Carnitine 
palmitoyl transferase 1 (CPT 1) undertakes this transport process, and is the initial 
rate limiting step in FFA oxidation. Its activity is tightly regulated such that malonyl 
CoA, the principle intermediate in DNL, inhibits CPT 1 (Zammit 1999). Therefore, 
factors influencing lipogenesis also influence mitochondrial oxidation, with insulin 
inhibiting and adrenaline stimulating oxidation of FFAs; these factors also influence 
substrate availability for oxidation (Blaak et al. 1994;Sidossis et al. 1996).  
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1.2.1.4 Hepatic VLDL metabolism 
The liver acts as an important buffer for FFAs, temporarily storing them in the 
cytosolic TG pool prior to transport/cycling back to adipose tissue stores by VLDL 
(Gibbons et al. 2004). Hepatic VLDL assembly and secretion is a complex and 
incompletely understood process intimately associated with apolipoprotein B 
metabolism (Olofsson and Boren 2005). In simplistic terms insulin acts to inhibit 
VLDL assembly and secretion directly, whilst  also reducing glucose and portal FFA 
flux which normally promote VLDL export post prandially (Gibbons et al. 2002).  
 
1.2.2 Long-term regulation of fatty acid metabolism 
 
The physiological control of energy metabolism requires us to achieve not only 
appropriate responses to acute feeding and fasting, but also appropriate longer term 
adaptations to the nutritional environment. Longer term regulators of fatty acid 
metabolism are less well understood than the acute adaptations which accompany the 
normal daily cycle of fasting and feeding. Growth hormone (GH), although not as 
potent and rapidly acting as adrenaline, may be important during exercise and fasting, 
increasing adipose lipolysis over a period of 2-3 hours (Moller et al. 1990). 
Accordingly, chronic GH deficiency is associated with accumulation of TG in 
adipose tissue (Rosen et al. 1993). More recently there has been interest in 
macrophage derived cytokines e.g. interleukin-6 (IL-6), and tumour necrosis factor α 
(TNFα) modulating adipose tissue lipolysis, although their physiological significance 
remains unclear (Jensen 2003;van Hall G. et al. 2003). Other stimulators of lipolysis 
include thyroid stimulating hormone, parathyroid hormone and cholecystokinin, all 
of which act through Gs coupled receptors. Inhibitors of lipolysis include insulin-like 
growth factor 1, adenosine, alpha adrenergic agonists, and prostaglandin E2 
(Coppack et al. 1994). 
 
Members of the nuclear hormone receptor family play a key role in ‘setting the 
scene’ for metabolic control in the longer term. These include peroxisome 
proliferator activating receptors (PPARs) and sex steroid receptors, which may exert 
their effects by altering adipocyte differentiation as much as by altering fatty acid 
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metabolism. The potency of these effects is illustrated by the dramatic differences in 
fatty acid metabolism between men and women (Koutsari and Jensen 2006) and by 
the effects of PPARγ agonists on fat distribution (Shadid and Jensen 2003). 
 
Glucocorticoid receptors are also expressed in adipose tissue and liver and 
glucocorticoid hormones may be important in both the acute and chronic regulation 
of fatty acid trafficking and metabolism, and in influencing adipose tissue 
differentiation and function. This will be discussed later in this chapter.  
 
1.2.3 Hepatic fatty acid metabolism 
 
Understanding FFA and TG metabolism within the liver, at both the “whole body” 
and molecular level may provide insights into the pathogenesis on NAFLD. Both 
will be reviewed here. Figure 1.1 demonstrates that the liver plays a central role in 
lipid metabolism. Intrahepatic FFAs reach the liver from a number of sources 
including the diet (via chylomicrons), from hydolysis of other circulating TGs (e.g. 
low density lipoprotein), from plasma FFAs derived from hydrolysis of adipose TG 
stores, and from de novo lipogenesis with the liver. In contrast, the liver can 
metabolise FFAs through oxidative pathways and can export FFAs incorporated into 
VLDL TG. 
 
1.2.3.1 Triglyceride synthesis 
The final common pathway of triglyceride (or triacylglycerol) synthesis, involving 
FFAs from any source, requires the incorporation of fatty acyl CoAs (activated FFAs 
from acyl CoA synthases) onto a glycerol-3-phosphate spine. Glycerol-3-phoshate 
acyltransferase (GPAT) incorporates the first fatty acid (as an acyl CoA), and 
diacylglycerol acyltransferase (DGAT) the final step (see Figure 1.2). It is proposed 
that GPAT is the rate limiting step in TG biosynthesis, although DGAT may also be 
important in determining the flux of FFA into TGs (Yen et al. 2008), with GPAT 
activity elevated in diet induced obesity, high sucrose diet, ob/ob mice and drug 
induced causes of fatty liver (Gudbrandsen et al. 2006;Linden et al. 2004;Postic and 
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Girard 2008). However, the supply of FFAs is also likely to be crucial and 
potentially rate limiting (Bradbury and Berk 2004). 
 
Figure 1.2 Pathways and enzymatic regulation of triglyceride synthesis 
Enzymatic pathways involved in FFA and TG metabolism.  Abbreviations: ACC; acetyl-CoA 
carboxylase, ACSL; long chain acyl-CoA synthetase, AGPAT; 1-acylglycerol-3-phosphate 
O-acyltransferase , ATGL; adipose triacgylceride lipase, CPT1; carnitine palmitoyl 
transferase, DAG; diacylglycerol, DGAT, DAG O acyltransferase, DNL; de novo lipogenesis, 
FAS;  Fatty acid synthase, GPAT; glycerol-3-phosphate O-acyltransferase, HSL; hormone 





At least four GPAT isoforms exist, with the mitochondrial isoform (GPAT1) being 
most abundant in the liver (Linden et al. 2004). Both GPAT1 and the FFA 
transporting enzyme carnitine palmitoyltransferase 1 (CPT1) are located on the 
outside of mitochondria, and overexpression of GPAT1 suppresses fatty acid 
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two specific DGAT enzymes exist; DGAT1 and DGAT2 (Yen et al. 2008). DGAT2 
is probably the dominant enzyme in vivo, as DGAT2 null mice die within a few days 
of birth and have virtually no fat, with low hepatic and plasma FFAs and TGs (Stone 
et al. 2004).   
 
1.2.3.2 FFA oxidation 
The process of β-oxidation, producing acetyl CoA and reducing equivalents (NADH, 
FADH2) from fatty acids, takes place in the mitochondria and peroxisomes, whereas 
the minor pathway of microsomal ω-oxidation takes place in the endoplasmic 
reticulum (also known as the microsome) (Reddy and Rao 2006). In health, 
mitochondrial β-oxidation is the predominant pathway for metabolising short chain 
(<C8), medium chain (C8-C12) and long chain fatty acids (C12-C20), with the 
subsequently produced acetyl CoA and reducing equivalents leading to the 
production of ATP via the electron transport chain (Reddy and Rao 2006). 
Peroxisomal β-oxidation is required for the metabolism of very long chain fatty acids 
(>C20), and other more complex and toxic compounds such as dicarboxylic fatty 
acids produced by ω-oxidation, prior to mitochondrial oxidation (Reddy and Rao 
2006). These alternative pathways are cytochrome P450 (CYP2E1 and CYP4A) 
dependent and can be upregulated in NAFLD, which may be significant as they are 
less efficient and generate reactive oxygen species (ROS) (Robertson et al. 2001).  
 
Following CPT1-mediated entry into mitochondria, the first step in β-oxidation 
requires dehydrogenation of fatty acyl CoAs by acyl CoA dehydrogenases (Reddy 
and Rao 2006). This is followed by a number of reactions catalysed by mitochondrial 
trifunctional protein (MTP) to produce acetyl CoA for entry into the Kreb`s cycle. 
Peroxisomal oxidation first relies on acyl CoA oxidases prior to a number of further 
reactions, again catalysed by a single protein (L-bi/multifunctional enzyme [L-
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1.2.3.3 Triglyceride export 
Pre-existing cytosolic TG stores account for the majority of FFAs incorporated into 
TG for VLDL export (Bradbury and Berk 2004). The underlying process is 
incompletely understood, but the enzyme hepatic triacylglyceride hydrolase (TGH), 
located on the endoplasmic reticulum, has been proposed to catalyse the mobilisation 
of hepatic TG  stores via a lipolysis and re-esterification pathway involving acyl 
transferases (Gilham et al. 2003). Within the liver, TG rich VLDL particles are 
packaged with apolipoprotein B100 (apoB100), and other apolipoproteins (e.g. apoE, 
apoC-II, and apoB48 in mice expressed from the Apobec-1 gene) for export into the 
circulation. This process is dependent on microsomal triglyceride transfer protein 
(MTTP) located within the endoplasmic reticulum, the significance of which will be 
discussed below (Raabe et al. 1999). 
 
Phosphatidylcholine is another component essential for VLDL export (Li and Vance 
2008). Choline, and methionine (and methyl-folate) metabolism is closely linked 
with phospatidylcholine synthesis and given that the dietary models of NAFLD in 
this thesis involve choline and methionine deficiency, their metabolism will be 
discussed in some detail here. 
 
Choline is an integral component of phospatidylcholine and acetyl choline. It is 
therefore essential for normal membrane function, neurotransmission, and 
transmembrane signalling, and plays an important role in lipid transport, as 
phosphatidylcholine is required for hepatic VLDL export (Zeisel and Blusztajn 1994). 
Choline is obtained mainly from the diet, although in mammals it can also be 
biosynthesised via the conversion of phosphatidylethanolamine (PE) by PE N-
methyltransferase (PEMT), requiring S-adenosyl methionine (from methionine) as a 
methyl donor. Choline can also be obtained by the action of phospholipases on pre-
existing phosphocholine, as well as from catabolism of acetyl choline (Li and Vance 
2008).  In animals, including humans, the PEMT pathway is only relevant in the liver 
where it produces 30% of hepatic phosphatidylcholine, although this is upregulated 
in choline deficiency (Li and Vance 2008). Figure 1.3 demonstrates that the final step 
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in phosphatidylcholine synthesis involves the reaction of DAG with CDP-choline (by 
CDP-choline:1,2-diacylglycerol cholinephosphotransferase). 
 
Choline is a quaternary amine containing three methyl groups and functions as an 
important methyl donor following its conversion to betaine. This allows conversion 
of homocysteine to methionine (by betaine: homocysteine methyltransferase). 
Similarly methionine is regenerated from homocysteine using methyltetrahydrofolate 
as a methyl donor (Figure 1.3). As early as the 1930s choline deficiency was shown 
to induce fatty liver in rodents (Best et al. 1932), and the deficiency of other 
components in methyl metabolism including methionine, folate and vitamin B12 
exacerbates fatty liver, hence the collective term lipotrope. 
 
Figure 1.3 Pathways of choline and methionine metabolism 
Adapted from Zeisel and Blusztajn (Zeisel and Blusztajn 1994). AC, acetyl choline; DAG, 
Diacylglcerol; GSH, Glutathione; HC, homocysteine; PC, phosphatidyl choline; Pchol, 
phosphocholine; CDP-Chol, Cytidinediphosphocholine; AdoMet, S-Adenosylmethionine; 
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1.3 PATHOLOGY ASSOCIATED WITH ALTERED FATTY ACID 
METABOLISM: INSULIN RESISTANCE AND NAFLD 
 
As discussed, NAFLD is considered the hepatic component of the metabolic 
syndrome which putatively has resistance to the metabolic actions of insulin as its 
central mechanism. The resistance to insulin`s actions in muscle, adipose and liver 
are likely to contribute to the metabolic consequences of this syndrome. However, it 
is not clear how many of the features of this syndrome are a cause versus a metabolic 
consequence of insulin resistance. Indeed, increased hepatic TG accumulation can be 
associated with improved insulin sensitivity suggesting that NAFLD may represent a 
protective mechanism against the toxic effects of intermediaries of TG metabolism. 
Conversely increased liver fat accumulation may lead to insulin resistance. 
Furthermore, abnormalities of hepatic fatty acid metabolism and/or insulin resistance 
may influence the development of NASH and liver fibrosis. In the following sections 
I will discuss the evidence that abnormalities of fatty acid metabolism can contribute 
to both insulin resistance and the development and progression of NAFLD.  
 
1.3.1 Fatty acid metabolism and insulin resistance 
 
There is a large body of research implicating FFAs in the pathogenesis of insulin 
resistance, either through direct mechanisms or via associated increased 
intramyocellular lipid accumulation (Boden 1997). In fact, elevated plasma FFAs 
predict the development of type 2 diabetes (Pankow et al. 2004) independently of 
insulin resistance and insulin secretory defects (Charles et al. 1997). Moreover, short 
term reductions in FFAs (using the lipolysis inhibitor acipimox) can improve insulin 
sensitivity in obese patients with diabetes (Santomauro et al. 1999).  
 
Over 40 years ago Randle et al proposed that increased FFAs competitively inhibit 
the oxidation of glucose, contributing to the development of insulin resistance in rat 
muscle (Randle et al. 1963). However, more recent studies (Boden and Shulman 
2002), corroborated by in vivo magnetic resonance spectroscopy findings (Petersen 
and Shulman 2002), suggest that inhibition of glucose metabolism by FFAs is 
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secondary to impaired insulin signalling rather than a direct result of substrate 
competition e.g. FFAs are a source of oxidative stress, which activates the 
proinflammatory cytokine nuclear transcription factor β (NFκB), potentially 
interfering with insulin signalling (Itani et al. 2002), and also reducing insulin 
binding with its receptor in vitro (Svedberg et al. 1990). Additionally, elevated FFAs 
can increase rates of hepatic gluconeogenesis and VLDL secretion (Chen et al. 
1999;Lewis et al. 1995), although the mechanisms contributing to this are not well 
understood (Krebs and Roden 2005). Finally, effects on pancreatic beta cells may 
contribute to hyperglycaemia. Elevated FFAs are toxic to pancreatic beta cells in 
rodents, but in humans increasing FFA levels within the physiological range for up to 
48 hours produced an increase in glucose induced insulin secretion, although clearly 
longer term changes may differ (Boden et al. 2001). 
 
The source and site of pathologically important elevated FFA levels remains 
controversial. A popular concept is of hyperlipolysis in visceral adipose tissue, 
increasing the flux of FFAs through the portal circulation and inducing hepatic 
insulin resistance, but the evidence for this is not conclusive. Although visceral 
obesity does correlate with FFA delivery to the liver (Nielsen et al. 2004), its 
contribution to systemic FFA levels is small (Miles and Jensen 2005). Subcutaneous 
adipose tissue is arguably more likely to influence peripheral insulin resistance in 
upper body obesity. Although visceral fat is more lipolytically active per kilogram fat 
than subcutaneous adipose tissue, the quantity of the latter is greater, contributing to 
the majority of circulating FFAs (Basu et al. 2001). Recent studies suggest a key 
concept is a lack of metabolic flexibility, whereby suppression of FFA release in the 
fed state is impaired in insulin resistant subjects (Frayn 2002). A reduced 
intracellular capacity to switch between FFA and glucose oxidation in response to 
nutrient supply is also a feature of insulin resistance, although whether this is a cause 
or consequence of reduced insulin sensitivity is unclear (Kelley et al. 2002).  
 
1.3.1.1 Intrahepatic lipid metabolism and insulin resistance 
It is unclear whether increased intrahepatic TGs per se or other intermediaries of 
lipid metabolism lead to the development of insulin resistance associated with 
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NAFLD. Although reducing hepatic TGs is often associated with improved insulin 
sensitivity, one cannot infer causation. Indeed, evidence from specific models of 
NAFLD (discussed below) suggest that TG may be acting as a buffer of potentially 
toxic FFAs or other intermediaries of FFA and TG metabolism such as fatty acyl 
CoAs, or diacylglycerol (DAG) (see Figure 2.1).  
 
Initial studies in Gpat1 knockout mice, as would be predicted, showed accumulation 
of intrahepatic fatty acyl CoAs (Neschen et al. 2005). This was associated with 
protection from hepatic insulin resistance (measured by euglycaemic 
hyperinsulinaemic clamp) and TG accumulation induced by a high fat diet (rich in 
safflower oil) suggesting that increased fatty acyl CoAs alone do not contribute to the 
pathogenesis of hepatic insulin resistance (Neschen et al. 2005). However, these 
findings were not reproduced in Gpat1 knockout mice fed a standard chow, with no 
change in insulin sensitivity (Hammond et al. 2002). In addition, impaired glucose 
tolerance with hyperinsulinaemia was found in Gpat1 knockout mice fed a lipogenic 
high sucrose, high fat diet rich in coconut oil for four months (Hammond et al. 2005). 
Despite these conflicting results, hepatic overexpression of GPAT1 in rats does lead 
to steatosis and hepatic insulin resistance associated with increased DAG and 
lysophosphatidic acid (LPA), supporting a role for these intermediaries in hepatic 
insulin resistance (Nagle et al. 2007). DAG is a potent activator of protein kinase C  
(PKC , a serine/threonine kinase that interferes with insulin signalling). This model 
was associated with an increase in PKC  activity, but without any increase in NF-κB 
or TNFα gene expression, suggesting that hepatic inflammation is not relevant in this 
model of steatosis and insulin resistance.  
 
Suppression of Dgat2, the predominant isoform in the liver, using a Dgat anti-sense 
oligonucleotide (ASO) in rats fed a high fat diet, reduced intrahepatic TGs and 
improved hepatic insulin sensitivity. This was despite elevated plasma FFAs and 
intrahepatic fatty acyl CoAs (Choi et al. 2007). Paradoxically Dgat “inhibition” was 
also associated with a reduction in measured DAG (and LPA) levels, possibly 
explained by reduced expression of various lipogenic genes (Gpat1, Srebp1c, Acc, 
Scd1) in response to the increase in intrahepatic fatty acyl CoAs (Choi et al. 2007). It 
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is well known that FFAs themselves can promote TG synthesis and act as ligands for 
transcription factors including PPARs (Schoonjans et al. 1996). Dgat2 ASO 
treatment has also been shown to reduce hepatic TGs in high fat fed and ob/ob mice 
associated with improved insulin sensitivity (Yen et al. 2008). 
 
In contrast, overexpression of DGAT2 in the liver leads to the development of 
hepatic steatosis without altering plasma TGs and without insulin resistance, 
demonstrating a dissociation of these two features of the metabolic syndrome 
(Monetti et al. 2007). Another model with apparent dissociation of intrahepatic TG 
accumulation and insulin resistance is the Mttp null mouse (Minehira et al. 2008). 
These mice have impaired VLDL export and steatosis with normal body weights and 
intramuscular TGs, despite low plasma TGs. Hyperinsulinaemic euglycaemic clamp 
studies demonstrated normal hepatic and peripheral insulin sensitivity despite 
elevated intrahepatic DAG levels (Minehira et al. 2008) as would be predicted, in 
contrast to what was found with Dgat2 inhibition (Choi et al. 2007). Lastly, the 
ApoB-38.9 mouse model of familial hypobetalipoproteinaemia (FHBL) is another 
model where hepatic TG content is not linked to insulin resistance (Schonfeld et al. 
2008). 
 
These studies demonstrate that insulin resistance is not a universal finding in 
NAFLD and, although it is not clear which intermediary of hepatic lipid metabolism 
is responsible, specific intermediaries of hepatic lipid metabolism may contribute to 
the pathogenesis of hepatic insulin resistance. 
 
1.3.2 Fatty acid metabolism and steatosis 
 
Given the intrahepatic accumulation of TG, simplistically, NAFLD can be 
considered an imbalance between the liver’s ability to process the influx of FFAs and 
to export TG as VLDL. Abnormalities of fatty acid metabolism which could lead to 
the development of steatosis therefore include: increased delivery of FFAs; increased 
hepatic de novo lipogenesis; impaired FFA oxidation; and impaired TG export (see 
Figure 1.1). Given the liver’s central role in metabolising lipids from peripheral 
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sources, adipose tissue FFA metabolism may also be of particular significance in the 
development of NAFLD. The role of each of these pathways will be discussed in 
more detail below, with reference to evidence mainly derived from animal studies.    
 
1.3.2.1 Increased FFA delivery 
A popular hypothesis linking obesity and fatty liver is an increased delivery of FFAs 
to the liver relative to oxidative capacity, promoting the esterification of excess FFAs 
to TGs. A simple overnight fast is sufficient to increase liver TGs in some animals 
(Yasuhara et al. 1991), presumably due to increased delivery of FFAs to the liver. 
Similarly, states of insulin deficiency e.g. in pancreatectomised dogs, increase FFAs 
and exacerbate hepatic steatosis (Scow et al. 1957). Likewise, insulin resistance at 
the level of the adipocyte is hypothesised to increase the flux of FFA to hepatocytes, 
in particular directly through the portal vein from metabolically active visceral 
adipose depots (Lewis et al. 1995).  
 
High fat diets lead to the development of visceral obesity and fatty liver in certain 
strains of mice and rats, associated with increased plasma FFA concentrations 
(Koteish and Diehl 2001). Therefore, increased dietary fat intake may contribute to 
fatty liver through increased availability of FFAs, both of which can be prevented by 
exercise training in rats (Gauthier et al. 2003). However, other factors may be 
important in high fat diet induced fatty liver, including the type of fat (saturated 
versus polyunsaturated), insulin resistance/ hyperinsulinaemia, and leptin 
resistance/hyperleptinaemia. Similarly, overfeeding by gavage or gastrostomy 
produces obesity, associated with fatty liver, and insulin resistance, although also 
associated with steatohepatitis (Deng et al. 2005;Zou et al. 2006). 
 
Adipose derived factors other than FFAs may also influence the pathogenesis of 
NAFLD in high fat feeding. Adipose tissue is also the source of adipokines, 
including adiponectin, leptin and resistin, which are proposed to modulate hepatic 
insulin resistance and fatty acid oxidation (Lafontan and Viguerie 2006). Additional 
adipose derived adipocytokines e.g. TNFα, IL6 and TGFβ are potential modulators 
of local adipose and hepatic lipid and carbohydrate (insulin signalling) metabolism, 
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whilst also being potent modulators of the immune system, of particular relevance to 
NASH (Choi and Diehl 2005). 
 
As discussed, insulin resistance at the level of the adipocyte increases FFA flux to 
the liver due to impaired suppression of lipolysis. A more specific example of the 
relevance of extra-hepatic causes of steatosis comes from mice lacking the FFA 
uptake receptor CD36 which have increased circulating FFAs and develop hepatic 
steatosis associated with hepatic insulin resistance but peripheral insulin sensitivity 
(Coburn et al. 2000;Goudriaan et al. 2003). In addition, mice with adipose 
overexpression of the glucocorticoid regenerating enzyme 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1), predicted to increase lipolysis secondary to 
elevated local glucocorticoid concentrations, have a three fold increase in portal vein 
FFA concentrations and develop fatty liver (Masuzaki et al. 2001). However, direct 
effects of increased portal glucocorticoid concentrations may also be of relevance 
(Paterson et al. 2002). Lastly, mice with Hsl deficiency, which are unable to 
efficiently hydrolyse adipose TGs to release FFAs, have low plasma FFAs and liver 
TG content (Voshol et al. 2003). 
 
The physiological association of fasting elevations in FFAs and fatty liver, along 
with the above models suggest that increased FFA flux to the liver is likely to be an 
important factor in the development of fatty liver. However, it is difficult to 
completely dissociate the potential effects of FFAs on other aspects of metabolism 
and insulin resistance, such as on the accumulation of lipids within muscle, and the 
effects of FFAs on insulin signalling (Petersen and Shulman 2002). Nevertheless, the 
unopposed lipolysis and increased hepatic triglycerides in pancreatectomised animals 
provides evidence for the potential role of increased hepatic FFA delivery in the 
absence of peripheral insulin resistance (Scow et al. 1957). 
 
1.3.2.2 Increased hepatic FFA synthesis 
Hepatic de novo lipogenesis (DNL) is an additional source of FFAs for the synthesis 
of TGs. Rodents fed low fat/high carbohydrate diets develop hepatic steatosis, 
inducing multiple enzymes involved in de novo lipogenesis such as acetyl CoA 
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carboxylase and fatty acid synthase (Postic and Girard 2008). High carbohydrate/low 
fat diets also promote hyperinsulinaemia, paradoxically increase plasma TGs, and 
lead to the preferential oxidation of carbohydrates (Scribner et al. 2008). This latter 
change may in part relate to inhibition of the rate limiting enzyme Cpt1a, required for 
the transport of fatty acids into mitochondria for oxidation, by malonyl CoA, the 
principal intermediary in the de novo synthesis of FFAs (Zammit 1999). 
 
Carbohydrate composition is important in the development of steatosis in these 
dietary models. Diets high in the disaccharide sucrose (table sugar), metabolised to 
glucose and fructose monosaccharides, strongly promote lipogenesis and (periportal) 
steatosis, whereas diets high in simple glucose do not lead to comparable changes, 
suggesting that fructose is the responsible factor in high sucrose diets (Koteish and 
Diehl 2001). Accordingly fructose metabolism bypasses the normal rate limiting 
mechanisms of glycolysis, producing lipogenic acetyl CoA and glycerol-3-phosphate, 
the backbone for triglyceride synthesis (Stanhope and Havel 2008). Interestingly, 
leptin has recently been shown to reverse the metabolic abnormalities induced by 
high sucrose diets in rats, demonstrating the complexity of the mechanisms involved 
in the pathogenesis of hepatic TG accumulation (Huang et al. 2007). 
 
A number of transgenic mice overexpressing key enzymes involved in de novo 
lipogenesis have been created, along with attempts to knockout or knockdown many 
of the same genes. In keeping with the above dietary models, mice overexpressing 
either a and c isoforms of SREBP1 in a tissue specific manner under rat Pepck and 
murine aP2 promoters, in the liver and adipose tissue respectively develop steatosis, 
whereas reduced expression of Chrebp leads to a reduction in lipogenesis (reviewed 
in (Anstee and Goldin 2006)). 
 
Stearoyl CoA desaturase (SCD1), catalyses the desaturation of fatty acids to 
monounsaturated fatty acids (MUFAs) e.g. palmitoleic (C16:1n-7) and oleic acids 
(C18:1n-9). For unclear reasons, Scd1-/- mice have low Srebp1c and Chrebp levels 
associated with suppressed lipogenesis and increased fat oxidation (Miyazaki et al. 
2007), and are protected from steatosis (Miyazaki et al. 2007). Leptin has been 
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shown to suppress Scd-1 activity independently of its actions on Srebp1c, and may 
partly explain leptin’s influence on liver TG accumulation (Biddinger et al. 2006). 
Similarly, increased lipogenesis, with increased fatty acid synthase and Srebp1c 
expression appears to be one of the mechanisms of TG accumulation in leptin 
deficient ob/ob mice, as well as leptin resistant db/db mice and Fa/Fa rats (Koteish 
and Diehl 2001).  
 
1.3.2.3 Altered fatty acid esterification and triglyceride synthesis  
A number of acyl transferases catalyse the final steps in TG synthesis (see Figure 
2.1). Mice deficient in Gpat1 are protected from steatosis, and have reduced plasma 
TGs/VLDL export (Hammond et al. 2002). In contrast, rodents overexpressing 
GPAT1 in the liver have increased liver TGs and plasma TGs/VLDL export (Nagle et 
al. 2007). Similarly, overexpression of DGAT2 in the liver leads to the development 
of hepatic steatosis, although without altering plasma TGs and without insulin 
resistance, demonstrating a dissociation of these two features of the metabolic 
syndrome (Monetti et al. 2007). This provides evidence that steatosis alone is not 
universally toxic and may actually protect against lipotoxicity, buffering toxic 
intermediates such as FFAs.  
 
1.3.2.4 Altered fatty acid oxidation 
Inhibition of FFA oxidation will lead to an increase in intrahepatic fatty acids and 
may contribute to oxidative stress within intracellular organelles. As discussed, 
CPT1 is essential for transport of fatty acids into mitochondria prior to oxidation and 
is inhibited by malonyl CoA (Zammit 1999), a cellular marker of de novo lipogenesis. 
Therefore impaired FFA oxidation may partially contribute to steatosis in models 
with significantly increased de novo lipogenesis such as high sucrose/fructose diets 
(Lambert et al. 2003). More specifically, given the requirement of CPT1 for carnitine, 
inhibiting carnitine biosynthesis can induce steatosis (Spaniol et al. 2001), as does 
CPT1 inhibition by etomoxir (Koteish and Diehl 2001). Examples of drugs impairing 
fatty acid oxidation include tetracycline, doxycycline, amiodarone, and tamoxifen, as 
well as glucocorticoids (Fromenty and Pessayre 1995;Letteron et al. 1997).  
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The first step in carnitine biosynthesis requires two essential nutrients; the methyl 
donor methionine and lysine to create trimethyl-lysine (Borum 2009). Given choline 
and methionine`s roles as methyl donors, discussed in detail below, deficiency of 
these nutrients can reduce tissue carnitine concentrations (Carter and Frenkel 1978) 
and has been shown to reduce CPT1 activity (Aarsaether et al. 1988). This may be 
important in methionine and/or choline deficient dietary models of NAFLD as 
discussed below. Similarly, juvenile visceral steatosis (JVS) mice have reduced 
activity of the (renal tubular) carnitine transporter, Octn2, and develop steatosis 
exacerbated by carnitine deficiency (Knapp et al. 2008) 
 
Mitochondrial β-oxidation is reliant on a large number of enzymes many of which 
have been disrupted in mice and are under the regulation of PPARα transcription 
factor (Schoonjans et al. 1996). Pparα knockout mice demonstrate the importance of 
fatty acid oxidation in preventing steatosis, as although they do not develop fatty 
liver under normal fed conditions, the increased release of FFAs associated with 
(24hour) fasting leads to severe steatosis (Kersten et al. 1999). Male Pparα knockout 
mice are extremely sensitive to the CPT1 inhibitor etoxomir, the effects of which can 
be ameliorated with β-oestradiol therapy suggesting an important role for oestrogens 
in the regulation of fatty acid oxidation (Djouadi et al. 1998). Indeed, aromatase 
deficient female mice develop centrilobular steatosis which can be prevented by β-
oestradiol and PPARα agonist therapy (Toda et al. 2001). This mechanism may also 
be partially responsible for tamoxifen associated steatosis (Fromenty and Pessayre 
1995). 
 
The oxidative pathways described above could be disrupted at a number of stages. 
The importance of MTP is demonstrated in mice with homozygous mutation in the 
Mtp gene which die shortly following birth (Ibdah et al. 2005). Mice heterozygous 
for a defect in Mtp develop steatosis after ~10 months, associated with hepatic 
oxidative stress, and insulin resistance assessed by GTT (Ibdah et al. 2005). In 
contrast, defects in peroxisomal oxidation are reproduced in mice lacking acyl CoA 
oxidase. These accumulate very long chain fatty acids in the blood, and develop 
steatosis which progresses to steatohepatitis (by four months of age). This then 
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resolves by six to seven months, possibly due to an increase in β-oxidation and 
hepatocellular regeneration (Fan et al. 1996;Reddy and Rao 2006).  
 
1.3.2.5 Impaired hepatic TG export 
If TG synthesis exceeds the capacity for TG export, then steatosis will develop. 
Processes which could contribute to impaired hepatic TG export include: decreased 
mobilisation of hepatic TG stores; impaired VLDL assembly; and decreased VLDL 
secretion (Bradbury and Berk 2004).  
 
Certain drugs including amiodarone and tetracycline have been shown to influence 
MTTP activity both in vitro and in vivo in mice (Letteron et al. 2003). This is in 
addition to the effects of these medications on mitochondrial β-oxidation which may 
increase their propensity to cause steatosis. Indeed, clinical studies of an MTTP 
inhibitor in familial hypercholesterolaemia showed an increase in transaminases and 
liver fat (Cuchel et al. 2007). Carbon tetrachloride (CCl4), a toxin commonly used to 
induce liver fibrosis in rodents, has also been reported to inhibit hepatic TG export, 
enhancing hepatic steatosis, which may be due to increased post translational MTTP 
breakdown (Pan et al. 2007). 
 
Hydrolysis of stored TGs is an essential step in VLDL export. Inhibition of hepatic 
triglyceride hydrolase (TGH) inhibits TG and apoB export in vitro (Gilham et al. 
2003), whereas human TGH transgenic mice have increased VLDL export, although 
hepatic TG content was not assessed (Wei et al. 2007). To date no in vivo studies of 
TGH inhibitors or molecular downregulation have been published. The role of TG 
hydrolysis has not been well studied in relation to NAFLD. Recently, hepatic 
overexpression of Hsl and Atgl, the predominant lipolytic enzymes in adipose tissue, 
using adenovirus transduction was shown to ameliorate steatosis in ob/ob mice (Reid 
et al. 2008). No increase in VLDL export was measured, but fatty acid oxidation was 
increased, suggesting that the action of these lipases in the liver may direct FFAs 
towards oxidation rather than VLDL export (Reid et al. 2008).  
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Both apoB100 and MTTP are essential for normal hepatic TG export. It is thought 
that apoB is synthesised in excess of its requirements, with post transcriptional 
regulation involving MTTP associated lipidation, preventing alteration of apoB100’s 
conformation that would otherwise lead to its degradation (Tietge et al. 1999). 
However, ApoB deficiency does exist in humans as familial 
hypobetalipoproteinaemia (FHBL) and can lead to the development of steatosis 
(Schonfeld et al. 2003). Similarly, the ApoB-38.9 mouse model of FHBL develops 
steatosis due to impaired VLDL export, and perhaps as an adaptive mechanism, has 
suppressed de novo lipogenesis and esterification, with unchanged fatty acid 
oxidation (Lin et al. 2002). In humans, deficiency of MTTP is responsible for the 
syndrome of abetalipoproteinaemia, an autosomal recessive condition characterised 
by very low apoB containing lipoprotein levels, fat and fat soluble vitamin 
malabsorption, and fatty liver (Wetterau et al. 1992). Liver specific inactivation of 
the Mttp gene in mice lowers plasma apoB100 levels by over 95%, associated with 
markedly reduced plasma lipids, and causes the development of hepatic steatosis 
(Raabe et al. 1999). In contrast, overexpression of the MTTP gene leads to an 
increase in VLDL export and plasma TGs suggesting that Mttp may be rate limiting 
(Tietge et al. 1999). 
 
ApoE also appears to play an important role in VLDL export (Mensenkamp et al. 
2001). ApoE deficient mice develop perivenous steatosis when fed normal chow, 
“cured” by reintroduction of hepatic apoE (Mensenkamp et al. 1999), whereas 
overexpression increases VLDL export (Tsukamoto et al. 2000). The mechanism is 
unclear, but appears to affect quite a late event in VLDL assembly in the 
endoplasmic reticulum, independent of Mttp activity (Mensenkamp et al. 2001). 
 
Excluding the specific models discussed in this Section (1.3.2.5), the significance of 
impaired VLDL export in fatty liver is unclear. Hepatic VLDL export is increased in 
humans with NAFLD and insulin resistance (Fabbrini et al. 2008). MTTP activity 
may actually increase in an attempt to increase TG export, perhaps in response to 
increasing TG accumulation (Bartels et al. 2002;Carpentier et al. 2002). However, 
decreased - or perhaps failure to upregulate - VLDL export may exacerbate fatty 
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liver e.g. in ob/ob mice (Li et al. 1997). Polymorphisms in the MTTP gene have been 
demonstrated in human NASH (Namikawa et al. 2004), in which there is also 
evidence of impaired apoB export (Charlton et al. 2002). 
 
Altered VLDL export has also been implicated in the pathogenesis of methionine 
and/or choline deficient models of fatty liver, although other mechanisms may also 
be important in these two contrasting models. 
 
1.3.2.6 Methionine and/or choline deficiency 
Choline and methionine are key micronutrients required for phosphatidyl choline 
synthesis and are essential for VLDL synthesis (Li and Vance 2008). Deficiency of 
these components leads to fatty liver in rodents, possibly due in part to effects on TG 
export. It has been widely quoted in the literature that TG accumulation in CDD and 
(extrapolating from this) MCDD is the result of impaired VLDL export (reviewed in 
(Kulinski et al. 2004)). This primarily comes from the work of Lombardi et al 
(Lombardi et al. 1968) employing the use of a radioactive palmitate tracer in CDD 
fed rats. The reduced incorporation of tracer into plasma TGs compared to control 
rats, with a greater delay in reduction of radioactivity from the liver, has been 
interpreted as impaired VLDL export (Lombardi et al. 1968). However, this could 
also simply imply an increased contribution of plasma FFAs to the accumulating 
hepatic TG pool in the CDD rats, with less radiolabelled VLDL TG exported per 
gram of stored hepatic TG. More recently in vitro studies, in hepatocytes isolated 
from CDD fed mice, have demonstrated normal VLDL export with choline 
deficiency alone (Kulinski et al. 2004). 
  
Differences between rodents fed a choline deficient diet (CDD) and a methionine and 
choline deficient diet (MCDD) are summarised in Table 1.2. A choline deficient diet 
(CDD) rapidly (<1 week) leads to the development of fatty liver in rodents, initially 
periportally (zone 1), before it rapidly spreads into other areas. In rats, prolonged 
administration (>12 weeks) leads to the development of liver cirrhosis, and 
spontaneous hepatic carcinogenesis occurs after 30 weeks of choline deficiency 
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(Nakae 1999). As a result of this latter finding, CDD has traditionally been used as a 
model of liver carcinogenesis rather than fatty liver.   
 
Table 1.2 Comparison on choline ± methionine deficient models of fatty liver in 
rodents 
 CDD MCDD 
Initial TG accumulation Zone 1 Zone 3 
Spontaneous fibrosis >12 weeks in rats Yes 
Impaired VLDL export Unclear Yes 
Hepatic insulin resistance No Yes 
Steatohepatitis No Yes 
Weight loss No Yes 
 
Figure 1.3 demonstrates that in the absence of dietary choline animals can still 
generate choline via the methionine dependent PEMT pathway. As a result of this 
animals are able to upregulate this pathway to maintain phosphatidylcholine 
synthesis required for VLDL export (Kulinski et al. 2004). In addition, upregulation 
of the CDP-choline pathway, increasing phosphatidylcholine synthesis, may divert 
potentially toxic intermediaries such as FFA and diacylglycerols which may explain 
the improved insulin sensitivity seen in mice placed on a high fat diet and fed a CDD 
(Raubenheimer et al. 2006).  
 
The cause of steatosis in this model is unclear. Gene expression studies have 
suggested that de novo lipogenesis and fatty acid oxidation are unaltered by choline 
deficiency, whereas the process of re-esterification of fatty acids to TG stores is 
upregulated (Raubenheimer et al. 2006). One of the earliest changes noted in rats fed 
a CDD is subcellular damage due to the development of reactive oxygen species 
(Nakae 1999), and mitochondrial dysfunction secondary to free radicals has recently 
been shown in choline deficiency (Petrosillo et al. 2007). Hence, despite a lack of 
detectable changes in gene expression, altered fatty acid oxidation may be relevant in 
isolated choline deficiency. 
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The combination of choline and methionine deficiency produces a different 
phenotype from simple CDD. In particular, rodents fed the MCDD diet develop 
steatohepatitis and early fibrosis, associated with hepatic insulin resistance (Leclercq 
et al. 2007;Schattenberg et al. 2005).  The MCDD diet also induces rapid weight loss 
leading to improved whole body insulin sensitivity in mice (Rinella and Green 2004), 
although there is also evidence from a study of pair fed rats that glucose tolerance is 
impaired following MCDD (Tahan et al. 2004). In contrast to isolated choline 
deficiency, MCDD fed rodents initially accumulate TG centrilobularly (zone 3). In 
this respect, histologically the MCDD model is similar to human NAFLD, but given 
its other phenotypic features it is perhaps a model of lipodystrophy rather the 
“primary” human NAFLD (Rizki et al. 2006). 
 
MCDD fed rodents develop a profound impairment of VLDL export, associated with 
a fall in plasma TG concentrations (Vetelainen et al. 2007). In keeping with the loss 
of adipose stores, plasma FFAs are also elevated, potentially stimulating hepatic TG 
synthesis (Rahman et al. 2007). De novo lipogenesis may also be increased (Rizki et 
al. 2006) and there may be abnormalities of fatty acid oxidation, which given the 
development of steatohepatitis in this model suggests that abnormalities of fatty acid 
metabolism may be influential in the development of hepatic inflammation. 
 
1.3.3 Fatty acid metabolism and non-alcoholic steatohepatitis (NASH)  
  
It is clear from the above that multiple abnormalities of fatty acid metabolism can 
lead to the accumulation of intrahepatic triglyceride or steatosis. Animal models of 
steatohepatitis are, however, much less abundant than those with isolated steatosis 
but provide important insights into the mechanisms influencing progression from 
simple steatosis to the development of liver inflammation.  
 
Although probably an oversimplication, the two hit hypothesis has been proposed to 
explain the progression from simple steatosis to steatohepatitis, with cytokines, FFAs 
and reactive oxygen species proposed as potential second hits in predisposed 
steatotic livers (Day and James 1998). Here I will discuss the major models of 
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steatohepatitis focussing on the evidence that abnormalities of fatty acid metabolism 
may be important in influencing the inflammatory process. 
 
1.3.3.1 The two hit hypothesis 
Ob/ob mice have a naturally occurring mutation (Lepob) in the gene encoding leptin, 
producing a truncated inactive form of the adipose derived satiety hormone, resulting 
in hyperphagia, obesity, and insulin resistance (Anstee and Goldin 2006;Ingalls et al. 
1996). Similar phenotypes are observed in hyperleptinaemic, leptin resistant Zucker 
rats, with a mutation (Leprfa) in the gene encoding the leptin receptor (commonly 
referred to as Ob-R), and in db/db mice, with a homozygous mutation (Leprdb) in the 
gene which encodes Ob-R. Multiple splice variants of the Ob-R exist and in db/db 
mice the long form important in central appetite regulation is truncated, whilst the 
short form is retained intact in the liver (Hoggard et al. 1997;Lee et al. 1996). Ob/ob 
mice have a number of abnormalities of fatty acid metabolism potentially 
contributing to steatosis including increased circulating FFAs, promoted by increased 
adipose TNFα, increased de novo lipogenesis, and possibly reduced fatty acid 
oxidation, associated with an increase in microsomal CYP2E1 and CYP4A mediated 
ω-oxidation (reviewed in (Anstee and Goldin 2006)).  
 
Although older male ob/ob mice may develop mild hepatic inflammation, younger 
ob/ob and db/db mice do not display features of steatohepatitis (Koteish and Diehl 
2001). Their steatotic livers are however particularly sensitive to toxic insults and 
develop steatohepatitis following lipopolysaccharide administration, ischaemia 
reperfusion injury and ethanol (Koteish and Diehl 2001). These findings provided the 
initial impetus for the “second hit” hypothesis that steatosis sensitises the liver to 
factors such as oxidative stress (Day and James 1998), although other factors may 
also be relevant e.g. leptin’s modulation of the immune response. Many immune 
cells possess leptin receptors and leptin deficiency has immunosuppressive effects on 
both the innate and acquired immune response (Matarese 2000). Leptin deficiency 
promotes a T helper 1 (pro-inflammatory) immune response, suppressing the T 
helper 2 (anti-inflammatory) response (Matarese 2000), suggesting that in these 
models at least the two hit hypothesis is an oversimplification. Nevertheless other 
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models of steatosis require a second hit to induce steatohepatitis e.g. impaired VLDL 
export in mice with reduced expression of hepatic Mttp is associated with increased 
susceptibility to lipopolysaccharide administration (Bjorkegren et al. 2002). 
 
1.3.3.2 Overnutrition and high fat feeding induced steatohepatitis 
A diet high in saturated fat is sufficient to act as a second hit in leptin resistant fa/fa 
rats, that readily develop steatohepatitis, when placed on such a diet (Carmiel-Haggai 
et al. 2005). Steatosis and fibrotic changes develop in the periportal region initially in 
this model. Fat aussie (foz/foz) mice, another model of hyperphagic obesity with 
insulin resistance (with a deletion in the mouse Alms1 gene), also progress from 
simple steatosis to fibrosing steatohepatitis when placed on a high fat diet (Arsov et 
al. 2006). Interestingly, this was associated with a profound reduction in adiponectin 
compared to chow fed controls, a factor reduced in patients with NASH, and known 
to upregulate Pparα and Ampk (Larter and Farrell 2006). Accordingly, foz/foz mice 
were unable to upregulate genes involved with fatty acid uptake, fatty acid oxidation, 
and export, suggesting an inability to adapt to a high fat diet. Despite the 
development of steatohepatitis there was no upregulation of microsomal oxidation 
and no increase in lipid peroxidation in this model (Arsov et al. 2006).  
 
These models suggest that the progression to steatohepatitis may relate to the liver’s 
(and adipose tissue’s) ability to cope with the metabolic challenge of a high fat diet. 
Specifically foz/foz mice appeared to be unable to adapt to the increased flux of 
intrahepatic fatty acids by increased fatty acid oxidation and TG export. 
 
Other investigators have attempted to induce fatty liver and steatohepatitis using high 
fat feeding in rodents. Lieber et al (Lieber et al. 2004) fed male Sprague-Dawley rats 
a synthetic liquid high fat diet (71% of calories), rich in unsaturated fat, ad libitum 
for 3 weeks which produced steatohepatitis with early fibrosis. This was associated 
with CYP2E1 induction, oxidative stress, increased hepatic TNFα concentrations, 
structural mitochondrial abnormalities, and hyperinsulinaemia (Lieber et al. 2004). 
Further models of high fat diet induced steatohepatitis in rats have since been 
published including the use of a high fat (58%), high calorie, solid diet, containing 
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predominantly saturated fat, more akin to the human intake (Svegliati-Baroni et al. 
2006). This well characterised model initially developed a perivenular and periportal 
steatosis by 4 weeks followed by progression to diffuse steatohepatitis by 3 months, 
and zone 3 fibrosis by 6 months, and was associated with obesity and hepatic insulin 
resistance (Svegliati-Baroni et al. 2006).  
 
Profound obesity can be difficult to induce in rodents when fed ad libitum (Zou et al. 
2006), hence intragastric feeding has been employed in an attempt to simulate human 
obesity. Gavage of a high fat (77%) emulsion diet, high in unsaturated fat, for 6 
weeks reliably induces steatohepatitis in rats (Zou et al. 2006). Similarly overfeeding 
C57Bl/6 mice a high fat (37%) liquid diet continuously via gastrostomy for 9 weeks 
has also been performed (Deng et al. 2005). This produced steatohepatitis similar to 
human NASH, associated with features of the metabolic syndrome, although it 
developed in less than 50% of mice. CYP2E1 was not induced, although CYP4A was 
elevated, and the development of steatohepatitis was not dependent on TNFα 
signalling. Steatohepatitis and fibrosis, with features of the metabolic syndrome, has 
also been induced in C57Bl/6 mice without gastrostomy but required 50 weeks of 
high fat feeding making this model of limited practical use (Ito et al. 2007). 
 
1.3.3.3 The methionine-choline deficient diet 
The methionine and choline deficient diet (MCDD) is a commonly employed model 
as, compared with some of the models above, it more rapidly and reliably leads to 
steatohepatitis. Histologically, livers in MCDD resemble human NASH, although 
weight loss and an associated improvement in peripheral insulin sensitivity means 
that it does not fully replicate the human syndrome. Therefore in an attempt to better 
model human disease some investigators use db/db mice, which when fed an MCDD 
diet do not lose weight and remain hyperleptinaemic and insulin resistant (Rinella et 
al. 2008). 
 
As discussed in Section 1.3.2.6 there is evidence that abnormalities of fatty acid 
metabolism may be key in the development of NASH in the MCDD mode, including 
impaired VLDL export. In addition, MCDD is commonly described as a model of 
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impaired mitochondrial β-oxidation (Koteish and Diehl 2002), although the evidence 
for this is limited (Rinella et al. 2008;Rizki et al. 2006). It does however, appear to 
be a model of increased (CYP2E1 and CYP4A mediated) microsomal oxidation, 
leading to increased free radical generation, oxidative stress and lipid peroxidation 
important in the pathogenesis of inflammation and liver cell necrosis (Weltman et al. 
1996). Lipid peroxidation also produces mitochondrial dysfunction, although 
alternatively the increased microsomal oxidation could be in response to impaired 
mitochondrial oxidation (Robertson et al. 2001). The TG accumulation and 
steatohepatitis is certainly worsened by impaired mitochondrial oxidation in PPARα 
null mice in the MCDD model (Kashireddy and Rao 2004), and PPARα agonists can 
ameliorate MCDD induced steatohepatitis, despite increased microsomal oxidation 
(Ip et al. 2003).  
 
These findings support an important role for intrahepatic fatty acids in promoting 
steatohepatitis, possibly through their effects to increase oxidative stress. Indeed, one 
recent study found a 2-3 fold increase in hepatic FFA levels in MCDD fed mice 
(Larter et al. 2008a). This may be important as FFAs can upregulate Fas/CD95 
receptors involved in apoptosis (Feldstein et al. 2003) and are directly cytotoxic via 
Jnk mediated mechanisms (Malhi et al. 2006). In keeping with this, previous studies 
have shown Jnk-1 activation to be important in the MCDD model (Schattenberg et al. 
2006). Scd-1 is downregulated in MCDD fed mice (Rizki et al. 2006) which may 
impair esterification of fatty acids, and is another explaination for elevated 
intrahepatic FFAs following MCDD. 
 
Studies of LPL activation in the MCDD model provide further evidence for a 
deleterious effect of FFAs on hepatic inflammation. Activation of LPL enhanced 
fatty acid oxidation, upregulating PPARα, CYP4a10 and acyl CoA oxidase, and also 
reducing pro-inflammatory cytokine expression and hepatic inflammation (Yu et al. 
2007). No differences were found in fatty acid uptake or de novo lipogenesis gene 
expression. 
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1.3.3.4 Other models involving methyl donor metabolism 
The above discussion of the MCDD model suggests that abnormalities of fatty acid 
metabolism are likely to be important in its pathogenesis, but methionine also has an 
important metabolic role as a methyl donor (Li and Vance 2008). Other rodent 
models involving methyl donor metabolism have provided further insights into the 
MCDD model. It can be seen from Figure 1.3 that S-adenosyl methionine acts as an 
important methyl donor following its conversion from methionine. Mice lacking the 
hepatic enzyme responsible for this reaction (methionine adenosyltransferase-1A 
[Mat1a]) have markedly reduced S-adenosyl methionine in the liver and have 
corresponding hypermethionaemia (Lu et al. 2001). These mice develop steatosis but 
do not develop periportal inflammation until 8 months of age, on a normal diet. This 
is associated with depletion of hepatic antioxidants (glutathione) and an increase in 
expression of multiple genes involved with the inflammatory response including; 
metallothioneins 1 and 2, Fas antigen, and IL-10 (Lu et al. 2001). They also have 
reduced expression of CYP4As, involved in fatty acid oxidation. Analogous to the 
MCDD model, Mat1a knockout mice are sensitive to choline deficiency and develop 
severe macrovesicular steatosis when placed on a CDD. However, the presence of 
steatohepatitis was not reported, albeit after only 6 days of dietary intervention (Lu et 
al. 2001), which may be too early to compare with the steatohepatitis seen in MCDD 
(Vetelainen et al. 2007).  
 
Pemt -/- mice lack the enzyme necessary for the methionine-dependent conversion of 
PE to PC and, when fed a diet devoid of choline, rapidly develop steatohepatitis. 
Although this is not a practical model of NAFLD, as mice die of liver failure within a 
few days of commencing the diet, it emphasises the importance of the PEMT 
pathway in maintining phosphatidylcholine synthesis when dietary choline is low 
(Walkey et al. 1998). These mice have similar histology and low circulating TGs to 
the MCDD fed mice consistent with impaired VLDL export due to reduced 
phosphatidylcholine availability. Antioxidant levels were not measured (although 
they would be predicted to be low), whereas bile acids were significantly increased, 
presumably relating to the role of phospholipids in the secretion of bile. This may be 
significant given the toxic effect of bile acids on hepatocytes (McNeilly et al. 2010). 
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The authors suggest altered membrane permeability may contribute to the 
pathogenesis of the Pemt-/- phenotype which may also be relevant in the MCDD 
model (Walkey et al. 1998). 
 
1.3.3.5 Oxidative stress and NASH 
It follows from the above the oxidative stress is likely to play an important role in the 
development of NASH. Indeed, patients with NASH have greater hepatic oxidative 
stress than those with steatosis (Sanyal et al. 2001). Glutathione is an essential 
hepatic antioxidant whose metabolism is closely linked with methionine as described 
above. Its synthesis is regulated by both glutathione synthase, and the catalytic 
subunit of the glutamate cysteine ligase (Chen et al. 2007). Accordingly, hepatocyte 
specifc disruption of the glutamate cysteine ligase encoding Gclc gene, leads to 
steatosis with progressive inflammation, lipid peroxidation, mitochondrial 
dysfunction and death from liver failure by one month of age in mice (Chen et al. 
2007). In contrast, vitamin E supplementation reduced MCDD induced inflammation 
and oxidative stress, although glutathione repletion via L-2-oxothiazolidine-4-
carboxylate failed to have the same effect (Phung et al. 2009). 
 
Nuclear respiratory factor (NRF) 1 and 2 are ubiquitous transcription factors 
important in mitochondrial DNA transcription and replication, and the response to 
oxidative stress e.g. inducing glutathione synthase via the antioxidative response 
element (Lu 2008). Liver specific knockout of Nrf1 in mice leads to steatohepatitis 
by 4 weeks of age, and the development of pericentral and pericellular fibrosis after 4 
months, followed by subsequent development of hepatic adenomas and carcinomas 
(Xu et al. 2005). Similar to mechanisms described in MCDD mice, this is associated 
with CYP4A upregulation and oxidative stress, suggesting that impaired 
mitochondrial oxidation increases the less efficient ROS producing microsomal 
oxidation which, when coupled with impaired antioxidant defences, produces 
steatohepatitis (Xu et al. 2005). Similarly, Nrf2 knockouts are more susceptible to 
MCDD induced steatohepatitis (Chowdhry et al. 2010;Sugimoto et al. 2010). 
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1.3.3.6 Pro-inflammatory cytokines and NASH 
The pro-inflammatory cytokine TNFα is secreted from both adipose tissue and 
hepatocytes and is an obvious candidate to influence the development of NASH. 
TNFα has a number of actions including activating the protein kinase I-κ-B kinase-β 
(IKKβ) which interferes with insulin signalling and helps activate the nuclear 
transcription factor NFκB, which itself promotes expression of the pro-inflammatory 
cytokines IL-6 and IL-8 (Perkins 2007). Other effects include antagonism of 
adiponectin and mitochondrial damage, triggering apoptosis (Jou et al. 2008). 
Cytokines may also modulate fatty acid metabolism e.g. TNFα inhibits the effects of 
insulin to suppress lipolysis, and IL-6 also promotes lipolysis (van Hall G. et al. 
2003), whereas conversely FFAs can also activate TNFα and NFκB (Feldstein et al. 
2004).  
 
TNFα expression is upregulated in MCDD fed mice (Yu et al. 2006), and its role in 
propagating steatohepatitis has been investigated using TNFα null mice, as well as 
TNF receptor 1 (TNFR1) knockouts. Initial findings suggested that TNFα is not 
essential for the development of steatohepatitis in MCDD mice, suggesting that 
NFκB activation is more important (Dela et al. 2005;Kirsch et al. 2006). However, a 
study in Tnfr1 and Tnfr2 double knockouts did show reduced development of 
steatohepatitis and liver fibrosis in the MCDD model over an 8 week period, 
although TG accumulation was also reduced (Tomita et al. 2006). Alanine 
aminotransferase (ALT) and Tgfb expression was unchanged between groups. 
Further support for a role of TNFα comes from studies using pentoxifylline which 
reduces TNFα production and attenuated steatohepatitis in MCDD fed mice, 
although glutathione levels were also increased by this treatment (Koppe et al. 2004). 
A role for IL-6 is supported by reduced MCDD induced liver inflammation in IL-6 
null mice (Mas et al. 2009). Osteopontin is another pro-inflammatory cytokine 
secreted from hepatocytes and macrophages which appears to be important in the 
pathogenesis of NASH (Sahai et al. 2004a;Sahai et al. 2004b).  
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A number of other factors including angiotensin II, plasminogen activator inhibitor-1, 
macrophage colony stimulating factor have also been implicated in the pathogenesis 
of NASH (Jou et al. 2008). 
 
1.3.3.7 Adipocytokines and NASH 
The role of leptin deficiency and leptin resistance in the pathogenesis of steatosis and 
progression to steatohepatitis has been discussed in Section 1.3.3.1. In contrast to 
leptin, serum adiponectin levels inversely correlate with hepatic fat stores and insulin 
resistance in humans (Bugianesi et al. 2005). It is implicated in both the development 
and progression of NAFLD due to effects modulating lipid metabolism, promoting 
FFA oxidation and inhibiting lipogenesis (Yamauchi et al. 2002), and levels have 
been found to be lower in individuals with NASH versus steatosis (Hui et al. 2004). 
Adiponectin also has anti-inflammatory properties, inhibiting TNFα (Masaki et al. 
2004). Indeed, recombinant adiponectin decreased steatosis and ALT in ob/ob mice 
(Xu et al. 2003). MCDD fed to mice unable to upregulate adiponectin leads to 
increased TG accumulation, steatohepatitis and fibrosis (Ikejima et al. 
2007;Okumura et al. 2006). Whether these effects are due to anti-inflammatory or 
anti-lipogenic effects of adiponectin are unclear.  
 
Using adiponectin knockouts and mice lacking AMP Kinase (AMPK) activity, a 
recent study tried to dissect the role of adiponectin in PPARγ agonist mediated 
improvements in MCDD induced steatohepatitis (Da Silva Morais et al. 2009). The 
results suggest that upregulation of adiponectin is an important mediator of the 
reduction in steatohepatitis seen with pioglitazone, but that suppression of SREBP1c 
rather than any effect on AMPK or PPARα is important (Da Silva Morais et al. 2009). 
Others have described reduced hepatic AMPK phosphorylation and PPARα activity 
in MCDD fed mice, despite elevated adiponectin levels, suggesting possible 
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1.3.3.8 Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) null 
mice 
A final murine model of NASH which may involve abnormal fatty acid metabolism 
involves the Pten tumour suppressor gene. Pten encodes a lipid phosphatase involved 
in the regulation of pathways down-stream of phosphoinositide-3 (PI3) kinase, and 
helps to suppress apoptosis, cell proliferation and oncogenesis (Stiles et al. 2004). 
Pten knockout mice are unviable, whereas liver specific Pten knockout mice develop 
hepatomegaly and steatohepatitis histologically resembling human NASH by 10 
weeks of age (Stiles et al. 2004). There is no preceding stage of simple steatosis 
however, and fibrosis does not develop until around 7 months of age. Mice are also 
prone to the subsequent development of hepatic adenomas and carcinomas. Of note, 
presumably relating to the role of PI3 kinase in insulin signalling (Stiles et al. 2004), 
these mice have increased hepatic insulin sensitivity, which could partially explain 
the increased de novo lipogenesis, although TG export is also increased which would 
normally be suppressed by insulin. Gene expression studies also suggest upregulation 
of mitochondrial and peroxisomal fatty acid oxidation, as well as PPARγ, associated 
with induction of adipogenic genes such as aP2 (Horie et al. 2004). 
 
These mice provide evidence that insulin resistance (and hyperleptinaemia) is not 
essential for the development of steatohepatitis, and that retained sensitivity to 
insulin within the liver may be important (Stiles et al. 2004). Intrahepatic FFAs were 
also measured in this model although they were not elevated (Horie et al. 2004). It is 
not entirely clear why these mice develop inflammation/steatohepatitis and whether 
it is separate from the process of tumorigenesis. Potential factors include oxidative 
stress, and hydrogen peroxide levels are markedly increased by week 10 (7 fold 
greater than controls), possibly due to peroxisomal oxidation. Additionally, altered 
PI3 kinase signalling may activate NFκB dependent cytokine induction (Watanabe et 
al. 2007). Hepatic Pten deficiency also leads to abnormalities of cell survival 
signalling, but perhaps surprisingly, there is no increase in apoptosis at 10 or 40 
weeks (Horie et al. 2004). DNA microarray technology has been used to assess 
candidate genes for inflammation in this model (Sato et al. 2006). Interestingly a 
number of candidates genes for inflammation included genes involved with both 
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fatty acid and anti-oxidant metabolism e.g. Cpt1a, acyl CoA oxidase, and glutathione 
S-transferase mu6. Other candidate genes included secreted phosphoprotein 1, 
pyruvate dehydrogenase kinase 4, suppressors of cytokine signalling 3, and tissue 
transglutaminase  (Sato et al. 2006). 
 
Interestingly, genome wide association studies have suggestd another phospholipase 
may be important in the progression to NASH. A SNP in the patatin-like 
phospholipase 3 gene (PNPLA3) was associated with the development of steatosis 
and NASH independently of BMI or insulin resistance (Romeo et al. 2008). The 
precise physiological role of PNPLA3 has yet to be fully elucidated but in vitro 
studies suggest it posseses both lipolytic and lipogenic properties, providing further 
support for a role of abnormalitites of fatty acid metabolism in the progression of 
NAFLD (Romeo et al. 2010). 
 
1.3.4 Liver fibrosis in NAFLD 
 
Over the past two decades there has been a marked increase in our understanding of 
the molecular mechanisms influencing hepatic fibrosis, aided by a number of 
available models. Models of liver fibrosis can be classified into three groups (Iredale 
2007): cell culture models, studies of human biopsy/samples from hepatic resection, 
and animal models. Each model has their advantages and disadvantages e.g. cell 
culture allows the very detailed study of cell behaviour amenable to manipulation, 
but may be difficult to extrapolate to the complex in vivo environment; conversely, 
human studies are necessary to confirm in vitro or animal studies, but sequential 
biopsy studies are not feasible because of ethical concerns, which often limits studies 
to being cross-sectional in nature; animal studies can overcome some of these 
limitations, allowing serial profiling of tissues from homogenous groups (including 
genetically modified mice), but are limited due to their inherent “non-human” nature 
(Iredale 2007). 
 
The two commonest models of experimental liver fibrosis are toxin induced damage 
(e.g. carbon tetrachloride [CCl4]) and bile duct ligation. Other models include 
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expression of hepatotropic viral proteins e.g. HbSAg, with some dietary models e.g. 
MCDD also inducing mild fibrosis.  
 
Current evidence suggests that inflammation drives the development of liver fibrosis, 
with a correlation between inflammatory features and fibrosis in human studies. 
Indeed, histological studies show sites of inflammation and fibrosis to be co-
localised, with animal studies manipulating the inflammatory response often 
attenuating the fibrotic response (Iredale 2007). Both innate and adaptive immune 
mechanisms are involved in the response to liver injury, and involve activation of 
resident cells within the liver as well as inflammatory cells from extra-hepatic 
sources. The major cellular and molecular mediators of hepatic fibrogenesis will be 
discussed in brief here. 
 
1.3.4.1 Hepatic stellate cells  
Models of fibrosis have elucidated some of the key players in the development and 
resolution of liver fibrosis, including hepatic stellate cells. Von Kupffer first 
described these star shaped cells or sternzellen in 1876, prior to being later termed Ito 
cells, and currently hepatic stellate cells (HSCs) (Iredale 2007). HSCs are lipid and 
vitamin A containing cells residing in the space of Disse where the ECM is rich in 
basement membrane type collagens (Geerts 2001). In response to inflammation, or 
injury, they develop a myofibroblast like phenotype, expressing contractile proteins 
such as alpha smooth muscle actin (αSMA) (Rockey et al. 1992). Proposed activators 
of HSCs include platelet-derived growth factor (PDGF), endothelin-1 (ET-1), 
fibroblast growth factor, vascular endothelial growth factor (VEGF), and TGFβ (Eng 
and Friedman 2000). Conversely, activated HSCs express surface molecules, e.g. 
intercellular adhesion molecule-1 (ICAM-1) which can recruit immune cells. 
 
As with all myofibroblasts, activated HSCs are essential for wound healing, 
proliferating and secreting fibrillar collagens in response to injury, thereby laying 
down the fibrotic ECM. Recent evidence suggests other sources of myofibroblasts 
such as the bone marrow may be important (Forbes et al. 2004). Indeed, within the 
liver different populations of activated HSCs may exist. HSCs also secrete factors 
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regulating ECM degradation (matrix metalloproteinases and their inhibitors-see 
below), HSC chemotaxis, and leucocyte chemoattraction (Iredale 2007). In contrast, 
HSC apoptosis is a feature of resolving fibrosis (Iredale et al. 1998). Activation of 
HSCs has been shown to predict progression to fibrosis in humans with NAFLD 
(Feldstein et al. 2005). 
 
1.3.4.2 Platelets 
Platelets are often recruited early in response to injury, forming part of the innate 
immune response and limiting blood loss. They secrete TGFβ and PDGF, both 
potent fibrogenic cytokines which activate HSCs (Pinzani et al. 1989).    
 
1.3.4.3 Neutrophils 
Neutrophils also represent an early component of the innate immune response and 
form part of the inflammatory cell infiltrate in NASH (Kleiner et al. 2005). However, 
studies of mice with dysfunctional or depleted neutrophils suggest that this rapid 
influx of neutrophils does not significantly influence the development of fibrosis 
(Saito et al. 2003;Xu et al. 2004). 
 
1.3.4.4 Macrophages  
Macrophages play a number of roles in hepatic fibrosis (and resolution) including, 
HSC activation, cell killing, regulation of inflammatory cells, and modification of the 
fibrotic and healing processes, and are recruited both from resident Kupffer cells as 
well as from circulating bone marrow derived monocytes (Henderson and Iredale 
2007). Recent evidence suggests that different populations of macrophages may exist 
with opposing roles within the liver (Henderson and Iredale 2007). They have been 
broadly classified as classically and alternatively activated macrophages. The 
classical response leads to pro-inflammatory cytokine production in response to a 
number of triggers including a Th1 CD4+ response (via interferon gamma) and 
degraded matrix components. In contrast, the alternatively activated macrophages 
depend on a Th2 (IL-4) response, and possibly glucocorticoids, producing an anti-
inflammatory response, including production of IL-10 and TGFβ (Henderson and 
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Iredale 2007). In the presence of myofibroblasts, this latter response is also pro-
fibrotic, whereas the classical response is more lytic.   
 
The timing of macrophage activation is also crucial. In an elegant study using 
transgenic mice (CD11b DTR) in which macrophages can be depleted by the 
administration of diphtheria toxin, Duffield et al (Duffield et al. 2005) demonstrated 
that macrophages play opposing roles at differing stages of liver injury and repair in 
a CCl4 model. Macrophage depletion in the fibrotic stage reduced scarring and 
myofibroblast activation, whereas depletion during the recovery phase impaired 
resolution of fibrosis. It is unclear whether this represents differing populations or 
highly plastic macrophages. 
 
Macrophages also regulate HSC apoptosis, an essential component in the resolution 
of fibrosis, firstly by promoting degradation of type 1 collagen which acts as a 
survival signal for HSCs (Friedman 2005), and also by expressing specific apoptotic 
signals (Issa et al. 2003). Scar associated macrophages are also the source of MMP-
13, the major collagenase in mice, without which resolution of fibrosis is impaired 
(Fallowfield et al. 2007). 
 
1.3.4.5 Matrix metalloproteinases 
Matrix metalloproteinases (MMPs), and their inhibitors (tissue inhibitors of 
metalloproteinases or TIMPs, types 1-4) regulate degradation of ECM. They both 
play an important role in the development of fibrosis, as well as in maintaining 
normal tissue homeostasis (Han 2006). Indeed, polymorphisms in the genes encoding 
MMPs (1, 3, and 9) may influence the development of liver fibrosis in humans 
(Okamoto et al. 2005). 
 
The MMPs are a family of zinc-dependent metallo-endoproteinases which can be 
classified as in Table 1.3 (Hemmann et al. 2007). Some overlap may occur e.g. 
MMP-2 also degrades fibrillar type I and II collagens, and species specific 
differences also exist e.g. there is no rodent homologue of MMP-1 (collagenase 1) 
(Hemmann et al. 2007). They are generally secreted into the extracellular space as 
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pro-enzymes, providing a further level of regulation, with activation by complex 
interactions with MT-MMPs and TIMPs. Once activated MMPs are mainly regulated 
by the binding of inhibitory TIMPs. 
 
Table 1.3 Classification of matrix metalloproteinases (MMPs)  
Adopted from (Consolo et al. 2009). 
Class MMP number. Alternative name 
Collagenases MMP-1 Collagenase-1 
 MMP-8 Neutrophil collagenase 
 MMP-13 Collagenase 3 
 MMP-18 Collagenase 4 
Gelatinases MMP-2 Gelatinase-A 
 MMP-9 Gelatinase-B 
Stromelysins MMP-3 Stromelysin-1 
 MMP-10 Stromelysin-2 
 MMP-11 Stromelysin-3 
Matrilysins MMP-7 Matrilysin PU MP 







 MMP-16 MT3-MMP 
 MMP-17 MT4-MMP 
 MMP-24 MT5_-MMP 
 MMP-25 MT6-MMP 
Others MMP-12 Macrophage metalloelastase 
 MMP-19 RASI 1 
 MMP-20 Enamelysin 
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Degradation of the ECM appears to help initiate hepatic fibrosis, releasing hepatic 
stellate cells from the “normal” matrix, rich in collagen type IV, and leading to their 
activation (Arthur 2000). Models of fibrosis demonstrate that early changes include 
upregulation of MMP-13 and MMP-3 (Watanabe et al. 2000). In the later stages of 
fibrosis this is followed by increased expression of MMPs -2, 9 and 14 (Arthur 2000). 
Activated Kupffer cells are thought to be the main source of MMP-13 and MMP-9, 
whereas activated HSCs are the principal source of MMP-2 and MMP-3 (Arthur 
2000).  
 
Whilst some of these changes in MMP activity may lead to further HSC activation, 
the accumulation of ECM in fibrotic livers suggests MMP matrix degradation is 
inadequate. TIMP-1 and TIMP-2 are potent inhibitors of MMPs secreted by activated 
HSCs and in liver injury are upregulated in response to inflammatory cytokines 
including IL-1b, IL-6, and IL-11, as well as TNFα and TGFβ (Roeb et al. 1993). 
Animal studies demonstrate both TIMP-1 and TIMP-2 are upregulated rapidly in 
models of fibrosis, persisting for the duration of liver injury. Low levels are seen 
during resolution (Arthur 2000). Similarly, TIMP expression is increased in human 
fibrosis (Benyon et al. 1996). The ratio of MMPs and TIMPs is critical for the 
development and resolution of fibrosis, although factors determining their temporal 
expression remain incompletely understood. 
 
1.3.4.6 Factors influencing development of fibrosis in NAFLD 
The development of fibrosis in NAFLD is highly variable, with a recent study 
suggesting the only predictors being the presence of portal tract fibrosis on initial 
biopsy, or weight gain (Ekstedt et al. 2006), the latter suggesting abnormalities of 
fatty acid metabolism may be important. Similarly, cross sectional studies have 
confirmed the association between obesity and the likelihood of hepatic fibrosis, 
along with increasing age and diabetes (Angulo et al. 1999).  
 
The factors determining progression to fibrosis in NAFLD are incompletely 
understood, but it follows that if the factors promoting (chronic) inflammation persist, 
associated with the appropriate millieu of cytokines, then this will also promote 
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fibrosis. Therefore in addition to influencing TG accumulation, abnormalities of 
hepatic TG metabolism may also contribute to the development of liver fibrosis. 
Probably the best evidence that abnormalities of intrahepatic fatty acid/TG 
metabolism can influence liver outcomes independently of hepatic TG levels comes 
from studies using Dgat2 ASO treatment which reduced steatosis but increased 
fibrosis and intrahepatic FFAs in methione-choline deficient db/db mice (Yamaguchi 
et al. 2007). Impaired VLDL export may also sensitise the liver to toxic insults as 
evidenced by an increase in lipopolysaccharide induced inflammation in mice with 
reduced hepatic Mttp expression compared to controls, albeit that baseline TGs were 
markedly higher in the reduced Mttp expression cohort (Bjorkegren et al. 2002). 
 
In keeping with the mechanisms discussed, TGFβ appears to be involved in the 
progession to fibrosis in MCDD induced NASH, with a TGFβ inhibitor reducing 
fibrosis and hepatic stellate cell activation (Uno et al. 2008). Interestingly, the 
inhibitor also appeared to upregulate hepatic FFA oxidation which could explain the 
reduced inflammation that was also seen. Accordingly, Tgfb expression is 
upregulated in MCDD rodents along with changes in both MMP and TIMP 
expression, with increased mRNA transcripts of Timp-1, Mmp-2 and 9, and reduced 
Mmp-13 expression after 12 weeks of MCDD in rats (Mu et al. 2010). Similarly, 
circulating TIMP1 levels have been found to be increased in patients with NASH and 
fibrosis (Miele et al. 2009). The role of MMPs in NASH has not been well studied. 
One study found a different MMP profile in patients with NASH than in other 
chronic liver diseases, with increased MPP 9 and 10 expression although patients 
may have been at different stages in disease progression (Ljumovic et al. 2004). 
 
Comparisons of ob/ob and db/db mice placed on an MCDD suggest that leptin is 
another factor important for the progression of NAFLD as ob/ob mice develop less 
inflammation and fibrosis than db/db and wild type mice (Sahai et al. 2004b). The 
authors suggest this is due to increased leptin mediated osteopontin expression via 
the short form leptin receptor (Ob-Ra). A number of other studies have investigated 
the role of leptin in the progression of liver disease which suggest that leptin is 
essential for the development of hepatic fibrosis, increasing TGFβ in Kupffer and 
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sinusoidal epithelial cells and preventing apoptosis of HSCs (Ikejima et al. 
2007;Leclercq et al. 2002). 
 
In contrast to leptin, adiponectin- which also modulates fatty acid metabolism- is an 
anti-fibrogenic adipocytokine, and acts to disrupt leptin signalling (Handy et al. 
2010). Adiponectin, inhibits hepatic stellate cells (Adachi et al. 2008), and mice 
deficient in adiponectin develop worse carbon tetrachloride induced liver fibrosis 
(Kamada et al. 2003). In addition, MCDD fed mice unable to upregulate adiponectin 
also develop increased TG accumulation, steatohepatitis and fibrosis (Ikejima et al. 
2007;Okumura et al. 2006).  
 
The effects of angiotensin II on hypertension, cardiac and renal disease are well 
known (Timmermans et al. 1993), but the renin angiotensin system may also be 
important in liver disease as hepatic stellate cells possess angiotensin II type 1 
receptors (Yoneda et al. 2009). Furthermore, angiotensinogen, the precursor to 
angiotensin II can be synthesised in adipose tissue, and may also influence fat 
distribution (Giacchetti et al. 2000). There is preliminary evidence that angiotensin 
receptor blockers may reduce hepatic fibrosis in NAFLD (Georgescu 2008). 
 
1.4 GLUCOCORTICOIDS IN NAFLD 
 
From the above it is clear that a complex series of factors may influence liver fat 
accumulation and the chances of progression to NASH and thence to fibrosis. 
Although relevant factors are numerous, a few may influence each of these processes, 
including fatty acid metabolism itself and hepatic inflammation. In addition to 
exploring the fundamental changes in fatty acid metabolism which occur in NAFLD, 
within this thesis I also investigated the modulatory role of glucocorticoids. Here I 
provide a brief review of the determinants of glucocorticoid actions in the liver and 
evidence that their disruption has a bearing on NAFLD. 
 
The liver has a central role in maintaining glucose and lipid homeostasis. The liver is 
also the principal site for the metabolism of glucocorticoids, as shown in Figure 1.4, 
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and may therefore influence both local and systemic glucocorticoid concentrations. 
Given the wide ranging actions of glucocorticoids, abnormalities of intrahepatic 
glucocorticoid metabolism may lead to adverse metabolic, as well as anti-
inflammatory effects. 
 
Figure 1.4 Pathways of cortisol metabolism 
Cortisol (F) and cortisone (E) can be interconverted by the 11β-hydroxysteroid 
dehydrogenases, and are principally metabolised by the A ring reductases (5α–reductases 
and/or 5β-reductase) in the liver as shown. The resultant dihydrometabolites are then 




























1.4.1 Enzymes regulating glucocorticoid levels 
 
Tissue concentrations of cortisol, the principal glucocorticoid in humans, are 
controlled not only by circulating levels, under the influence of the hypothalamic 
pituitary adrenal (HPA) axis, but also by local metabolism (see Figure 1.4). There is 
accruing evidence that abnormalities of glucocorticoid metabolism may contribute to 
the metabolic consequences of obesity. In particular, much research has focussed on 
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the role of the enzyme 11beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1), 
which is highly expressed in both adipose tissue and the liver, acting to amplify local 
glucocorticoid levels and glucocorticoid receptor activation within tissues (reviewed 
in (Seckl and Walker 2001;Tomlinson et al. 2004)). Cortisol (corticosterone in 
rodents) is metabolised by both A-ring reductases (5α− and 5β-reductase) and 3α-
hydroxysteroid dehydrogenase (3α-HSD) which convert glucocorticoids to their 
tetrahydrometabolites for subsequent conjugation and excretion in urine (Tomlinson 
et al. 2004). In contrast, cortisone (11dehydro-corticosterone in rodents) is not 
metabolised by 5α−reductase. (see Figure 1.4). Further metabolism by 20α− and 
20β− hydroxysteroid dehydrogenases leads to the production of cortols and 
cortolones. Specific alterations in these enzymes may also influence circulating 
glucocorticoid levels and HPA axis function. It follows that alterations in both local 
and systemic glucocorticoid levels could influence the development and progression 
of NAFLD e.g. through glucocorticoid’s effects on fatty acid metabolism at the 
adipocyte or liver, or through effects on peripheral insulin sensitivity to drive 
hyperinsulinaemia. 
 
1.4.2 Glucocorticoids and fatty acid metabolism 
 
In addition to their role in cellular growth and development, glucocorticoids have 
multi-systemic effects that are essential for survival in times of stress, influencing the 
regulation of blood pressure, salt and water balance, immune function and cellular 
energy metabolism. In the short-term, these acute effects contribute to adaptive 
responses. For example, glucocorticoids are catabolic, increasing availability of 
substrates for mitochondrial oxidation (from glucose, amino acids, and fatty acids). 
The consequences of failure of these adaptive responses is clearly demonstrated in 
the syndrome of adrenal insufficiency (in Addison’s disease or ACTH deficiency), 
characterised by lethargy, weight loss and postural hypotension, in which severe 
stress or sepsis can be life-threatening (Addison 1855). If sustained in the long term, 
however, the effects of glucocorticoids may become maladaptive. Chronic 
glucocorticoid excess (Cushing’s syndrome) leads to morbidity and mortality 
through a variety of factors including obesity, osteoporosis, hypertension, 
 - 68 - 
hyperglycaemia, and impaired response to infection (Cushing 1912). These chronic 
adverse effects are important, not least because large numbers of patients receive 
treatment with synthetic glucocorticoids for a wide range of inflammatory conditions 
such as rheumatoid arthritis and asthma (Wei et al. 2004). 
 
Although many of the manifestations of Cushing’s syndrome are predictable on the 
basis of the acute effects of glucocorticoids (eg to raise blood pressure, induce 
insulin resistance, promote skeletal muscle wasting, and elevate plasma glucose) it 
appears to be a paradox that the acute lipolytic effect of glucocorticoids is not 
manifest in long-term weight loss in Cushing’s syndrome. Indeed, chronic 
glucocorticoid excess in rodents usually induces weight loss rather than weight gain 
(Elliott et al. 1971), but some limited studies in humans with Cushing’s syndrome 
suggest that lipolytic rates are reduced or unaltered, rather than enhanced 
(Birkenhager et al. 1976;Saunders et al. 1980). Moreover, in Cushing’s syndrome 
there is marked redistribution of body fat, with accumulation in depots in the 
abdomen, nape of the neck and cheeks, but wasting of fat in many subcutaneous 
adipose compartments. There may also be excessive accumulation of triglycerides in 
‘ectopic’ sites such as the liver in Cushing’s syndrome (Rockall et al. 2003). This 
pattern of central fat accumulation, associated with glucose intolerance and 
hypertension, results in remarkable similarities between the clinical features of 
Cushing’s syndrome and those of the Metabolic Syndrome (Reaven and Hoffman 
1987), and could in part relate to glucocorticoid effects on fatty acid metabolism. 
 
Based on the key studies summarised in Table 1.4, it is clear that glucocorticoids 
have important acute and long-term effects on fatty acid metabolism, but the data 
available at present is not conclusive. In the following sections I will review the role 



































































   In vivo in humans  
 In vitro Acute Chronic 11β-HSD1 inhibition 
Lipolysis     
  - Adipose ↑ (Baxter and Forsham 
1972;Slavin et al. 
1994;Villena et al. 2004) 
↑ (Divertie et 
al. 1991) 
↑ (Gravholt et al. 2002;Krsek et al. 2006), 
↔ (Miyoshi et al. 1988;Saunders et al. 1980),  
↓ (Birkenhager et al. 1976)* 
↓ (Berthiaume et al. 2007a) 
 
  - Intravascular ↑ (Appel and Fried 
1992;Fried et al. 
1993;Rebuffe-Scrive et 
al. 1988) 
↑ (Samra et al. 
1996a) 
? ↑ ** ↔ in adipose 
↑ in muscle  




↑ (Hillgartner et al. 
1995;Wang et al. 
2004;Williams and 
Berdanier 1982) 
Unknown Unknown ↓ in adipose  
↔ in liver  
(Berthiaume et al. 2007a) 
 
Oxidation ?↑(Short et al. 2004), 
↓(Letteron et al. 1997) 
↑ (Djurhuus et 
al. 2002) 
↔ (Burt et al. 2006;Burt et al. 2007) ↑ (Berthiaume et al. 2007a) 
 
VLDL export ↑ (Wang et al. 1995) Unknown ↑ (Taskinen et al. 1983) ↓ (Berthiaume et al. 2007b) 
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1.4.3 Acute effects of glucocorticoids on adipose tissue and intravascular 
lipolysis: results of in vitro studies 
A great deal of effort has been expended on studies in cells in culture which may or 
may not reflect measurements undertaken in vivo (Lillioja et al. 1986). Re-
esterification is also difficult to interpret in vitro due to factors such as the 
concentration of albumin in the culture medium (Edens et al. 1990). Most 
importantly, adipocyte differentiation in vitro is dependent on high concentrations of 
insulin and glucocorticoids, so that many of the effects ascribed to direct ‘regulation’ 
of gene transcription may in fact be indirect manifestations of the change in cellular 
phenotype in the presence of glucocorticoids. Nevertheless, in vitro studies have 
generally shown increased FFA release from adipocytes in response to 
glucocorticoids (reviewed in (Baxter and Forsham 1972)). Cortisol has also been 
shown to amplify the induction of lipolysis by catecholamines in cells primed with 
GH, but in the presence of insulin, reduced the basal lipolytic rate and responsiveness 
to catecholamines (Ottosson et al. 2000).  
 
Both Hsl (Slavin et al. 1994) and Atgl are induced by glucocorticoids (Villena et al. 
2004). In human adipocytes LPL activity and mRNA expression are also increased 
by glucocorticoids with differences between sexes and adipose depots studied (Fried 
et al. 1993;Ong et al. 1992). Omental adipose tissue has a higher concentration of 
glucocorticoid receptors (Rebuffe-Scrive et al. 1990) and showed a greater response 
to dexamethasone than subcutaneous fat, especially in men (Fried et al. 1993). 
Synergistic increases in LPL activity in response to insulin and dexamethasone were 
seen in both depots and were not fully explained by increased mRNA transcription, 
suggesting post-translational modification of LPL in the presence of glucocorticoids, 
e.g. reducing LPL degradation (Appel and Fried 1992). Conversely, the 
glucocorticoid antagonist RU38486 reduced adipose LPL activity in vitro (Ottosson 
et al. 1995). 
 
These findings suggest that glucocorticoids may increase both the uptake and 
turnover of fatty acids in adipose tissue and, analogous to their effects to increase 
glucose/glycogen turnover, may modulate the dynamic responsiveness to other 
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stimuli such as insulin or catecholamines, potentially promoting the flux of FFA to 
the liver.  
 
1.4.3.1 Acute effects of glucocorticoids on adipose tissue and intravascular lipolysis: 
results of in vivo studies 
A variety of techniques are commonly employed to study lipid metabolism in vivo. 
Fatty acid turnover can be measured using isotope dilution techniques involving 
infusion of stable or radioactive isotopomers of fatty acids (e.g. 13C1-palmitate) and 
whole body lipolysis can also be estimated using glycerol tracers to measure rates of 
appearance (Ra)(Wolfe and Peters 1987). Regional rates of lipolysis can be assessed 
by arteriovenous (A-V) sampling or microdialysis techniques measuring glycerol 
concentrations (Frayn et al. 1997). To minimise the influence of other hormones on 
lipolysis a pancreatic clamp can be employed by infusing somatostatin, with 
controlled insulin, growth hormone and occasionally glucagon replacement.  
 
Results of short-term infusions of glucocorticoids suggest that lipolysis is increased, 
as in the in vitro experiments, but that there are counter-regulatory effects mediated 
by other hormones. Thus, using a pancreatic clamp with very low dose insulin 
replacement, the Mayo Clinic group demonstrated a 60% increase in the Ra of 
palmitate in response to hydrocortisone infusion after 4-5 hours, clearly 
demonstrating the potential of glucocorticoids to promote adipose tissue lipolysis 
(Divertie et al. 1991). In contrast, without a pancreatic clamp Dineen et al (Dinneen 
et al. 1993) mimicked physiological cortisol concentrations using a combination of 
metyrapone (to reduce glucocorticoid production) and variable hydrocortisone 
infusion for 15 hours, and showed no difference in the fasting Ra of palmitate during 
relative hypercortisolaemia, although only a single premeal measurements was taken, 
so subtle changes could have been missed. However, hypercortisolaemia did increase 
the Ra of palmitate after a mixed meal, despite a higher post-prandial insulin 
response suggesting resistance to inhibition of lipolysis by insulin (Dinneen et al. 
1993).  It is not possible to delineate whether the observed increase in the Ra of 
palmitate was secondary to adipose tissue lipases or increased FFA spillover from 
LPL acting on circulating TG, but it appears that cortisol does increase FFA release 
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from circulating TGs (Samra et al. 1998), suggesting a combination of increased LPL 
activity and increased adipose lipolysis during acute hypercortisolaemia. 
 
Studies without tracer infusion have demonstrated that adrenaline and cortisol have 
synergistic effects on FFA concentrations during somatostatin administration (Pernet 
et al. 1986), but have no effect on the anti-lipolytic effect of insulin during 
hyperinsulinaemia (20mU/m2/min) (Clerc et al. 1986). Both growth hormone (GH) 
and glucocorticoids may influence sensitivity to adrenaline by reducing anti-lipolytic 
α2-adrenoreceptor availability (Djurhuus et al. 2004;Yip and Goodman 1999), but 
acute in vivo studies have demonstrated additive independent effects of GH and 
cortisol on lipolysis during a pancreatic clamp, suggesting separate mechanisms of 
action (Djurhuus et al. 2004). Perhaps crucially, glucocorticoids also increase pro-
lipolytic β-adrenergic receptor numbers via GR dependent mechanisms (Lacasa et al. 
1988;Nakada et al. 1987).  
 
Several investigators have explored differences in glucocorticoid effects in different 
regions of body fat, with somewhat inconsistent results. Samra et al (Samra et al. 
1998) induced supraphysiological plasma cortisol concentrations of ~1500nmol/l and 
measured increased systemic rates of lipolysis. However, subcutaneous adipose 
tissue lipolysis (measured by A-V difference in the anterior abdominal wall) was 
reduced and LPL activity (calculated from adipose tissue blood flow and TG 
extraction) was not altered (Samra et al. 1998), suggesting that the subcutaneous 
adipose tissue may be excluded from the acute lipolytic effect of cortisol. However, 
Djurhuus et al (Djurhuus et al. 2002), who also measured increased systemic rates of 
lipolysis, found contradictory results using microdialysis techniques: subcutaneous 
adipose lipolysis was increased in both abdominal and leg adipose compartments in 
response to hypercortisolaemia (~900nmol/) during a pancreatic clamp with low dose 
insulin replacement (Djurhuus et al. 2002). The discrepancies between these studies 
are most likely explained by the higher insulin levels in the study by Samra et al 
(Samra et al. 1998). The key experiment, comparing glucocorticoid effects on 




Further in vivo support for an acute effect of cortisol on lipolysis comes from studies 
blocking glucocorticoid release. Plasma cortisol levels follow a diurnal rhythm, 
peaking 2-4 hours before wakening in humans, and reaching a nadir around midnight. 
Studies have confirmed that these physiological variations in cortisol influence fuel 
availability at a tissue level, by demonstrating reduced subcutaneous adipose tissue 
lipolysis and LPL activity (by A-V difference technique) following abolition of the 
morning rise in cortisol using metyrapone (Samra et al. 1996a). No effect of 
glucocorticoids on adipose tissue blood flow or FFA re-esterification rates was 
demonstrated (Samra et al. 1996a). 
 
These results imply that acute elevations of cortisol within the normal physiological 
range can modulate adipose tissue function. In particular, effects on lipolysis may be 
most important when insulin levels are low, eg in patients with diabetes (Johnston et 
al. 1982;Schade et al. 1978) and when adrenaline levels are high. How this control is 
modulated in different adipose tissue depots remains, however, uncertain. 
 
1.4.3.2 Chronic effects of glucocorticoids on adipose tissue and intravascular 
lipolysis 
The above acute in vivo studies examined lipolysis in response to short term 
variations in cortisol levels lasting a number of hours. Few studies have examined 
the effects of prolonged administration of steroids, but these suggest that the acute 
induction of systemic lipolysis by glucocorticoids is not sustained, even if there may 
be ongoing enhanced lipolysis in subcutaneous adipose tissue. Gravholt et al found 
no change in systemic or leg adipose tissue lipolysis after one week of 30mg 
prednisolone/day, although subcutaneous abdominal adipose tissue lipolysis was 
increased (Gravholt et al. 2002). Miyoshi et al administered 50mg prednisolone/day 
for four days, and found no difference in rates of intracellular re-esterification or 
systemic lipolysis (Miyoshi et al. 1988). Similarly, Johnston et al found no difference 
in FFA concentrations, a surrogate marker of lipolysis, during partial insulin 
deficiency induced by somatostatin following 36-60 hours of 1mg tetracosactrin 
daily (Johnston et al. 1982). 
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Patients with Cushing’s syndrome are heterogeneous in their characteristics and 
degree of glucocorticoid excess. However, consistent with the lack of effect of more 
than a few hours of glucocorticoid administration on systemic lipolysis in healthy 
volunteers, tracer studies reveal either unaltered or reduced systemic rates of 
lipolysis in patients with Cushing’s syndrome when expressed as an absolute rate or 
relative to total body mass (Birkenhager et al. 1976;Saunders et al. 1980). However, 
in neither of these studies was the Ra of FFAs expressed relative to fat mass, or more 
specifically fat free mass (FFM), an indicator of resting energy expenditure (REE) 
considered by some authors to be the main determinant of FFA turnover. For 
example, an increase in FFA turnover in obesity is only measurable when it is 
expressed relative to FFM rather than total body mass (reviewed by (Koutsari and 
Jensen 2006)). Importantly, insulin levels are elevated in Cushing’s patients, possibly 
suppressing any lipolytic tendency (Saunders et al. 1980). Subcutaneous adipose 
tissue lipolysis may be selectively increased in patients with Cushing’s syndrome, at 
least when measured using microdialysis (Krsek et al. 2006), but biopsies of 
subcutaneous adipose tissue from such patients exhibit impaired lipolytic activity in 
vitro (Rebuffe-Scrive et al. 1988). Interestingly, LPL activity was increased in these 
biopsies when compared with both non-obese and obese controls, suggesting that 
contrasting regulation of LPL and intracellular lipolysis might explain some of the 
inconsistencies observed in vivo. However, LPL activity, as assessed by VLDL 
clearance, was unchanged following surgical treatment of Cushing’s syndrome 
(Taskinen et al. 1983). 
 
These somewhat inconsistent results suggest that chronic glucocorticoid excess is not 
associated with increased lipolysis measured at whole body level, although depot 
specific increases and compensatory decreases in lipolysis cannot be excluded. 
  
1.4.3.3 Adipocyte differentiation and cell size 
Compared to normal weight controls, individuals with Cushing’s syndrome have an 
approximately two-fold and five-fold increase in subcutaneous and intra-abdominal 
(visceral) fat respectively, although limb subcutaneous adipose tissue may be 
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reduced, contributing the classical “lemon on sticks” description of Cushing’s 
syndrome (Mayo-Smith et al. 1989). As well as regional differences in FFA 
metabolism, changes in adipocytes size and/or number may contribute to fat 
redistribution, with reduced adipocyte size seen in femoral adipose tissue in 
Cushing’s disease (Rebuffe-Scrive et al. 1992;Rebuffe-Scrive et al. 1988). It is 
unclear whether these changes in fat distribution directly influence insulin resistance 
or metabolic fluxes to the liver. 
 
1.4.3.4 Effects of glucocorticoids on de novo lipogenesis 
Although effects on lipolysis have attracted most research effort, altered regional 
lipid synthesis could also influence fat redistribution following chronic 
glucocorticoid excess. Insulin is the main hormone promoting fatty acid synthesis 
and, in contrast to their apparently opposing effects on lipolysis, glucocorticoids may 
act synergistically with insulin to upregulate lipogenesis. Studies of 
adrenalectomised rats suggest that glucocorticoids are necessary for the lipogenic 
response to refeeding after starvation (Williams and Berdanier 1982). In vitro, 
glucocorticoids are necessary to potentiate the action of insulin on a number of 
lipogenic enzymes in rat hepatocytes (reviewed in (Hillgartner et al. 1995)), and 
synergism of insulin and dexamethasone has been shown in human adipocytes 
(Wang et al. 2004).  
 
Most studies in humans have measured either whole body DNL indirectly using 
indirect calorimetry, or have specifically examined the contribution of hepatic DNL 
to VLDL secretion. Traditionally, DNL has been thought to make only a minimal 
contribution to adipose tissue TGs, with the majority of FFAs being derived from the 
diet, and until recently in vivo tracer studies examining DNL in adipose tissue have 
been lacking due to methodological considerations (Strawford et al. 2004). However, 
recent studies using prolonged (5-9 weeks) deuterated water administration suggest 
that approximately 20% of newly deposited adipose TGs are derived from DNL in 
non-obese subjects (Strawford et al. 2004). Further evidence of the importance of 
DNL is provided by recent findings in non-alcoholic fatty liver disease 
demonstrating that an increased proportion of hepatic TG is derived from hepatic 
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DNL and is associated with elevated rates of fasting DNL (Donnelly et al. 2005). 
Glucocorticoids increase rates of hepatic DNL contributing to VLDL, reducing the 
contribution from the stored cytosolic TG pool, thereby potentially contributing to 
hepatic steatosis and to increased export of TGs to adipose tissue depots (Dolinsky et 
al. 2004). Induction of DNL by glucocorticoids in selected adipose depots could also 
contribute to the obese Cushingoid phenotype, but has not yet been studied.  
 
1.4.3.5 Effects of glucocorticoids on hepatic fatty acid metabolism 
By contrast with the extensive literature describing effects of glucocorticoids on 
adipose tissue lipid metabolism, investigations in the liver have focused on effects on 
glucose rather than fat metabolism. In vitro studies suggest that glucocorticoids 
promote VLDL secretion possibly by increasing production and reducing 
degradation of apolipoprotein B (Wang et al. 1995). Accordingly, VLDL production 
rates are elevated in Cushing’s syndrome, and since VLDL clearance is unaltered this 
accounts for increased circulating VLDL and atherogenic LDL levels (Taskinen et al. 
1983). Additionally, glucocorticoids act to increase the activity of a number of 
enzymes involved in hepatic TG synthesis (Bates and Saggerson 1979;Lau and 
Roncari 1983;Pittner et al. 1985) which could promote steatosis. 
 
1.4.3.6 Effects of glucocorticoids on fatty acid oxidation and energy expenditure 
In order to preserve glucose for energy provision in the CNS, glucocorticoids might 
be expected to increase oxidation of FFAs in peripheral tissues. In vitro studies 
suggest that glucocorticoids have no direct effects on CPT1 activity, the essential rate 
limiting enzyme required for mitochondrial β-oxidation (Agius et al. 1986), although 
the capacity for mitochondrial β-oxidation in muscle may be increased (Short et al. 
2004), and peroxisomal β-oxidation may be increased in the liver (Norrheim et al. 
1990). However, there is also some in vitro data to suggest that glucocorticoids may 
inhibit FFA oxidation (Letteron et al. 1997). In vivo studies of effects of 
glucocorticoids on β-oxidation have been inconclusive; these studies are problematic 
as altered substrate availability and compensatory hormonal changes may also 
influence fatty acid oxidation. For example, in one study lipid oxidation, measured 
 77 
by indirect calorimetry, was augmented by hypercortisolaemia, but this may have 
been secondary to increased Ra of FFAs (Djurhuus et al. 2002).  
 
Both resting energy expenditure (REE) and lipid oxidation have been shown to be 
unaltered in Cushing’s syndrome and unchanged after successful treatment (Burt et 
al. 2006;Burt et al. 2007), whereas exogenous glucocorticoids may actually slightly 
increase REE (Brillon et al. 1995;Chong et al. 1994), in contrast to their effects to 
reduce thermogenesis in rodents (Soumano et al. 2000). 
 
1.4.3.7 Appetite and food selection 
Central effects of glucocorticoids on appetite are well known  (reviewed in (Dallman 
et al. 2004)), and increased energy intake could clearly contribute to glucocorticoid 
induced weight gain. Tataranni et al demonstrated increased food intake in response 
to glucocorticoids in humans, greatly in excess of a slight increase in energy 
expenditure (Tataranni et al. 1996). Stimulation of appetite by glucocorticoids occurs 
despite elevations in the satiety hormone leptin (Udden et al. 2003). Although 
Tatarinni’s study suggested that glucocorticoids mainly stimulate protein and 
carbohydrate intake in humans (Tataranni et al. 1996), studies in adrenalectomised 
and streptozotocin treated rodents suggest that insulin is key in influencing food 
choice and increasing fat intake in response to glucocorticoids (la Fleur et al. 2004). 
Thus, again prevailing insulin concentrations may be important in determining the 
response to glucocorticoids, suggesting the hyperinsulinaema associated with insulin 
resistance may be influencial. 
 
1.4.4 Glucocorticoid treatment and NAFLD in humans 
It is unclear whether the above changes in fatty acid metabolism contribute to the 
development of NAFLD in humans. There is a pausity of clinical data to support the 
hypothesis that chronic glucocorticoid therapy leads to steatosis, with only 20% of 
patients with Cushing’s syndrome having NAFLD, albeit with non-gold standard 
imaging (CT) (Rockall et al. 2003). One case series of patients with systemic lupus 
erythematosis (SLE), a connective tissue disease, not infrequently requiring 
treatment with glucocorticoids, found 73% of patients to have evidence of fatty liver 
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on liver histology (Matsumoto et al. 1992), with an association between total 
prednisolone dose and the severity of fatty liver. In a subsequent series, of liver 
biopsy and autopsy findings in SLE patients with high and low glucocorticoid 
exposure, only high total steroid dosage associated with severe steatosis, with 6% 
having evidence of steatohepatitis (Matsumoto et al. 2007). However, clearly these 
cases series have multiple confounders, most notably, the underlying severity of the 
SLE and the case selection bias.   
 
Other limited evidence includes a few isolated cases reports of glucocorticoid 
induced steatohepatitis, (reviewed in (Matsumoto et al. 2007)), including cases with 
both acute and chronic glucocorticoid exposure. Perhaps for this reason, as well as 
the concern over exacerbating any associated metabolic abnormalities and steatosis, 
there have been no therapeutic trials of steroids in NASH to date, despite their 
apparent success in treating acute alcoholic steatohepatitis (Forrest et al. 2007).   
 
1.4.5 Glucocorticoids and inflammation 
 
HPA axis activation, leading to increased glucocorticoid production, is an essential 
component of the stress-inflammatory response, as evidenced in patients with adrenal 
insufficiency in whom infection is life threatening (Kapcala et al. 1995). However, 
chronic overactivity e.g. in Cushing`s syndrome leads to immunosuppression and 
increased susceptibility to infection (Lionakis and Kontoyiannis 2003), suggesting 
glucocorticoids have a complex role in modulating the inflammatory/immune 
response.  
 
In brief, inflammation can be considered the tissue response to injury, and can be 
both acute and chronic. In general, acute inflammation involves the innate immune 
system and acts to enhance healing and protect against spread of pathogens, whereas 
chronic inflammation involves the more specific adaptive immune system and can 
lead to complications such as tissue damage and fibrosis.  
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Acute injury leads to a pro-inflammatory response from resident cells producing 
histamine and cytokines such as TNFα and IL-1 thought to be important in the 
development of NASH (Koppe et al. 2004). This leads to an increase in vascular 
permeability and leukocyte migration, contributing to the classical signs of swelling, 
redness, heat and pain. Resolution of acute inflammation involves phagocytosis of 
the acute inflammatory infiltrate (mainly apoptotic neutrophils) by macrophages 
(Coutinho and Chapman 2010). Possible delays in this mechanism may lead to 
phagocytic consumption of necrotic versus apoptotic neutrophils which, coupled 
with ongoing toxic insults may promote a chronic inflammatory response (Botto et al. 
1998). Chronic inflammation is characterised by the accumulation of activated 
macrophages which may promote tissue damage through the release of pro-
inflammatory and pro-fibrotic mediators (Coutinho and Chapman 2010).  
 
1.4.5.1 Glucocorticoids and the resolution of inflammation 
The term immunomodulatory is often used to describe glucocorticoids` effects on the 
immune system which are permissive, stimulatory, and suppressive (Yeager et al. 
2004). The balance of these effects is likely to depend on the concentration of 
endogenous and/or exogenous glucocorticoids available as well as timing in relation 
to the onset of inflammation.  
 
The glucocorticoid receptor is almost ubiquitously expressed and many aspects of the 
inflammatory and immune response are regulated by glucocorticoids. Firstly, they 
inhibit prostaglandin production by a number of mechanisms including decreasing 
cyclo-oxygenase 2 expression, indirectly inhibiting phospholipase A2 production, 
and by blocking the MAPK pathway by increasing MAPK phosphatase 1 (Rhen and 
Cidlowski 2005). Glucocorticoids also inhibit NFκB a key transcription factor 
regulating pro-inflammatory cytokine and prostaglandin production (McKay and 
Cidlowski 1999), and influence gene transcription of a number of transcription 
factors for pro-inflammatory cytokines and their receptors, whilst increasing 
expression of anti-inflammatory cytokines e.g. IL-10 (Barnes 1998). NFκB is also 
upregulated by FFAs and is thought to be a key factor in the development of NASH 
(Boden et al. 2005).  
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Numerous other effects of glucocorticoids may be relevant in NASH including 
effects on leucocyte trafficking, and cellular differentiation, as well as gene 
transcription in monocytes/macrophages, neutrophils and granulocytes (Coutinho 
and Chapman 2010). In particular glucocorticoids increase the phagocytic capacity of 
macrophages, and promote an anti-inflammatory phenotype in differentiating 
monocytes/macrophages (Giles et al. 2001). More rapid non-genomic effects of 
glucocorticoids may also influence the development of inflammation including 
effects on vasodilatation (Hafezi-Moghadam et al. 2002). In general glucocorticoids 
tend to promote the resolution of inflammation, suppressing the acute inflammatory 
response and would be predicted to reduce the development of steatohepatitis, albeit 
that this may be offset by the metabolic cosequences of increased glucocorticoids. 
 
1.4.5.2 11β-HSD1 and inflammation 
In addition, alterations in local 11β-HSD1 activity may also provide additional “fine 
tuning” and amplification of tissue glucocorticoid concentrations in response to 
injury, and has been shown to influence the inflammatory response in a number of 
animal models (Coutinho and Chapman 2010). 
 
The influence of 11β-HSD1 on amplifying local glucocorticoid signalling has been 
discussed in Section 1.4.1. 11β-HSD1 is present in most immune cells and its 
expression increases on activation of macrophages, and T and B lymphocytes (Zhang 
et al. 2005). Its activity is upregulated by the pro-inflammatory cytokines TNFα and 
IL-1 (Escher et al. 1997), as well as the Th2 cytokines IL-4 and IL-13 (Thieringer et 
al. 2001).  
 
Studies examining the inflammatory response e.g. thioglycollate induced sterile 
peritonitis in 11β-HSD1 knockout mice and using 11β-HSD1 inhibitors in cell lines, 
demonstrate that 11β-HSD1 plays an important role in suppressing pro-inflammatory 
cytokines and increasing phagocytic activity of macrophages, promoting the 
resolution of inflammation (Gilmour et al. 2006;Ishii et al. 2007). Similarly, 11β-
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HSD1 inhibition reduced the macrophage chemoattractant protein MCP-1 levels in 
ApoE-/- mice (Hermanowski-Vosatka et al. 2005).  
 
In addition to effects on inflammatory cells, pro-inflammatory cytokines induce 11β-
HSD1 activity in a number of other cells types including adipocytes, osteoblasts, 
mesangial cells, synovial fibroblasts, vascular smooth muscle, and both ovarian 
granulosa and surface epithelial cells (reviewed in (Chapman et al. 2009)). More 
recent work has focussed on the role of 11β-HSD1 in modifying the vascular 
inflammatory response (Hadoke et al. 2009). 
 
Interestingly studies have shown increased 11β-HSD2 activity in macrophages from 
patients with rheumatoid arthritis, possibly hampering anti-inflammatory effect of 
glucocorticoids in this chronic inflammatory disease, and adding further complexity 
to the regulation of glucocorticoid metabolism in inflammation (Hardy et al. 2008).   
 
1.4.6 Glucocorticoids and fibrosis 
 
It follows from the above that glucocorticoids have a myriad of effects on the 
immune system that could suppress the development of inflammation and fibrosis in 
NAFLD, although with the risk this could be offset by their metabolic side effects. I 
will briefly discuss the evidence that glucocorticoids influence hepatic fibrogenesis. 
 
In addition to their anti-inflammatory effects, glucocorticoids are able to reduce type 
1 collagen synthesis, the final common pathway in fibrogenesis, by interfering with 
TGFβ signalling (Cutroneo and Sterling, Jr. 2004). Type III collagen is also 
important in the wound healing response and its expression is reduced by 
glucocorticoids, associated with a decrease in Timp1 and Timp2 expression, in the 
skin at least (Oishi et al. 2002). Additional results from cultured hepatic stellate cells 
confirm that glucocorticoids interrupt TGFβ signalling and secretion (Bolkenius et al. 
2004). Furthermore, glucocorticoids have been shown to reduce TGFβ induced 
apoptosis, a possible driver of the fibrotic process, in a hepatoma cell line (Evans-
Storms and Cidlowski 2000;Wanke et al. 2004). Another potential antifibrotic 
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mechanism of glucocorticoids may relate to reducing angiotensin 1 receptor 
expression in hepatoma cells (Wintersgill et al. 1995). 
 
As discussed, carbon tetrachloride (CCl4) injury and common bile duct ligation are 
commonly employed models of liver fibrosis and have been used to confirm the 
antifibrotic effects of glucocorticoids e.g. glucocorticoids have been shown to reduce 
the extent of fibrosis following bile duct ligation (Eken et al. 2006) and the 
glucocorticoid antagonist RU38486 increased acute CCl4 induced liver injury, 
associated with a reduction in hepatic TGs, the former possibly via reduced IL-10 
expression (Swain et al. 1999). However, selective delivery of dexamethasone to 
Kupffer cells actually produced an increase in fibrosis and Timp1 expression, desite a 
reduction in ROS production, suggesting the site of glucocorticoids actions are 
essential in determining their effects (Melgert et al. 2001). 
 
1.4.7 Abnormalities of glucocorticoid metabolism and NAFLD 
 
The above metabolic and anti-inflammatory effects of glucocorticoids emphasise 
their potential role in the pathogenesis of NAFLD. Although circulating 
glucocorticoid levels are not abnormal in NAFLD, local glucocorticoid actions on 
the liver are determined by hepatic glucocorticoid metabolism, and a number of 
findings suggest that abnormalities of glucocorticoid metabolism may be important 
in relation to NAFLD. These will discussed below.  
   
1.4.7.1 Altered glucocorticoid metabolism and NAFLD 
Mice overexpressing 11β-HSD1 in adipose tissue (under the aP2 promoter) develop 
central obesity, hypertension, dyslipidaemia, and glucose intolerance (Masuzaki et al. 
2001;Masuzaki et al. 2003), whereas mice overexpressing 11β-HSD1 in the liver 
(under the ApoE promoter) develop insulin resistance and hypertension but not 
obesity (Paterson et al. 2004). Both have increased liver TGs. Conversely, 11β-HSD1 
null mice are protected from the metabolic syndrome, resisting hyperglycaemia and 
obesity induced by a high fat diet, with redistribution of fat in favour of subcutaneous 
depots (Kotelevtsev et al. 1997;Morton et al. 2004). In addition to effects on 
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glucose/insulin homeostasis, these tissue-specific manipulations of 11β-HSD1 in 
mice are associated with a host of alterations in fatty acid metabolism. aP2 11β-
HSD1 overexpressors have a three fold increase in plasma FFA (as well as 
corticosterone) levels in the portal vein, with a less pronounced elevation in the 
systemic circulation (Masuzaki et al. 2001). Serum TG levels are also increased. 
ApoE 11β-HSD1 overexpressors have increased serum FFAs on a low fat diet 
(Paterson et al. 2004). In addition, hepatic gene expression studies suggest that both 
fatty acid synthesis and lipid oxidation is basally upregulated, although the lipogenic 
response to high fat feeding was attenuated compared to controls (Paterson et al. 
2004). In contrast, 11β-HSD1 null mice have a favourable plasma lipoprotein profile 
with increased hepatic insulin sensitivity, but also an apparent increase in hepatic 
lipid oxidation as measured by gene expression studies (Morton et al. 2001). These 
findings suggest that variations in glucocorticoid concentrations selectively within 
either the adipose tissue or the liver influence FFA metabolism and hepatic TG 
accumulation.  
 
Pharmacological inhibition of 11β-HSD1 as a novel therapy for type 2 diabetes is a 
current goal for a number of pharmaceutical companies, with promising results for 
glucose/insulin homeostasis in animal models (reviewed in (Stimson and Walker 
2007)) and now humans (Rosenstock et al. 2010). In rats fed a high fat diet an 11β-
HSD1 inhibitor reduced serum FFA levels, reduced mesenteric adipose tissue weight, 
decreased adipose tissue expression of genes involved in lipid synthesis and FFA/TG 
cycling (lipolysis and re-esterification), and increased those involved in lipid 
oxidation (Berthiaume et al. 2007a). Activity of key lipogenic enzymes in the liver 
was unaltered by 11β-HSD1 inhibition but fasting serum TG levels were reduced 
through reduced VLDL secretion (Berthiaume et al. 2007b). Uptake and oxidation of 
TG derived FFA appeared to be increased in peripheral tissues, but interestingly 
muscle LPL activity was not increased (Berthiaume et al. 2007b). 11β-HSD1 
inhibitors also improve the serum lipoprotein profile and reduce the progression of 
atherogenesis (Hermanowski-Vosatka et al. 2005). 
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Inactivation of other glucocorticoid metabolising enzymes can also influence the 
development of NAFLD. Inactivation of the predominantly hepatic isoform of 
5α−reductase (type 1), predicted to increase intrahepatic glucocorticoid levels, leads 
to fatty liver and insulin resistance (Livingstone et al. 2009b).  
 
These findings demonstrate that transgenic and pharmacological modulation of 
glucocorticoid metabolism can influence systemic and hepatic fatty acid metabolism 
leading to the development of NAFLD, but what is the evidence that abnormalities of 
glucocorticoid metabolism exist in NAFLD? 
 
1.4.7.2 NAFLD and alterations in glucocorticoid metabolism 
Obese individuals have increased 11β-HSD1 mRNA transcripts and enzyme activity 
in subcutaneous adipose tissue in vitro (Kannisto et al. 2004;Lindsay et al. 
2003;Rask et al. 2001;Wake et al. 2003) and increased rates of cortisol regeneration 
in subcutaneous adipose tissue in vivo (Sandeep et al. 2005). In contrast, 11β-HSD1 
activity is reduced in the liver in obesity (Rask et al. 2001;Stewart et al. 1999), with 
upregulation of 5α- and 5β-reductases (Andrew et al. 1998). Whether 11β-HSD1 is 
also up-regulated in visceral adipose tissue in obesity is uncertain, with some studies 
showing increased activity (Desbriere et al. 2006;Michailidou et al. 2007) and others 
showing no change (Alberti et al. 2007;Goedecke et al. 2006;Tomlinson et al. 2002), 
although most recent evidence suggests there is negligible visceral adipose cortisol 
production (Stimson et al. 2009).  
 
Similar changes in hepatic glucocorticoid signalling have been found in rodent 
models of obesity including Zucker obese rats (Livingstone et al. 2005;Livingstone 
et al. 2000a) and high fat fed rats (Drake et al. 2005). These models develop steatosis 
and have upregulation of 5α- and 5β-reductases associated with downregulation of 
hepatic 11β-HSD1, predicting increased clearance of glucocorticoids, and reduced 
intrahepatic glucocorticoid levels, although compensatory HPA axis activation may 
act to maintain circulating glucocorticoid concentrations. These changes in hepatic 
metabolism may therefore be acting to protect the liver from metabolic consequences 
of GR activation. 
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Limited studies in humans have provided conflicting results, perhaps reflecting the 
heterogeneity of patient groups studied. In a study of non-obese (mean BMI 26.4) 
individuals with increased liver fat, subcutaneous and hepatic 11β-HSD1 activity 
were not altered, whereas intrahepatic 5β-reductase activity was elevated 
(Westerbacka et al. 2003). In a more recent study, currently only published in 
abstract form, patients with biopsy proven NAFLD had increased 5α-reductase 
activity, with reduced hepatic 11β-HSD1 activity, thus seeming to limit hepatic 
glucocorticoid exposure. Total glucocorticoid production rate was also increased, 
consistent with HPA axis activation. However, in the group of patients with 
steatohepatitis, hepatic 11β-HSD1 mRNA transcripts and immunohistochemical 
staining was markedly increased (Ahmed et al. 2010). In contrast, another recent 
human study of 75 patients found no association with 11β-HSD1 activity and NASH, 
whilst 5α and 5β-reductase activity was increased in patients with NAFLD with and 
without NASH (Konopelska et al. 2009).  
 
In keeping with increased clearance of glucocorticoids, a number of clinical studies 
have now suggested overactivation of the HPA axis in NAFLD (Targher et al. 
2005;Westerbacka et al. 2003;Zoppini et al. 2004), which may increase adrenal 
androgen production (Saruc et al. 2003). Furthermore, in one study 24 hour urinary 
free cortisol concentrations and post dexamethasone suppression cortisol levels 
strongly correlated with the degree of hepatic inflammation and fibrosis in NAFLD, 
although abnormal metabolism of dexamethasone in NAFLD is a potential 
confounder (Targher et al. 2006). Nevertheless, increased glucocorticoid clearance 
would be predicted to reduce intrahepatic glucocorticoid levels, potentially 
exacerbating hepatic inflammation in NAFLD. 
 
It is noteworthy that 5β-reductase is also responsible for the synthesis of bile acids 
from cholesterol (Danielsson and Sjovall 1975). Bile acids, especially hydrophobic 
ones such as CDCA, are inherently toxic to hepatocytes, and alterations in bile acid 
metabolism may have implications for the pathogenesis of NASH.  
 
 86 
Lastly, it is possible that differences in glucocorticoid signalling in metabolic 
syndrome and NAFLD are a consequence rather than cause of variations in fatty acid 
metabolism. Although they do not appear to influence cortisol and ACTH secretion 
(Mai et al. 2006), plasma FFAs and dietary macronutrient content have been shown 
to influence local glucocorticoid metabolism in some (Stimson et al. 2007;Wake et al. 
2006) but not all human studies (Mai et al. 2005). There are also reports that FFAs 
alter GR function (Sumida 1995). However, the most recent evidence supports the 
concept that variations in 11β-HSD1 influence fatty acid metabolism.  
 
 
1.5 HYPOTHESIS AND AIMS 
 
There is increasing evidence that abnormalities of peripheral and intrahepatic fatty 
acid metabolism may contribute to both the development and progression of non-
alcoholic fatty liver disease. In particular, factors promoting the accumulation of 
intrahepatic fatty acids may promote progression to steatohepatitis and fibrosis, and 
influence the metabolic complications of NAFLD. In addition, abnormalities of 
glucocorticoid metabolism have been implicated in the development of the metabolic 
complications of obesity, including NAFLD. The liver plays a central role in 
regulating glucocorticoid metabolism which, given the metabolic and anti-
inflammatory properties of glucocorticoids, make it vulnerable to changes in local 
glucocorticoid levels. It is not clear to what extent local changes in hepatic 
glucocorticoid metabolism, e.g. those predicted to reduce intrahepatic glucocorticoid 
levels, contribute to the development of steatosis, steatohepatitis and/or liver fibrosis. 
This is important as inhibitors of 11β-HSD1 may be introduced as a treatment for 
type 2 diabetes, a condition associated with NAFLD.  
 
The hypotheses in this PhD were as follows: 
 
1) by studying dietary models of NAFLD in rodents in which the risk of insulin 
resistance, steatohepatitis and fibrosis differs, one can identify pathways that play a 
key role in determining these risks.  
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2) altered patterns of fatty acid metabolism, predicted to increase intrahepatic fatty 
acids, associate with patterns of risk in NAFLD and increase susceptibility to 
steatohepatitis and fibrosis. 
 
3) altered glucocorticoid metabolism, with reduced 11β-HSD1 activity or increased 
A-ring reductase activity, predicted to reduce intrahepatic glucocorticoid levels, 
associates with patterns of risk in NAFLD and increases susceptibility to 
steatohepatitis and fibrosis. 
 
 
To address the above hypotheses, I undertook studies with the following aims: 
 
1) in Chapter 3, I investigated the susceptibility to steatohepatitis and carbon 
tetrachloride (CCl4) induced liver fibrosis in choline deficient diet (CDD) and 
methionine and choline deficient diet (MCDD) models of fatty liver in mice to 
address the following: 
 
a) To confirm whether a MCDD produces significantly greater steatohepatitis 
than CDD in mice 
b) Whether steatohepatitis in MCDD is associated with upregulation of pro-
inflammatory cytokines 
c) Whether steatohepatitis in MCDD mice increases susceptibility to CCl4 
induced hepatic fibrosis 
d) Whether susceptibility to liver fibrosis is associated with downregulation of 
specific matrix metalloproteinases (MMPs) and/or upregulation of their 
inhibitors (TIMPs) 
 
2) in Chapter 4, I investigated in vivo fatty acid metabolism in CDD and MCDD 
models of fatty liver, using a number of methodologies, to address the following: 
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a) whether weight loss in MCDD, associated with steatohepatitis, is a result of 
increased peripheral lipolysis increasing the flux of fatty acids to the liver, or 
impaired export of fatty acids from the liver, reducing the supply of 
triglycerides to adipose tissue 
b) whether increased hepatic de novo lipogenesis, predicted to increase 
intrahepatic fatty acids, is associated with steatohepatitis in MCDD mice 
 
3) in Chapter 5, I investigated glucocorticoid metabolism in CDD and MCDD mice 
treated with carbon tetrachloride to induce liver fibrosis, to establish the likely 
contribution to NAFLD, NASH and fibrosis severity. Real time PCR studies and 
enzyme activity assays were performed to address the following: 
 
a) whether differences in hepatic glucocorticoid metabolism associate with 
differing susceptibility to steatohepatitis in CDD and MCDD fed mice 
b) whether impaired 11β-HSD1 activity, predicted to reduce intrahepatic 
glucocorticoid levels, associates with susceptibility to steatohepatitis and/or 
fibrosis in MCDD mice 
c) whether increased clearance of glucocorticoids by A-ring reductases, 
predicted to reduce intrahepatic glucocorticoid levels, associates with 
susceptibility to steatohepatitis and/or fibrosis in MCDD mice 
 
Finally in Chapter 6, I discuss the significance of the above results and their 
relevance for the development of progressive non-alcoholic fatty liver disease in 
humans. 
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All chemicals were from Sigma (Poole, UK) unless otherwise stated.  
Solvents were glass-distilled HPLC grade (Rathburn, Walkerburn, UK).  
Stable-isotope labelled tracers (clinical grade) were from Cambridge Isotopes 
(Andover, MA, USA). 
Radioactively labelled steroids were from Amersham (Buckinghamshire, UK). 
Human albumin solution (20%w/v) was from the Scottish National Blood 
Transfusion Service (Lothian, UK). 
All sterile needles (Microlance) and syringes (Plastipak) were from Becton 
Dickinson (Oxford, UK). 
Pyrex glass reaction tubes and screw top vials were purchased from Fisher Scientific 
(Loughborough, Leicestershire, UK). 




All experiments were carried out under a UK Home Office animal license. 
C57BL/6J mice (Harlan, Bicester, UK) were maintained under controlled conditions 
of light and temperature. Mice were housed in a 12 hour light (07.00h to 19.00h) 12 
hour dark cycle, with a temperature range of 22+/-2oC. Diets were from Dyets Inc. 
Bethlehem, PA), and the dietary compositions are shown in Table 2.1; to prevent 
unavoidable contamination of choline and methionine from protein, the protein 
content was replaced by pure L-amino acids (Nakae 1999).  
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Table 2.1 Composition of rodent diets 
Diets were purchased from Dyets Inc (Bethlehem, PA), with reference codes in brackets. CS; 
(518574), CDD; (518753), and MCDD; (518810). All diets contained 50g/kg corn oil 
(source of polyunsaturated fat) and 100g/kg Primex (hydrogenated vegetable oil) as lipid 
sources. Carbohydrate was composed of corn starch, dextrin, cellulose, and sucrose, the 
latter differing marginally between the groups (392, 406 and 408g/kg for the CS, CDD and 
MCDD, respectively). 
 









Kcal/gram 4.3 4.3 4.3 
Kcal%    
   Protein (as L-amino acids) 15 15 15 
   Carbohydrate 55 55 55 
   Fat 30 30 30 
Choline Bitartate (g/kg) 14.48 0 0 




2.3 COMMONLY USED SOLUTIONS 
 
TBAHS buffer: dibasic potassium phosphate (0.2M) & tetrabutylammonium 
hydrogen sulphate (0.05M) adjusted to pH 9.0 with potassium hydroxide (1M) and 
stored at 4oC. 
Iodomethane solution: Iodomethane in dichloromethane (1:10, v/v), prepared daily. 
Chloroform-methanol solution: (2:1, v/v) containing 50µg/ml butylated 
hydroxytoluene. 
Stock solutions: palmitate (1µg/µl in chloroform), 7,7,8,8-4[H2] palmitate (D4 
palmitate) (1µg/µl in chloroform) and heptadecanoic acid (internal standard, 1µg/µl 
in chloroform) were stored at -80oC. 
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Citric acid buffer: 0.01M citric acid buffer adjusted to pH 6.0 with 1M sodium 
hydroxide. 
DEPC treated water: Distilled water (500ml) mixed with 500µl (0.1% v/v) diethyl 
pyrocarbonate (DEPC). The solution was allowed to stand for 12-24 hours before 
being sterilised by autoclave. 
10x TBE buffer: 108g Tris-base, 55g boric acid, 40ml 0.5M EDTA (pH 8.0), 
adjusted to 1L with distilled water. The solution was sterilised by autoclave before 
use. 
KREBS buffer: 118mM NaCl, 3.8mM KCL, 1.19mM KH2PO4, 2.54mM CaCl2, 
1.19mM MgSO4, 25mM NaHCO3 (all sterilised by autoclave before use), adjusted to 
1L with ultrapure water (Milli-Q Academic system, Millipore, Watford, UK) 
adjusted to pH 7.4 with 5M HCl. The solution was stored at 4ºC. 
 
 
2.4 INTRODUCTION TO METHODS 
 
The majority of the assays and techniques had previously been used in our laboratory 
and I subsequently learned the methods as required. Some of the techniques had not 
previously been employed: e.g. the use of stable isotope metabolic tracer techniques 
in mice requiring fatty acid measurement by gas chromatography mass spectrometry; 
mass isotopomer distribution analysis of labelled dietary acetate; solid phase 
extraction of plasma and tissue lipids; jugular venous cannulation in mice; and 
administration of intravenous tyloxapol to measure VLDL export. I undertook 
development of these new techniques and methods.  
 
2.5 HISTOLOGY AND IMMUNOHISTOCHEMISTRY 
 
2.5.1 Introduction  
 
In Chapters 3 and 4 sections of liver were stained using routine tinctorial stains and 
immunohistochemistry undertaken as described below. 
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2.5.2 Tinctorial stains 
 
Sections of liver were fixed in 10%v/v formalin solution for 12 hours prior to 
embedding in paraffin. ~5µm sections of the paraffin embedded tissue were cut using 
a microtome and stained with sirius red, and haematoxylin and eosin by the 
University of Edinburgh histology department as follows. 
 
2.5.2.1 Haematoxylin and eosin 
Routine staining with haematoxylin and eosin (H&E) staining enables gross 
visualisation of hepatic architecture, staining nuclei blue and matrix pink. Liver 
sections were dewaxed in xylene for 10mins followed by rehydration through 
alcohols (5mins each in 100%, 100%, 70%, 50%v/v ethanol). Sections were then 
placed in Harris’ haematoxylin for 30 seconds, washing in running tap water 
(~60secs) and rinsed with Scott’s tap water (~5secs). After a further wash in tap 
water sections were then differentiated in acid-alcohol (3secs) and staining in eosin 
(60secs). Sections were then dehydrated in increasing concentrations of alcohols, 
cleared in xylene and mounted using DPX. 
 
2.5.2.2 Picosirius red 
Liver sections were dewaxed and rehydrated as described above. They were then 
stainined in picosirius red/fast green solution for two hours. After a brief wash in 
running tap water the sections were dehydrated in increasing concentrations of 
alcohol, cleared in xylene and fixed as before. 
 
2.5.3 Immunohistochemical staining 
 
The immunohistochemical staining of liver sections for alpha smooth muscle actin (a 
marker of activated hepatic stellate cells), macrophages and neutrophils is described. 
These techniques were used in Chapters 3 and 4.  
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2.5.3.1 Alpha smooth muscle actin 
For immunostaining for alpha smooth muscle actin (αSMA), liver sections were de-
waxed in xylene and rehydrated in alcohol. Antigen retrieval was achieved by 
microwaving in 0.01M citric acid buffer (pH 6.0). Endogenous peroxidase activity 
was blocked by washing in 1%v/v hydrogen peroxide solution, and slides mounted in 
Shandon Sequenza racks (Thermo Fisher Scientific Inc, Leics, UK), after washing in 
phosphate buffered saline (PBS). A commercial avidin/biotin blocking kit (Vector 
Labs, Burlingame, CA, USA) was used to block any background staining, washing 
with PBS (x3) between stages. Samples were further blocked with MOM mouse 
immunoglobulin blocking agent (Vector Labs, Burlingame, CA, USA) for 60mins. 
Sections were then incubated overnight at 4ºC with a 1 in 6000 dilution of the 
primary αSMA antibody (A5228 monoclonal mouse anti αSMA, Sigma, UK) 
prepared in MOM diluent. After 0.1%v/v tween and PBS washes, sections were 
incubated with the biotinylated secondary antibody (MOM biotinylated anti-mouse 
IgG reagent, Vector Labs, Burlingame, CA, USA) for 10mins at room temperature. 
After additional tween and PBS washes, sections were incubated with 3 drops of 
Vector RTU ABC (Avidin and Biotin horseradish peroxidase macromolecular 
Complex) reagent for 30mins at room temperature. Cells positive for αSMA were 
visualised by diaminobenzidine (DAB) staining. Sections were counterstained in 
haemotoxylin (~15secs), and rinsed in Scott`s tap water (~5secs) prior to dehydration 
through alcohol, clearing in xylene and mounting in DPX mountant. 
 
2.5.3.2 Macrophage staining 
Immunostaining for hepatic macrophages was performed using an anti F4/80 
antibody (Ab6640 rat monoclonal anti F4/80 antibody, Abcam, Cambridge, UK). 
Sections were processed as described above up until and including the biotin 
blocking stage, except that no antigen retrieval step was required. Sections were 
blocked using normal rabbit serum (DAKO, Ely, UK) diluted 1:4 in PBS, incubating 
for 30mins at room temperature. Samples were then incubated with the primary anti 
F4/80 antibody, diluted 1in 300 in rabbit serum (60mins at room temperature). After 
further washes, sections were incubated with a 1:300 dilution of the secondary rabbit 
anti-rat antibody (DAKO) for 30mins at room temperature. Sections were incubated 
 94 
with 3 drops of the Vector RTU ABC reagent (30mins at room temperature) and 
F4/80 positive cells were then visualised using DAB as before and samples 
counterstained and dehydrated as described above. 
 
2.5.3.3 Neutrophil staining 
Immunostaining for neutrophils was identical until the incubation with a 1 in 200 
dilution (in rabbit serum) of the primary anti-granulocyte antibody (108413 Rat anti-
mouse GR1 antibody, Cambridge Biosciences, Cambridge, UK) overnight at 4ºC. 
After 0.1%v/v tween and PBS washes, sections were incubated for 60mins at room 
temperature with a 1:300 dilution (in normal rabbit serum) of the secondary rabbit 
anti-rat antibody (DAKO). Processing then continued as above using the Vector 
ABC reagent and DAB, before dehydrating and mounting. 
 
 
2.6 MESSENGER RNA (mRNA) EXTRACTION AND QUANTIFICATION 
  
Gene expression studies, quantifying mRNA transcription in murine livers, were 
undertaken in Chapters 3 and 5. 
 
2.6.1 RNA extraction  
 
Total hepatic RNA was extracted from frozen liver using a Qiagen RNeasy 
extraction kit (Crawley, UK) as per the manufacturer’s instructions. 20-30mg of liver 
was homogenised in 600µl RLT buffer (Qiagen, Crawley, UK) prior to centrifuging 
at 12,000 x g for 3mins at 4ºC. The supernatant was then added to 700µl 50% ethanol, 
and 700µl of the mixture added to the RNeasy mini column, prior to centrifugation 
(as above) for 15secs. The eluate was discarded and the remainder of the ethanol 
containing mixture passed through the mini columns and discarded. Columns were 
washed with further buffers (RWI and RPE, Qiagen, Crawley, UK) and centrifuged 
as above for 15 seconds. A final RPE wash was undertaken followed by 
centrifugation as above for 2mins, followed by elution of the RNA into RNAase free 
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water (30µl). Samples were split into aliquots to reduce the need for repeat thawing, 
and stored at -80ºC. 
 
2.6.2 RNA quantification and integrity  
 
The integrity of extracted RNA was assessed by agarose gel electrophoresis. After 
cleaning the tank with RNase Away solution (Molecular BioProducts, CA, USA), a 
1.2%w/v agarose (Lonza, Basel, Switzerland) gel was prepared using 0.5%w/v tris 
borate EDTA (TBE) buffer and 10µl/100ml SYBR safe DNA stain (Invitrogen, 
Paisley, UK). For each sample, 1µl of extracted RNA solution was added to 10µl 
RNAase free water, and 2µl of loading dye, and loaded into wells. Electrophoresis 
was performed in 0.5%w/v TBE buffer at 100V for approximately 60mins. The 
separated 28S and 18S ribosome bands were then visualised at 254nm, using a 
UVIpro system (UVItec, Cambridge, UK), expecting an approximate 2:1 ratio if 
RNA integrity maintained. 
 
Total RNA was quantified by measuring ultraviolet absorbance at 260nm (RNA) and 
280nm (protein) by spectrophotometry (NanoDrop 1000, Thermoscientific ) using 
2µl of RNA solution loaded onto the spectrophotometer pedestal, after calibration 
using a 2µl RNAase free water ‘blank’. A measured RNA concentration >100ng/µl, 
and an A260/A280 ratio >1.8 was deemed acceptable (pure RNA has a ratio of 2.1).  
To ensure similar quantities of RNA were reverse transcribed, aliquots of RNA were 
diluted with RNAase free water to achieve a concentration of 100ng/µl. 
 
2.6.3 Synthesis of complemetary DNA (cDNA) by reverse transcription 
 
A commercial reverse transcription kit (Qiagen, Cawley, West Sussex, UK) was used 
to eliminate genomic DNA contamination and then reverse transcribe mRNA (0.5µg) 
to cDNA. Genomic DNA ‘wipeout’ was undertaken using a reaction mixture 
containing the mRNA (5µl), water (7µl) and gDNA wipeout buffer (2µl), incubating 
at 42ºC for 2mins, followed by cooling to 5ºC. Reverse transcriptase (1µl), 5x RT 
buffer, containing 12.5mM MgCl2 (4µl), and primer mix (1µl) was added to each 
 96 
RNA sample creating a 20µl reaction mixture. Control samples were also prepared, 
except either the reverse transcriptase (-RT control), or RNA (negative template 
control), was substituted with water. Reverse transcription was performed using a 
thermal cycler (G-storm 1, Genetic Research Instrumentation Ltd, Essex, UK) 
programmed to 42ºC for 30mins (reverse transcription), 95ºC for 5mins (enzyme 
inactivation) and 4ºC for 5mins (to prevent reannealing). cDNA was stored at -20ºC 
until analysis. 
 
2.6.4 Real Time Polymerase Chain Reaction (PCR) 
 
Quantification of hepatic gene transcripts was performed by real time PCR using the 
Roche Lightcycler 480 system (Burgess Hill, UK). Primers and probes were 
designed from the Roche UPL library or were purchased pre-made (TaqMan Gene 
Expression Assays, Applied Biosystems, Southhampton, UK). Synthesised primers 
(Invitrogen, Paisley, UK) were dissolved in Tris EDTA buffer to achieve stock 
solutions of 100µmol/l. 
 
cDNA from each sample was diluted 1:40 in nuclease free water. 10µl reaction 
volumes were loaded on to 384 multi-well PCR plates, consisting of cDNA (2µl), 
Lightcycler 480 RNA master hydrolysis probes mix (Roche Diagnostics, West 
Sussex, UK) (5µl), forward primer (0.1µl of 1:5 dilution of stock solution), reverse 
primer (0.1µl of 1:5 dilution), probe (Roche Diagnostics, West Sussex, UK) (0.1µl) 
and nuclease free water (2.7µl). The PCR plates were sealed and centrifuged at 2000 
x g for 1min at 4ºC for 2minutes, to ensure adequate mixing. The Lightcycler was 
programmed as per the manufacturer’s instructions: 95ºC for 5mins (DNA 
polymerase activation), 95ºC for 10secs (denaturation), and 60ºC for 30secs 
(annealing and extension), repeating the latter two stages for 40 cycles. 
 
The hydrolysis probes contain a fluorescent dye reporter (FAM) and closely linked 
quencher (TAMRA). The Taq DNA polymerase degrades the annealed probe 
releasing the fluorescent dye, proportional to the amount of accumulating PCR 
product, enabling quantification. Fluorescence was monitored during each PCR cycle, 
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at 483nm and 533nm, corresponding to the excitation and emission wavelengths of 
the probes.  
 
Seven point standard curves were created by pooling equal volumes of cDNA from 
each sample, and serial dilutions (1:8, 1:16, 1:32, 1:64, 1:128, 1:256, 1:512) prepared 
with nuclease free water. Samples were analysed in triplicate and the second 
derivative maximum or crossing point (Cp) method used for construction of the 
standard curve and relative quantification of PCR product. The variability of 
triplicates was considered acceptable if standard deviation was <0.5, and a standard 
curve efficiency of >1.7 was deemed acceptable. Transcript levels were normalised 
to abundance of transcripts of housekeeping, internal control genes. 
 
 
2.7 BACKGROUND TO METABOLIC TRACER TECHNIQUES 
 
In Chapter 4 I undertook detailed physiological studies of fatty acid metabolism in 
mice which included the use of stable isotope tracers to quantify rates of fatty acid 
turnover and synthesis. In the following section I will discuss the background to 
these techniques followed by the methods used, discussing the development of new 
techniques where relevant. 
 
2.7.1 Principles of metabolic tracer techniques 
 
Atoms consist of a tightly packed central core of positively charged and neutral 
subatomic particles known as protons and neutrons respectively, the number of 
which determines its mass (denoted by the symbol A) in atomic mass units (AMUs). 
The number of protons is given by the symbol Z such that the fictitious molecule X 
can be written as follows: 
 
Otherwise identical atoms can differ in mass due to variations in the numbers of 






identical and are known as isotopes. Both 12C and 13C are examples of stable isotopes 
which, unlike radioactive isotopes e.g. 14C, do not spontaneously decay to produce 
radiation (and other elements). Stable isotopes are naturally occurring, and can be 
measured using gas chromatography mass spectrometry, with 13C contributing to 
~1.1% of the total carbon pool, whereas radioisotopes are measured by scintigraphy. 
Both radioactive and stable isotopes can be used to label molecules for use in 
metabolic tracer studies e.g. in Chapter 4 I used 1,2,3,4-[13C]4-palmitate to study 
fatty acid metabolism.     
 
A tracer can be defined as a compound which is chemically and functionally 
identical to the naturally occurring tracee compound of interest but is distinct in 
some way that enables its detection. The detectable nature of the tracer then allows 
information to be gathered on the metabolism of the tracee compound in the body 
(Wolfe 1992).  
 
The use of stable isotopes as metabolic tracers began in the 1930s with the use of 2H, 
13C and 18O (Dole M 1935;Schoenheimer and Rittenberg 1935;Wood et al. 1941), 
and actually preceded the use of more easily detectable radioactive tracers which 
became more popular following their increase in availability after World War II. The 
use of stable isotopes then had a resurgence in the 1970s in line with an improved 
sensitivity of gas chromatography mass spectrometry (Wolfe 1992). Stable isotopes 
also pose little or no risk to human subjects as they contain no radioactivity and can 
be used repeatedly in a single volunteer. 
 
There are three main ways in which tracers are used in metabolic research, the latter 
two were employed in the experiments undertaken in Chapter 4. 
 
i) to measure a compound’s kinetics following bolus administration 
ii) to measure the tracer’s incorporation into another compound to calculate a rate of 
synthesis e.g. of hepatic de novo lipogenesis 
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iii) to determine the rate of substrate turnover or its rate of appearance into the 
plasma using the tracer dilution technique e.g. to quantify the rate of appearance of 
fatty acids in the plasma. 
 
2.7.2 Isotope dilution technique terminology 
 
2.7.2.1 Rate of appearance 
Rate of appearance (Ra) is a key term in metabolic tracer studies employing the 
isotope dilution technique (see Figure 2.1). To understand the isotope dilution 
technique it is necessary to conceptualise a substrate pool within the body 
(represented by the bucket of water in Figure 2.1) with the assumption that the pool 
is homogenous and freely mixing. At steady state, the influx (or Ra) of water is equal 
to output (or rate of disappearance [Rd]). If we then infuse a tracer at a constant rate 
for long enough for it to reach equilibrium then Ra = Rd, and at this time point of 
isotopic equilibrium the ratio of tracer to tracee will remain constant at a plateau. Ra 
of substrate can then be calculated using the formula (Steele 1959):  
 
Ra (µmol/kg per min) = F/IE, 
 
 where F is the isotope infusion rate (µmol/kg per min) and IE is the isotopic 
enrichment at plateau expressed as the tracer to tracee ratio (TTR) 
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Figure 2.1 Principles of the isotope dilution methodology  
Once steady steady of tracer enrichment has been achieved, the rate of appearance (Ra) of 
the tracee in plasma is calculated using the equation as shown where F is the tracer infusion 
rate and IE is the isotopic enrichment or tracer to tracee ratio. 
• At steady state:
Ra* = Rd =      F
IE
Measure isotopic enrichment (IE)








The Ra of a compound is also referred to as the turnover rate or occasionally the flux 
rate. 
 
It is noteworthy that the Ra is not dependent on the actual amount/duration of tracer 
infused, only that a steady state is achieved. The time to achieve steady state is 
dependent on the turnover rate of the substrate (and the pool size), with long infusion 
periods needed for substrates with a slow turnover rate. A priming dose of tracer is 
therefore often used in this situation with the aim of achieving isotopic equilibrium 
more rapidly, without altering the final enrichment plateau. 
 
The required priming dose (P, umol/kg) can be expressed as a function of the pool 
size and the substrates Ra (Wolfe 1992) using the equation: 
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P/F = C*V/ Ra 
 
Where C is the concentration of the unlabelled trace in µmol/ml and V is the volume 
of distribution (ml/kg). Therefore if there is some knowledge of the pool size and 
expected Ra then the P/F ratio can be estimated and pilot studies used to determine if 
the chosen values are satisfactory. F represents the tracer infusion rate as before. 
 
The isotope dilution technique was used in Chapter 4 using a labelled palmitate 
tracer to measure the Ra of the fatty acid palmitate in plasma, representing the release 
of fatty acids from stored triglycerides into the circulating free fatty acid pool in mice. 
It follows that in addition to knowing the tracer infusion rate the istopic enrichment 
must be measured as will be described below. 
 
2.7.2.2 Isotopic enrichment 
When a radioactive tracer is used isotopic enrichment is expressed as specific 
activity (SA) which represents the ratio of the amount of measured radioactive 
tracer/measured amount of unlabelled tracee (Wolfe 1992). However, when a stable 
isotopic tracer is used its concentration cannot be measured directly. Additionally, 
“background” amounts of stable isotopes create indistinguishable naturally occurring 
mass isotopomers which need to be subtracted from the measured enrichment during 
the study. The unit tracer/tracee ratio (TTR) is therefore used as a measure of 
enrichment and represents the molar ratio of two discretely measurable species. In 
practice, what is measured is isotope abundance ratios obtained using GCMS. 
However, these are not identical to the true TTR due to overlap in spectra between 
the tracer and tracee, and possible other artefacts produced by GCMS. Corrections 
therefore have to be made to determine the true TTR, which can be achieved 
mathematically (using skew correction factors to correct for overlapping spectra) or 
alternatively a standard curve can be used which also takes into account some GCMS 
artefacts (Patterson et al. 1998). 
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A series of standard solutions of known isotopic enrichment are used to construct a 
standard curve such that the measured TTR determined by GCMS can be corrected 
to the “true TTR”. 
 
2.7.2.3 Mass isotopomers distribution analysis (MIDA) 
The term isotopomer is used to describe a molecule into which a tracer has been 
incorporated. Positional isotopomers differ in respect to the site of incorporation of 
the isotopic tracer, whereas mass isotopomers differ by mass. 
 
MIDA is a technique used to enable calculation of the rate of synthesis of a polymer 
synthesised from a monomer (Chinkes et al. 1996). When the monomer is labelled 
then its incorporation into the polymer will lead to the production of mass 
isotopomers of the polymer product. Measuring the relative abundance of the 
different mass isotopomers by GCMS makes it possible to indirectly calculate the 
enrichment of a labelled monomer precursor pool necessary for the calculation of 
synthetic rates using the precursor product relationship as described below. Figure 
2.2 demonstrates how different precursor pool enrichment leads to different 
distributions of mass isotopomers. 
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Figure 2.2 Comparison of precursor pool enrichments for MIDA  
Red circles represent the labelled precursor molecule to be incorporated into the synthesised 
polymer. The mass isotopomer distribution in the product is dependent on the degree of 
precursor enrichment. Analysis of the pattern of mass isotopomers distribution, determined 
using gas chromatography/mass spectroscopy allows calculation of the enrichment of the 
precursor pool. 
 
The MIDA approach was developed simultaneously by Hellerstein’s (Hellerstein and 
Neese 1992) and Kelleher’s (Kelleher and Masterson 1992) groups, with slight 
variations adopted by others (Chinkes et al. 1996;Lee et al. 1992). All are based on 
the same underlying principle of a combinatorial precursor-product biosynthesis 
model correcting for naturally occurring isotopomers which interact with a varyingly 
diluted enriched precursor pool (Chinkes et al. 1996). Comparison of these slightly 
varying methodologies have shown the results to be very similar (Chinkes et al. 
1996). However, because the models and algorithms of Hellerstein and Kelleher do 
not use conventional expressions of isotopic enrichment (TTR or MPE), and because 
they require the use of graphical matrices and “look up” tables to calculate the 
precursor enrichment, I opted to use the method of Chinkes et al (Chinkes et al. 
1996) which uses algebraic equations and calculates palmitate enrichment using 
TTRs. 
 
2.7.2.4 Calculation of precursor enrichment using the method of Chinkes et al 
To understand this method let us consider the synthesis of palmitate from eight acetyl 
CoA subunits using labelled 1-13C1-acetate. Prior to administration of any tracer 
Precursor enrichment 1 
1
Precursor enrichment 2 
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naturally occurring mass isotopomers exist with the theoretical relative abundance 
100%, 19.12%, and 2.14% for methyl palmitate M+0, M+1, and M+2 respectively 
(Chinkes et al. 1996). It should be noted that due to hydrogen abstraction and GCMS 
artefacts the actual measured isotope abundance ratios may significantly differ from 
these theoretical values (Patterson et al. 1998) and the measured background values 
should therefore be used. Any additional incorporation of 1-13C1-acetate into 
palmitate will alter this distribution of mass isotopomers dependent on the 
enrichment of labelled acetate. 
 
From Figure 2.2 we can see that if 50% of the acetyl CoA precursor pool is labelled 
then on average each palmitate molecule will contain four labels corresponding to 
M+4 measured by GCMS. In comparison, if only 25% of the precursor pool is 
labelled on average each palmitate molecule will contain two labels, demonstrating 
that different precursor enrichments produce characteristic mass isotopomer patterns 
or distributions. In reality the palmitate pool will be diluted by pre-existing 
unlabelled palmitate. However, the relative distribution of the (newly synthesised) 
mass isotopomers will remain the same and so using the MIDA technique the 
precursor enrichment can still be calculated. 
 
The method requires the assumption that the precursor pool enrichment (not 
necessarily the product enrichment) is constant over time, and requires that a 
minimum of three peaks are measured.   
 
Firstly, TTRs are calculated for the M+1 and M+2 isotopomers using the following 
formulae. 
 
TTR[M+1] = (M+1/M+0)post – (M+1/M+0)pre 
 
TTR[M+2] = (M+2/M+0)post – (M+2/M+0)pre – dT1*TTR[M+1] 
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Where dT1 is the theoretical percentage of singly labelled product that has a heavy 
atom in a position other than the labelled position. This removes the contribution of 
singly labelled (M+1) palmitate to the M+2 peak due to overlapping spectra.  
 
Assuming precursor enrichment (p), is at steady state it can be calculated from the 
TTRs, and expressed in moles percent excess (MPE), as follows: 
 
p = (2 * TTR[M+2]/TTR[M+1])/ ((n-1) + 2 * (TTR[M+2]/TTR[M+1])) 
 
where n is the number of precursor molecules used to synthesis one product molecule 
e.g. 8 acetate molecules are contained in one palmitate molecule. 
 
Precursor and product enrichment must be expressed in the same units. Therefore the 
precursor enrichment can be converted from units of MPE precursor enrichment to 
MPE of singly labelled product. In the case of an acetate tracer, acetyl CoA 
enrichment is converted to palmitate enrichment. The formula used to calculate 




The equation corrects for the probability that a randomly formed product has one 
label incorporated, using p the calculated percentage of labelled precursor molecules 
i.e. the precursor (acetyl CoA) enrichment in MPE. 
 
The fractional synthesis rate i.e. the fraction of the tissue TG-palmitate pool that is 
newly synthesised, per unit of time, can now be calculated using the formula: 
 
FSR= [Eb(t2) – Eb(t1)]/ [(t2-t1)*EF] 
 
Where Eb is the product enrichment at timepoints t2 and t1 and EF is the precursor 
enrichment (converted to singly labelled product enrichment). 
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The absolute synthesis rate (ASR) is the calculated amount of product that has been 
synthesised over a specific time period. 
 
ASR = FSR * pool size  
 
Thus, when comparing groups it is possible for the FSR to be lower in one group but 
its ASR to be higher than a comparison group if its pool size is greater.  
 
In Chapter 4 we opted to use doubly labelled [13C]2-acetate as recommended by 
Chinkes et al to improve the specificity of the analysis (Chinkes et al. 1996). The 
method is essentially unchanged except M+2 and M+4 are used instead of M+1 and 
M+2, thereby reducing the background enrichment to be subtracted. dT2, used to 
correct for overlapping spectra, is 1.75%. 
 
2.8 BASICS OF GAS CHROMATOGRAPHY/ MASS SPECTROMETRY 
(GCMS) 
 
Gas chromatography provides a physical method for separating and quantifying 
components of complex mixtures of organic compounds and was therefore used in 
Chapter 4, in combination with mass spectrometry, to measure isotopic enrichment in 
the metabolic tracer studies. Separation of compounds is achieved by the partitioning 
of different components into two phases; stationary and mobile. In gas 
chromatography the stationary phase is a liquid or polymer film bonded to the inside 
of a capillary tube (or column), and the mobile phase is a pressurised carrier gas e.g. 
helium, that moves through the capillary tube. Components that spend more time in 
the gas/mobile phase therefore move along the column more rapidly. Factors 
influencing time spent in the mobile phase include temperature, and the chemistry of 
the stationary phase which effects the interaction with the components of interest. 
The retention time describes the time taken to pass through the column is represented 
on the gas chromatogram by a corresponding peak which gives some indication on 
the nature of the molecule (Goodman 1980).   
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Gas chromatography is a very sensitive tool for separating complex mixtures, but on 
its own provides only limited information on the identity of eluted molecules. It 
requires to be coupled with a mass spectrometer to provide more detailed 
information by measuring molecular weight. The output of the mass spectrometer is 
the mass spectrum and aids identification of molecules based on their mass and 
pattern of breakdown or fragmentation within the instrument following ionisation. 
Ions are presented as a bar graph by their relative abundance and mass to charge ratio 
(m/z ratio), where m is the mass in Daltons (Da) and z is the charge of one electron, 
which usually equals 1. A diagram of a GCMS setup is shown in Figure 2.3. 
 
Figure 2.3 Sample analysis and instrumentation by gas chromatography mass 
spectrometry 
Schematic diagram demonstrating the necessary steps required to analyse stable isotopes 






















Blood samples are taken during the stable isotope infusion. The compound(s) of 
interest can then be extracted from plasma for analysis by GCMS. Derivatisation 
describes the process whereby components of interest are chemically altered to make 
them more volatile and suitable for separation by gas chromatography e.g. fatty acids 
are derivatised to fatty acid methyl esters (FAMEs) (Patterson et al. 1999).  
 
A small volume of the derivatised sample is then injected onto the analytical column 
through the inlet system which vapourises the sample. The column is also maintained 
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at temperature and is housed within an oven. The GC operates at atmospheric 
pressure, whereas the MS operates within a vacuum to prevent interference form 
particles with air.  
 
The mass spectrometer contains three main components: the ion source; the analyser; 
and the detector. The capillary column is coupled, through a heated sheath, to the ion 
source which is kept under vacuum. Molecular ionisation is required to allow mass 
measurement, and two methods can be employed within the ion source; electron 
impact ionisation (EI) and chemical ionisation (CI). In both methods, the sample 
passes through a beam of electrons, although in CI, a reagent gas (typically methane) 
is present in the ion source which indirectly ionises the analyte. The higher energy EI 
method is used more commonly but leads to greater fragmentation of the molecular 
ions. Once molecular ions are produced they pass through focusing lenses into the 
analyser component of the mass spectrometer. A number of different types of 
analysers exist, but commonly either magnetic or quadrupole mass analysers are used. 
Ions are separated depending on their mass to charge ratios which are then collected 
by the detector plate the signal converted to allow data analysis by computer. 
Typically a mass spectrum is scanned every 0.2 to 0.5 seconds.   
 
Total ion current or total ion chromatogram (TIC) represents the sum of all mass 
spectra produced by the GCMS system, and each peak is therefore a sum of all the 
fragments/isotopomers of that molecule. TIC mode is often used to initially identify 
the time at which a standard is eluted from the column.  
 
Selective ion monitoring (SIM) is an alternative to TIC and allows the mass 
spectrometer to measure only specific ions of interest, increasing sensitivity. SIM 
mode is commonly employed in metabolic tracer studies to measure the mass 
isotopomers corresponding to the tracer and tracee molecule for calculation of the 
TTR. Knowledge of the tracer’s molecular fragmentation pattern can therefore be 




2.9 ASSAY DEVELOPMENT  
 
The isotope dilution technique and mass isotopomers distribution analysis methods 
employed in Chapter 4 required GCMS analysis of fatty acids. GCMS assay 
development was therefore undertaken for fatty acids, as analysis of these tracers had 
not previously been performed locally.  
 
2.9.1 GCMS analysis of palmitic acid 
 
Palmitic acid is a 16 carbon (C16:0), saturated fatty acid constituting approximately 
30% of plasma free fatty acids. Isotopes of palmitate (e.g. 14C-palmitate, U-13C-
palmitate, D2-palmitate) infused in albumin are used to study fatty acid kinetics and 
are representative of plasma fatty acids (Mittendorfer et al. 2003). After initially 
developing the assay for a singly labelled 13C1-palmitate tracer, commonly used in 
human studies, we opted to use a 1,2,3,4-[13C]4-palmitate to improve specificity. 
Stable isotopes of palmitate are safe, and combined with GCMS provide a relatively 
sensitive and accurate means of undertaking metabolic tracer studies avoiding the 
exposure to radioactivity.  
 
Prior to GCMS analysis FFAs must be derivatised to fatty acid methyl esters 
(FAMEs), but first must be extracted from plasma using a variety of solvents as 
water inhibits the generation of FAMEs (Patterson et al. 1999). FFAs have 
classically been separated from total extracted lipids by thin layer chromatography, 
and FAMEs prepared using derivatising agents such as boron trifluoride and 
methanol (Morrison and Smith 1964;Wolfe 1992). However, this is time consuming, 
can lead to breakdown of FFAs (chemical fractionisation), reducing recovery of 
some fatty acid species, and is less efficient than more modern methods (Patterson et 
al. 1999). We therefore elected to use the method of Patterson et al (Patterson et al. 
1999) derivatising FFAs using iodomethane (dissolved in dichloromethane) which 
importantly has not been shown to react with or hydrolyse triglycerides or other 
esterified lipid species to produce interfering FAMEs (Patterson et al. 1999).  
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GC analysis was initially undertaken using a Hewlett Packard 5890 series II gas 
chromatograph (Palo Alto, Ca) with a BPX5 25m x 35mm id 0.25µm film Forte GC 
capillary column (SGE, Milton Keynes, UK) interfaced to a mass spectrometer 
(ThermoQuest Trio-1) operated in electron impact ionisation mode (70eV) using 
source and interface temperatures of 200ºC and 250ºC respectively. 
.  
To optimise GCMS conditions, stock solutions of unlabelled and 13C1- palmitate 
(1µg/µl in chloroform) were prepared and 250µl aliquots reduced to dryness under 
oxygen free nitrogen at 60oC in glass Reactivials. As per the final stages of the 
Patterson method (Patterson et al. 1999) TBHAS buffer (250µl) and iodomethane 
derivatising solution (250µl) were added and samples vortexed (10mins) to form 
FAMEs. FAMEs were then extracted into hexane (3ml), reduced to dryness under 
oxygen free nitrogen at 60oC, and redissolved in heptane (150µl) for analysis by 
GCMS.  
 
Palmitate and 13C1- palmitate solutions were first analysed in total ion chromatogram 
(TIC) mode and the appropriate mass/charge (m/z) ratios of the FAMEs derivatives 
identified (See Figure 2.4A). Subsequently selected ion monitoring (SIM) was used 
to measure 12C methyl palmitate as molecular ion [M+0]+ at m/z 270 [retention time 
(tR) 8.1min], 
13C methyl palmitate as [M+1] + at m/z 271 (Figure 2.4B). A series of 
injection temperatures were assessed from 200-300oC and areas under the curve 
compared for peaks identifying 280oC as the optimum. A splitless injection system 
was used and 1µl of sample injected, with a 5 second pull out delay. The GC was 
programmed from an initial 1minute hold at 60oC, and then the temperature was 
increased to 220oC with a 25oC/minute ramp, then to 300oC with a 10oC/minute ramp 
with a 1minute final hold.  
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Figure 2.4 GCMS chromatograms for methyl palmitate isotopomers 
A) Mass chromatogram and corresponding mass spectrum for methyl palmitate, B) Selective 
ion monitoring mode for D4 methyl palmitate internal standard (m/z 274), C13 methyl 
palmitate (m/z 271), and methyl palmitate (m/z 270) recovered from human plasma. 
A) 
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Subsequent steps of the Patterson method (Patterson et al. 1999) for the extraction of 
plasma FFAs and derivatisation to FAMEs were added, using aliquots of the stock 
solutions with the addition of an internal standard (initially D4-palmitate, although 
this was later changed to heptadecanoic acid with the 1,2,3,4-[13C]4-palmitate tracer) 
to improve reproducibility. Ultimately the full assay was successful in extracting 
palmitate from plasma (250µl) with addition of internal standard (10µg). 
 
Xcalibur software (ThermoFinnigan, Austin, Tx, USA) was used to calculate areas 
under the curve and integrate peaks corresponding to labelled and unlabelled 
palmitate, as well the internal standard. Palmitate standard curves were prepared 
using samples of known quantities/concentrations of palmitate and were deemed 
acceptable if R values were >0.99. Plasma samples could then be analysed to 
measure palmitate concentrations, and the reproducibility of the technique assessed, 
producing a coefficient of variability of precision (n=5) of less than 2%. To assess 
the ability of the assay to measure dynamic changes in plasma concentrations, 
analysis of stored plasma samples from a previous study was undertaken (Sandeep et 
al. 2005). Samples were analysed from baseline and during hyperinsulinaemic clamp 
(expected to suppress plasma FFAs) (Figure 2.5). 
 
Figure 2.5 Dynamic changes in plasma palmitate concentrations  











































































Given that mice generally have higher levels of FFAs than humans, and because only 
small volumes of plasma would be available from mice, the method was scaled down 
to use 50µl of plasma. An alternative, more sensitive, GC-MS instrumentation was 
also used as described in Section 2.9.3.  
 
Murine plasma free fatty acids were extracted and derivatised using a modified 
method of Patterson et al (Patterson et al. 1999) as follows. Aliquots of plasma 
(50µl), water (150µl), and internal standard (5µg), plus heptane (140µl) were added 
to 13 x 10mm screw top Pyrex glass reaction tubes. Samples were vortexed (3mins) 
prior to addition of ice cold acetone (3ml) to precipitate plasma proteins, briefly 
vortexed again, and placed at -20oC for 15 minutes. Samples were then centrifuged 
(1500 x g, 5mins, 4oC) and the supernatant transferred to fresh glass reaction tubes. 
Hexane (2ml) and water (2ml) were added before mixing gently on a horizontal 
platform shaker (15mins, room temperature) and samples centrifuged again as before. 
The upper lipid containing solvent phase was then transferred fresh glass reaction 
tubes and reduced to dryness under oxygen free nitrogen at 60oC. TBHAS buffer 
(250µl) and iodomethane derivatising solution (250µl) were added and samples 
vortexed (10mins) to form FAMEs. FAMEs were extracted into hexane (3ml), 
reduced to dryness under oxygen free nitrogen at 60oC, and redissolved in heptane 
(150µl) for analysis by GCMS.  
 
2.9.2 Tissue and plasma TG-palmitate enrichment 
 
To measure the uptake/flux of fatty acids into plasma and tissue TG pools it is first 
necessary to isolate the TG lipid component, prior to hydrolysis of the TG ester 
bonds, liberating constituent fatty acids (including the palmitate tracer) for 
derivatisation to FAMEs. Again these techniques had not previously been undertaken 
in our lab and a modification of the classic Folch (Folch et al. 1957) extraction 
method was used to extract plasma and tissue lipids. This was combined with solid 
phase extraction (SPE) to isolate the TG lipid fraction (Burdge et al. 2000). SPE was 
chosen in preference to thin layer chromatography for separation of lipid classes as it 
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is less time consuming, and has been shown to obtain superior results, with no cross 
contamination of lipid classes, and good recovery (Burdge et al. 2000). Polar and 
neutral lipids (phospholipids and FFAs, and cholesterol esters [CEs] and TGs 
respectively) were separated by SPE, followed by further separation using solvents 
of increasing polarity as described below. 
 
The published method (Burdge et al. 2000) also describes elution of FFAs using 
chloroform-methanol-acetic acid (100:2:2, v/v) following prior elution of 
phospholipids by chloroform methanol (3:2, v/v) and methanol washes. This proved 
to be unsuccessful due to marked contamination seen in blanks and lack of sensitivity 
with the small volume of plasma analysed. This “contamination” was present when 
blanks derivatised by both iodomethane and sulphuric acid methanol suggesting that 
it was not contamination due to TGs. Possible plasticisers present within the column 
and manifold may have been to blame and contamination appeared to be reduced 
when the manifold was not used to drain the columns. 
 
To measure plasma TG-palmitate enrichment plasma lipids were extracted from 50µl 
of murine plasma using triheptadecanoin (5µg in chloroform) as an internal standard 
using a modified Folch technique (Folch et al. 1957). Plasma and internal standard 
were added to 13 x 10mm screw top Pyrex glass reaction tubes, followed by 
chloroform-methanol (2ml) solution, and samples mixed for 15 minutes at room 
temperature. 1M NaCl (300µl) solution was added and samples briefly vortexed prior 
to centrifugation (1125 x g at 4°C for 10mins). The aqueous phase was removed and 
the lower organic phase aspirated and transferred to a new reaction tube. The 
interfacial protein disc was vortexed for 15minutes in chloroform-methanol solution 
(1ml) and 1M NaCl (150µl), followed by centrifugation as above. The organic phase 
was aspirated and combined with the first extract, then reduced to dryness under 
oxygen free nitrogen at 60°C, prior to being redissolved in chloroform (1ml) for solid 
phase extraction (SPE) to separate TGs as described below (Burdge et al. 2000). 
 
A similar method was used to extract TGs from liver tissue. Tissue (200mg) was 
homogenised in 40 volume of chloroform:methanol solution and sonicated for 
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15mins (Ametaj et al. 2003). 1M NaCl solution (0.2 volume) was added, and the 
samples briefly vortexed, prior to centrifugation (2000 x g for 20minutes at 10oC). 
The lower organic phase was extracted and the upper methanol and NaCl containing 
phase discarded. The remaining homogenate was redissolved in 1ml chloroform and 
filtered. Following additional chloroform washes (1ml and 2ml), the chloroform was 
added to the original organic phase and the mixture reduced to dryness under oxygen 
free nitrogen at 60oC. The samples were then redissolved in chloroform (1ml) for 
SPE. 
 
2.9.2.1 Triglyceride separation by solid phase extraction 
Aminopropyl silica cartridges (Bondelut Varian, 100mg packed silica per 1ml 
column, Speck and Burke analytical, UK) were placed in a vacuum manifold and 
preconditioned with chloroform (2mls). Glass collection tubes were placed and 
samples applied under gravity, removing the residual with vacuum. Two further 
chloroform (1ml) washes were applied, and this first fraction containing cholesterol 
esters and TGs reduced to dryness under oxygen free nitrogen at 60oC. The eluted 
neutral lipids were redissolved in hexane (1ml) and a further set of aminopropyl 
silica cartridges preconditioned with hexane (4 x 1ml). The sample was applied 
under gravity, followed by hexane washes (2 x 1ml) under vacuum to elute 
cholesterol esters. Collection tubes were placed and TGs eluted under vacuum with 
hexane-chloroform-ethylacetate (100:5:5, v/v) (2 x 1ml). The void fraction was 
reduced to dryness under oxygen free nitrogen at 60oC. 
 
2.9.2.2 Triglyceride hydrolysis and derivatisation 
The eluted TGs were redissolved in toluene (1ml), briefly vortexed and derivatised 
using acidified methanolic sulphuric acid (2% v/v), incubating for 18 hours at 50oC 
(Burdge et al. 2000). The reaction mixture was then neutralised with buffer (KHCO3 
[0.25M] and K2CO3 [0.5M]). The lipids were extracted into hexane (2ml) by mixing 
for 15 minutes on a horizontal platform shaker and centrifuging (1125 x g for 10mins 
at 14°C). The hexane layer was aspirated and reduced to dryness under oxygen free 
nitrogen at 60oC and samples redissolved in heptane (75µl for plasma samples and 
200µl, followed by 1 in 200 dilution for tissue samples) for analysis by GCMS.  
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2.9.3 Gas chromatography mass spectrometry instrumentation 
 
Electron impact ionization GC-MS analysis was undertaken on a ThermoFinnigan 
Voyager gas chromatograph mass spectrometer with an Agilent HP-Innowax column 
(30m, 0.320mm, 0.5µm) operated in electron impact ionization mode (70eV). Source, 
interface and injection temperatures were 200oC, 250oC and 260oC respectively. The 
column temperature was programmed from a 1.5minute hold at 50oC, with a 
13oC/min ramp and 1.5minute hold at 260oC. Fatty acid methyl esters derived from 
plasma FFA and TG pools were analysed using selective ion monitoring of 
molecular ions with m/z 270, 272, 274 and 284, corresponding to [M+0], [M+2], and 
[M+4] isotopomers of methyl palmitate and the methyl heptadecanoate internal 
standard respectively (see Figure 2.6). To avoid concentration dependent effects of 
methyl palmitate on ionization, each sample was analysed several times using a 
range of injection volumes as previously described (Patterson et al. 1998), and tracer 
to tracee ratios determined from a standard curve. 
  
Figure 2.6 GCMS chromatogram measuring endogenous and exogenous fatty 
acid methyl esters depicting m/z ratios  
Chromatograms depicting m/z rations measuring A) Methyl palmitate, B) [13C]4 methyl 
palmitate, and C) methyl heptadecanoate. 

































































2.10 OTHER EX VIVO ASSAYS 
 
2.10.1 Free fatty acids 
 
Plasma FFAs were analysed in duplicate using a commercial colourimetric kit (Wako, 
Fuggerstrabe, Germany) utilising acyl CoA synthase (ACS) and acyl coA oxidase 
(ACOD). 
 
In the presence of adenosine triphosphate (ATP), magnesium ions and co-enzyme A 
(CoA), ACS converts FFAs to the thiol esters of CoA, acyl-coA, as well as adenosine 
monophosphate (AMP) and pryrophosphate (PPi). Acyl-coA is then oxidised by 
ACOD to produce hydrogen peroxide, which in the presence of peroxidase (POD) 
and two reagents (4-amino antipyrine and methyl-N-ethyl-N-(betahydroxyethyl) 
aniline [MEHA]) yields a purple coloured product.  
 
A standard curve was prepared from a 1000µmol/l FFA (oleic acid) standard by 
serial dilutions with the provided buffer solution, including a buffer blank. Plasma 
(and standard curve samples) were incubated at 37°C for 10mins with each of the 
two reagents (“A” and “B”), then allowed to equilibrate to room temperature. After 
ensuring no bubbles were present, absorbance was measured at 540nm using a 
platereader. The standard curve was deemed acceptable if R2 > 0.98, and 
samples/standards run in duplicate, accepting a variance of <10%. The FFA content 
of each plasma sample was calculated and corrected for sample volume to µmol/l.  
 
2.10.2 Plasma triglycerides 
 
TGs were measured enzymatically with the Infinity triglycerides liquid stable reagent 
(ThermoTrace, Noble Park, Australia).  
 
Briefly, TGs were first hydrolysed to FFAs and glycerol by a lipase and subsequently 
phosphorylated to glycerol-3-phosphate by glycerol kinase (GK), consuming ATP. 
Hydrogen peroxide (H202) was then produced by the oxidation of glycerol-3-
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phosphate to dihydroxyacetone phosphate (DAP) by glycerolphosphate oxidase. A 
peroxidase enzyme (POD) then reacts H202 with two reagents (4-amino antipyrine 
and 3,5-dichloro-2-hydroxybenzene sulphate to produce a red coloured dye (see 
Figure 2.8). The absorbance of the dye was proportional to the concentration of TG 
in the sample. 
 
Figure 2.8 Triglyceride assay reaction 
Summary of the steps involved in a commercial triglyceride assay. 
 
200µl of the reagent mix was added to 2µl of sample. A calibration standard (2µl, 
2.5mmol/l) and blank were also measured. The mixture was incubated at 37°C for 
5minutes and a platereader used to measure absorbance at 500nm. Samples were 
analysed in duplicate when possible, accepting a variance of 10%. 
 
Plasma TGs (mmol/l)  =   [Average OD of sample/ average OD of standard] x 2.5  
 
• TG + H2O  Glycerol +  3X FFAs 
• Glycerol + ATP  Glycerol - 3 - phosphate +ADP 
• Glycerol - 3 - phosphate + 02 DAP + 2H 20 2






2.10.3 Liver triglyceride concentration 
 
To measure hepatic TG content, 100mg of liver was homogenised in 20 volumes of 
propan-2-ol. The homogenate was shaken in an orbital shaker for 45 minutes, 
centrifuged at 3000 x g for 10 minutes at 4ºC and 2µl of the supernatant assayed 
using a commercial triglyceride kit (ThermoTrace) as described above. Results were 
converted to µmol/g liver and µmol TG/liver, the latter representing the total liver 




Plasma bilirubin concentration was determined using a commercial kit (Alpha 
laboratories Ltd, Eastleigh, UK) adapted for use on a Cobras centrifugal analyser 
(Roche Dignostics Ltd, Welwyn Garden City, UK). The assay is based on an acid 
diazo method (Pearlman and Lee 1974). Both conjugated and unconjugated bilirubin 
react with diazotised sulphanilic acid to produce an azobilirubin, the absorbance of 
which is proportional to that of bilirubin in the sample measured at 550nm. Standards 
were run in duplicate, with a variance of <10% and an R value greater than 0.99 
deemed acceptable. 
 
2.10.5 Alanine aminotransferase 
 
ALT activity was measured using a commercial kit (Randox laboratories, Co. Antrim, 
UK) based on the method of Bergmeyer (Bergmeyer et al. 1978), adapted for use on 
a Cobras centrifugal analyser (Roche Dignostics Ltd, Welwyn Garden City, UK). In 
summary, ALT converts L-alanine and 2-oxoglutarate to pyruvate and L-glutamate. 
In the presence of lactate dehydrogenase and NADH the pyruvate is reduced to 
lactate, whilst the oxidation of NADH to NAD+ produces a chromphore, the 
abundance of which may be quantified at 340nm. Standards were run in duplicate, 
with a variance of <10% and an R value greater than 0.99 deemed acceptable. 
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2.10.6 Aspartate aminotransferase 
 
AST activity was measured using a commercial kit (Randox laboratories, Co. Antrim, 
UK) based on the method of Bergmeyer (Bergmeyer et al. 1978), adapted for use on 
a Cobras centrifugal analyser (Roche Dignostics Ltd, Welwyn Garden City, UK). 
ALT converts oxoglutarate and L-aspartate to form L-glutamate and oxaloacetate. In 
the presence of NAPH and malate dehydrogenase, oxaloacetate is converted to 
malate and NAD+ leading to a chromophore, the abundance of which may be 
quantified at 340nm. Standards were run in duplicate, with a variance of <10% and 
an R value greater than 0.99 deemed acceptable. 
 
2.10.7 Plasma leptin  
 
Plasma leptin levels were measured using an ultrasensitive mouse ELISA 
(CrystalChem Inc, Chicago, IL) as per the manufacturer’s instructions. In brief, 45µl 
of diluent were added to the antibody coated wells along with 50µl of guinea pig 
anti-mouse leptin serum. 5µl of plasma (or standard) was added and incubated for 
twenty hours at 4ºC. After washing with buffer (x5) 100µl of the anti-guinea pig IgG 
enzyme conjugate solution was added to each well, incubating for 3 hours at 4ºC. 
After additional washes (x7) 100µl of the enzyme substrate solution was added to 
each well and incubated for 30 minutes at room temperature. An enzyme stopping 
solution was then added and absorbance measured at 450nm (subtracting absorbance 
at 630nm). Concentrations were calculated from a standard curve prepared from a 
standard solution. Standards were run in duplicate accepting a variance of <10%, and 
the standard curve was deemed acceptable if R values were > 99%.  
 
2.11 MURINE SURGICAL TECHNIQUES 
 
2.11.1 Mouse jugular venous cannulation 
 
To enable tracer infusions in live unanaesthetised mice, as in Chapter 4, cannulation 
of a large central vein is necessary. This can then be tunnelled subcutaneously for 
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externalisation after the mouse has recovered from the procedure. I learned this 
method from a local investigator with previous experience of the technique and 
describe the method in detail below.  
 
Mice were anaesthetised using a combination of intraperitoneally administered 
medetomidine (Domitor, Orion Pharma, Espoo, Finland) and ketamine (Vetalar, 
Boehringer Vetmedica Inc, MO, USA) and jugular venous cannulae sited as 
described below with the aid of an operating microscope.  
 
After assessing that the mouse was adequately anaesthetised, a collar of hair was 
shaved around the neck and the area sterilised with alcohol. Lacrilube ointment was 
then applied to both cornea to prevent abrasions during surgery. The mouse was 
placed prone on a heat pad and covered with clingfilm to help maintain body 
temperature during surgery.  
 
An approximately 1cm long incision was cut from the angle of the jaw to the clavicle 
on the right hand side and superficial fat dissected to reveal the jugular vein. Fine 
forceps were used to pass sutures (5-0 Mersilk, Ethicon, Johnson and Johnson, 
Langhorne, PA, USA) under the rostral and caudal ends of the jugular vein. An 
additional looped suture was passed through the mid-section which was then cut at 
the looped end to provide two additional sutures to secure the cannula. The rostral 
stitch was first tied to occlude venous inflow and both rostral and caudal stitches 
anchored using haemostat clamps (Fine Science Tools, Heidelberg, Germany) 
creating tension on the vessel. 
 
A length of Microrethane implantation tubing (0.025" O.D. x 0.012" I.D, Sandown 
Scientific, Middlesex, UK) was “locked” with 1:10,000 heparin solution. The vein 
was punctured using an angled 25 gauge needle and the cannula inserted into the 
vein whilst removing the needle tip. The cannula was advanced approximately 0.5cm 
and aspirated to confirm correct position and securely fixed in place using the sutures 
and tissue adhesive (Vetbond, 3M, MN, USA). 
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The cannula was cut to approximately 8cm in length, tied in a knot at its distal end, 
and a suture tied beneath the knot leaving 3-4cm of suture which would later be used 
to locate the cannula. A small incision was cut on the back of the neck and the 
cannula externalised through the incision prior to being burrowed subcutaneously 
along the dorsum of the mouse. The stitch ends were left external to the incision. 
Surgical clips were used to close the dorsal and neck wounds. 
 
Antipamezole (Antisedan, Pfizer AH, Kent, UK), anaesthetic reversal agent, and 
analgesia, buprenorphine (Vetergesic, Alstoe Animal Health, Leics, UK) were 
administered and mice were placed on a heat mat to recover. Mice were allowed 3-4 
days to recover prior to being studied. 
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3 Chapter 3-Susceptibility to steatohepatitis and hepatic fibrosis in 




Associated with obesity and type 2 diabetes, there is increasing public health concern 
over the long term consequences of non-alcoholic fatty liver disease (NAFLD). 
Present in up to one third of the US population (Szczepaniak et al. 2005), NAFLD 
encompasses a spectrum of disease, and whereas simple steatosis may be relatively 
benign, hepatic inflammation (non-alcoholic steatohepatitis, NASH) may ensue, 
potentially progressing to hepatic fibrosis, and its end stage, cirrhosis, with an 
associated increased risk of hepatocellular carcinoma.  
 
The factors influencing both the development and progression of NAFLD are 
incompletely defined, but abnormalities of fatty acid metabolism may be critical. 
Fatty acids are inherently toxic to hepatocytes and hepatic steatosis may represent a 
protective mechanism, acting as an acute store, “mopping up” the overspill of toxic 
fatty acids in obesity (Yamaguchi et al. 2007). However, when hepatic triglyceride 
storage, and/or VLDL export and mitochondrial beta oxidation are overwhelmed, 
then excess fatty acids are directed towards alternative, less efficient, cytochrome 
P450 (CYP2E1 and CYP4A) dependent pathways which generate reactive oxygen 
species (ROS), promoting inflammation, which may lead to fibrosis (Robertson et al. 
2001). 
 
Diets deficient in methyl donors such as methionine and/or choline, important in 
phosphatidyl choline synthesis, reliably induce fatty liver in rodents (Nakae 1999). A 
diet deficient in both methionine and choline is commonly employed as a model of 
steatohepatitis with hepatic insulin resistance (Leclercq et al. 2007;Schattenberg et al. 
2005), although associated weight loss improves peripheral insulin sensitivity 
(Rinella and Green 2004). In contrast, a simple choline deficient diet, with adequate 
methionine, leads to generalised steatosis without obvious inflammation, and 
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improves insulin sensitivity in mice fed a high fat diet, which may relate to 
differences in intra-hepatic fatty acid metabolism (Raubenheimer et al. 2006). In 
addition to hepatic inflammation, methionine and choline deficiency can also lead to 
mild hepatic fibrosis and, although not previously studied in mice, prolonged 
administration of a choline deficient diet in rats results in hepatic cirrhosis (Mu et al. 
2010;Sakaida et al. 1998).    
 
A carbon tetrachloride (CCl4) toxin induced model is arguably the most widely 
studied and best characterised model of liver fibrosis. CCl4 is rapidly metabolised to 
a trichloromethyl radical (CCl3*) by cytochrome P450 (CYP) 2E1, CYP2B and 
possibly CYP3A, leading to hepatic necrosis (Goodman 1980;Yamazaki et al. 2005). 
Repeated administration by intraperitoneal injection reliably leads to induction of 
hepatic fibrosis and (following more prolonged administration) cirrhosis in rodents 
(Constandinou et al. 2005). 
 
We aimed to establish whether CDD and MCDD dietary models of NAFLD in mice 
have a contrasting predisposition to hepatic fibrosis as well as their reported 
contrasting inflammation, and to dissect the cellular and molecular basis underlying 
any observed differences. 
 
 




All chemicals were purchased from Sigma (Poole, UK) unless otherwise stated and 
solvents were glass-distilled HPLC grade (Rathburn, Walkerburn, UK).  
 
3.2.2 Induction of liver fibrosis 
 
All experiments were carried out under a UK Home Office animal license using 12 
week old male C57BL/6J mice (Harlan, Bicester, UK) maintained under controlled 
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conditions of light and temperature. Following a 2 week period of acclimatisation, 
mice (n=7/group) were offered either control (choline and methionine supplemented) 
chow (CS), choline deficient diet (CDD) or methionine-choline deficient diet 
(MCDD) (Dyets Inc., Bethlehem, PA) for 4 weeks and treated with twice weekly 
intraperitoneal injections of 0.3µl/g CCl4 (1:3 v/v in olive oil) or olive oil alone as 
controls. Injections were performed in a ventilated fume hood, using a gas-tight 
Teflon lined 100µl glass syringe (Hamilton, Bonaduz, Switzerland) and disposable 
25 gauge needles. Mice were sacrificed by decapitation 3 days following the last 
CCl4 injection, being culled in the ad libitum fed state. Trunk blood was collected 
and sections of liver fixed in 10%v/v formalin. The remainder of the liver was snap 
frozen and stored at -80ºC prior to analysis.  
 
3.2.3 Histology and immunohistochemistry 
 
Liver sections were processed and stained as described in Section 2.5. 
 
3.2.4 Histological characterisation 
 
3.2.4.1 Quantification of liver fibrosis  
Picosirius red, which stains polymeric and monomeric collagen matrix, was used to 
quantify hepatic fibrosis. 30 randomly selected high power field (200x) photographs 
were captured per liver section using Axiovision software, and AxioCam MRc 
digital camera, attached to an Axiovert 200 microscope (Zeiss, Germany) and 
analysed in a blinded manner using commercial software (Adobe photoshop CS3 
version 10.0, Adobe systems Inc., San Jose, CA, USA) to provide a continuous 
variable representing hepatic fibrosis. Pixels staining red were identified, divided by 
the total number of pixels per photograph and multiplied by 100, to give a percentage 
positive staining for collagen. To avoid confounding, sections containing large blood 
vessels were avoided.    
 
3.2.4.2 Cell counts  
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Cell counts of neutrophils and activated hepatic stellate cells (αSMA stain) were 
undertaken in a blinded manner, averaging the number of cells in 20 representative 
high power fields per liver section. 
 
3.2.4.3 Macrophage activation  
Given the relatively uniform staining of hepatic macrophages, image analysis 
software was used to determine F4/80 staining in a manner analogous to that 
described for picosirius red. 
 
3.2.5 Messenger RNA (mRNA) extraction and quantification  
 
mRNA expression of pro-inflammatory and pro-fibrogenic genes was assessed using 
real time PCR as described in detail in section 2.6. Primers and probes were designed 
from the Roche UPL library and are listed in Table 3.1. The relative amount of 
mRNA was derived from standard curves prepared from serial dilutions of cDNA 
and transcript levels were normalised to mean values of an internal control house 








Genbank RefSeq Sequence Direction UPL 
probe 
no. 
Il1b NM_008361.3 ttgacggaccccaaaagat Forward 38 
  agctggatgctctcatcagg Reverse  
Tnf NM_013693.2 tgcctatgtctcagcctcttc Forward 49 
  gaggccatttgggaacttct Reverse  
Ccl2 (Mcp-1) NM_011333.3  gcctgctgttcacagttgc Forward 102 
  caggtgagtggggcgtta Reverse  
Tgfb1 NM_011577.1 tggagcaacatgtggaactc Forward 72 
  cagcagccggttaccaag Reverse  
Col1a2 NM_007743.2 gcaggttcacctactctgtcct Forward 46 
  cttgccccattcatttgtct Reverse  
Acta2 (Sma2) NM_007392.2 gacaccacccacccagagt Forward 20 
  acatagctggagcagcgtct Reverse  
Mmp2 NM_008610.2 taacctggatgccgtcgt Forward 77 
  ttcaggtaataagcacccttgaa Reverse  
Mmp9 NM_013599.2 acgacatagacggcatcca Forward 19 
  gctgtggttcagttgtggtg Reverse  
Mmp12 NM_008605.3 ttgtggataaacactactggaggt Forward 51 
  aaatcagcttggggtaagca Reverse  
Mmp13 NM_008607.1 cagtctccgaggagaaactatgat Forward 62 
  ggactttgtcaaaaagagctcag Reverse  
Timp1 NM_001044384.1 gcaaagagctttctcaaagacc Forward 76 
  agggatagataaacagggaaacact Reverse  
Timp2 NM_011594.3 cgttttgcaatgcagacgta Forward 21 
  ggaatccacctccttctcg Reverse  
 
3.2.6 Liver triglycerides 
 
Liver TGs were measured using a commercial triglyceride kit (ThermoTrace, 
Australia) as described in Section 2.10.3.   
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3.2.7 Leptin assay 
 
Plasma leptin levels were measured using an ultrasensitive mouse ELISA 
(CrystalChem Inc, Chicago, IL) as described in Section 2.10.7.  
 
3.2.8 Statistical analysis 
 
Results are presented as mean ± standard error (SEM). Between groups differences 
were compared by two way ANOVA, with Bonferroni’s post hoc multiple 
comparison test when appropriate, using GraphPad Prism software (La Jolla, CA, 




3.3.1 Influence of choline ± methionine deficiency on body weights and 
composition in olive oil treated mice 
 
Starting body weights did not differ between CS, CDD and MCDD groups injected 
with olive oil twice weekly (Figure 3.1). As expected, MCDD mice lost weight 
(~30% by 4 weeks) compared to both CS and CDD mice, whilst the final body 
weights of CDD and CS mice did not differ. Despite weight loss, MCDD mice were 
otherwise well with no external signs of distress.  
 
Weight loss in MCDD mice was associated with loss of both subcutaneous and 
perigonadal adipose tissue compared with both CS and CDD mice, whereas there 
was no difference in adipose tissue weights between CDD and CS mice (Table 3.2). 
Weight loss in MCDD mice was associated with a lower plasma leptin concentration 
versus both CS and CDD mice, whilst leptin did not differ between CS and CDD 
mice (Figure 3.2). In contrast, there was no difference in muscle mass, as a 
percentage of total body weight, between MCDD and CS or CDD mice, with no 
additional difference between CDD and CS mice. 
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Liver TG concentrations were similarly increased in both MCDD and CDD 
compared to CS fed mice (Table 3.2). Liver weights were lower in MCDD mice 
versus CS and CDD mice, but were in proportion to total body weights (Table 3.2). 
 
3.3.2 Influence of choline ± methionine deficiency on hepatic inflammation in 
olive oil treated mice 
 
Immunohistochemistry confirmed an acute inflammatory infiltrate, with increased 
neutrophil staining in MCDD mice alone, compared to both CS and CDD mice, 
whilst there was no statistically significant increase in neutrophil staining in CDD 
mice (Figure 3.3). There was no detectable increase in macrophage staining in either 
dietary group. This was despite an increased abundance of mRNA trancripts of Ccl2 
(MCP1) in both MCDD and CDD mice (Figure 3.4A) compared to CS controls. 
mRNA levels of the genes encoding the pro-inflammatory cytokines TNFα and IL-
1b were also increased in the MCDD group, versus both CS and CDD mice, and CS 
mice respectively, whilst there was no significant increase in CDD mice on post hoc 
analysis. 
 
3.3.3 Influence of choline ± methionine deficiency on hepatic fibrosis in olive oil 
treated control mice  
 
Quantification of picosirius red staining demonstrated no significant difference in 
hepatic fibrosis between dietary groups (Figure 3.5), with only a trend (P=0.067) for 
an influence of diet on picosirius red staining. Diet did influence hepatic stellate cell 
activation (αSMA staining), with increased αSMA staining in MCDD mice, 
compared with both CS and CDD mice, with no difference between CDD and CS 
mice (Figure 3.5). Similarly, the abundance of hepatic transcripts of Acta2 and Tgfb1 
was increased in MCDD versus CS and CDD mice (Figure 3.4A), whilst there was 
no significant increase in CDD mice alone. There was no influence of diet on Col1a 
mRNA levels.   
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MCDD upregulated Mmp gene expression, increasing mRNA transcripts of Mmps 12, 
and 13 compared with both CS and CDD mice, whilst Mmp 9 mRNA levels were 
increased versus CS mice alone (Figure 3.4B). In contrast, Mmp gene expression was 
unchanged in CDD mice. Timp1 and Timp2 mRNA levels were also increased in 
MCDD mice versus CS, although not CDD mice, whilst there was no significant 
increase in expression in CDD mice.  
 
3.3.4 Body weights and composition in CCl4 treated choline ± methionine 
deficient mice  
 
Starting body weights were similar in CCl4 treated CS, CDD and MCDD mice with 
no differences between their olive oil treated counterparts (Figure 3.1). As with olive 
oil treated controls, MCDD mice lost weight compared to both CS and CDD groups, 
but there was no additional effect of CCl4. In contrast, although the final body 
weights of CCl4 treated CS and CDD mice did not differ from each other, CCl4 
treated CS and CDD mice did not gain weight as well as their olive oil treated 
controls (Figure 3.1). 
 
CCl4 influenced perigonadal but not subcutaneous fat deposition, with a reduction 
perigonadal fat in CCl4 treated CS mice. There was no significant difference in 
adipose depot weights in CCl4 treated CDD mice, despite less significant weight gain. 
CCl4 did not influence body composition in MCDD mice (Table 3.2). Similarly, CCl4 
had no influence on muscle mass (quadriceps weights as a percentage of body mass) 
in either dietary group (Table 3.2). Plasma leptin levels were reduced in CCl4 treated 
MCDD versus both CS and CDD mice, although there was no additional effect of 
CCl4 in either group (Figure 3.2). 
 
Liver TG concentrations remained elevated in both CCl4 treated MCDD and CDD 
mice versus CS controls, but there was no additional effect of CCl4 (Table 3.2). 
There was a trend (F[1,36]=3.75, P=0.061) for a reduction in liver weight in response 




3.3.5 Effect of CCl4 treatment on hepatic inflammation in choline ± methionine 
deficiency 
 
CCl4 did not significantly influence hepatic neutrophil staining in any dietary group, 
although neutrophil counts remained significantly higher in MCDD than both CS and 
CDD mice (Figure 3.3). There was no detectable influence of CCl4 treatment on 
macrophage staining (Figure 3.3). There was no additional effect of CCl4 treatment 
on mRNA levels of Tnf, Il1b, and Ccl2 (Figure 3.4A). 
 
3.3.6 Effect of choline ± methionine deficiency on sensitivity to CCl4 induced 
hepatic fibrosis 
 
Picosirius red staining confirmed that twice weekly injections of CCl4 induced 
hepatic fibrosis in all three dietary groups (Figure 3.5). The increase in picosirius red 
staining in response to CCl4 was less pronounced in MCDD mice, although there was 
only a trend for an interaction between diet and CCl4 treatment by two way ANOVA 
(F[2,36]=2.81, P=0.74).  
 
CCl4 induced hepatic stellate cell activation, with post hoc analysis demonstrating a 
significant increase in αSMA staining in response to CCl4 in MCDD mice alone 
(Figure 3.5). However, two way ANOVA did not demonstrate any interaction 
between diet and CCl4 treatment.  
 
Unlike the immunohistochemistry results, there was no additional effect of CCl4 on 
mRNA levels of Acta2 (encoding αSMA) (Figure 3.4). In addition, CCl4 did not 
influence Col1A or Tgfb1 mRNA levels.  
 
CCl4 treatment did not influence expression of Mmp 9, 12 and 13, or Timp 1 (Figure 
3.4B). There was an effect of CCl4 on Timp2 mRNA levels, although post hoc tests 
did not reveal any significant differences. CCl4 also influenced mRNA transcripts of 
Mmp2, although post hoc testing showed a significant difference in CDD mice alone.   
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Figure 3.1 Effect of choline ± methionine deficiency and carbon tetrachloride 
treatment on body weight 
A) Body weights in olive oil (OO) treated controls and B) CCl4 treated CS, CDD and MCDD 
fed mice. Data are mean ± SEM (N=7/group). Final body weights were analysed by two way 
ANOVA with Bonferonni`s post hoc test where appropriate. There was a significant 
influence of diet on final body weights F(2,36)=154.15, P<0.0001, with P<0.0001 for 
MCDD vs CDD and CS mice. Carbon tetrachloride (CCl4) also had a significant influence 
on final body weights F(1,36)=16.47, P<0.001; P<0.05 for CCl4 treated CS mice, and 
P<0.01 for CCl4 treated CDD mice. There was a significant interaction between diet and 
CCl4 F(2,36)=3.99, P=0.027 and simple main effects analysis found an effect of CCl4 on 
final body weights in CS (F=9.42, P<0.01) and CDD (F=14.97, P<0.001) mice.   





























































































Figure 3.2 Leptin levels in choline ± methionine deficiency 
Results are mean ± SEM. Differences between groups were analysed by two way ANOVA. 
N=6-7/group.  The was a significant influence of diet on plasma leptin levels F(2,35)=15.98, 
p<0.0001. P<0.0001 for MCDD vs CS, P<0.001 for MCDD vs CDD using Bonferonni’s 














































Table 3.2 Influence of choline ± methionine deficiency and carbon tetrachloride 
(CCl4) treatment on body composition 
Data are mean ± SEM. N=7/group. Differences between groups were analysed by two way 
ANOVA with Bonferroni’s post hoc tests where appropriate. ****F(2,36)=24.51, P<0.0001, 
for an effect of diet on liver weights; P<0.0001 for MCDD vs CS and CDD mice. 
††††F(2,36)=20.38, P<0.0001 for an effect of diet on liver triglyceride (TG) concentrations; 
P<0.0001 for CDD vs CS and MCDD vs CS. §§§§F(2,36)=54.81, P<0.0001 for an effect of 
diet on gonadal fat; P<0.0001 for MCDD vs CS and CDD mice, and §§§F(1,36)=8.61, 
P=0.006 for an effect of CCl4 on gonadal fat; P<0.05 for CCl4 treated CS mice. 
‡‡‡‡F(2,36)=21.44; P<0.0001 for an effect of diet on subcutaneous adipose tissue; P<0.0001 
for MCDD vs CS and CDD mice. 
 
  Controls   CCl4  
 CS CDD MCDD CS CDD  MCDD 
Liver        
Weight (g) **** 1.29±0.05 1.28±0.09 0.87±0.03 1.21±0.08 1.14±0.1 0.78±0.03 
Weight (% body 
weight) 
5.1±0.1 5.1±0.3 5.3±0.2 5.2±0.2 5.0±0.4 4.7±0.1 
Liver TGs (µmol/g) †††† 19.6±4.1 34.4±2.6 39.9±2.2 17.4±2.8 40.2±5.4 40.3±4.0 
Fat depots (as % body 
weight) 
      
Gonadal§§§§/§§§ 1.7±0.1 1.7±0.2 0.5±0.1 1.3±0.1 1.4±0.1 0.4±0.1 
Subcutaneous‡‡‡‡     2.4±0.3 2.4±0.2 1.3±0.1 2.4±0.1 2.2±0.1 1.4±0.1 
Muscle weight (as % 
body weight) 
      




Figure 3.3 Hepatic neutrophil and macrophage staining in carbon tetrachloride 
treated choline ± methionine deficient mice 
A) Hepatic neutrophil staining (anti GR1 antibody) and B) cells counts from male C57Bl6 
mice fed a CS, CDD or MCDD and treated with carbon tetrachloride (CCl4) or olive oil 
(OO). C) F4/80 staining of hepatic macrophages, and D) quantification by pixel analysis. 
Images x200 magnification. Results are mean ± SEM. N=7/group. Differences between 
groups were analysed by two way ANOVA with Bonferroni’s post hoc analysis where 
appropriate. There was a significant effect of diet on neutrophil counts F(2,36)=19.70, 
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Figure 3.4 Influence of choline ± methionine deficiency and carbon tetrachloride 
on hepatic gene expression  
Abundance of gene transcripts are expressed relative to that of internal control genes. 
Transcripts of proinflammatory and profibrotic genes are presented in panel A and matrix 
metalloproteinase (Mmp) and tissue inhibitors of matrix metalloproteinases (Timps) in panel 
B. Data are expressed as a ratio to the abundance of transcripts of control gene, as means ± 
SEM. N=5-6/group. Differences between groups were analysed by two way ANOVA with 



































































































































































































































































































































































































































































F(2,35)=4.15, P<0.05 for an effect of diet,







































































































































































































































































































































































































Figure 3.5 Hepatic fibrosis and hepatic stellate cell activation in carbon 
tetrachloride treated choline ± methionine deficient mice 
A) Picosirius red staining (PSR) in CS, CDD, and MCDD mice treated with olive oil (OO) 
or carbon tetrachloride (CCl4). Magnification x50. B) PSR image analysis C) αSMA staining 
and D) hepatic stellate cells per high power field (D). Magnification x200. Results are mean 
± SEM. N=7/group. Differences between groups were analysed by two way ANOVA with 
Bonferroni’s post hoc analysis where appropriate. F(1,36)=79.66, P<0.0001 for an 
effect of CCl4 on PSR staining. F(2,36)=12.68, P<0.0001 for an effect of diet on 
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Liver histology and immunohistochemistry demonstrated an acute inflammatory 
infiltrate in mice fed the methionine and choline deficient diet (MCDD), confirming 
that MCDD, and not an isolated choline deficient diet (CDD), leads to significant 
steatohepatitis after four weeks. However, the data demonstrates that steatohepatitis 
secondary to MCDD does not increase susceptibility to carbon tetrachloride (CCl4) 
induced liver fibrosis in mice. Indeed, CCl4 induced hepatic fibrosis was, if anything,  
lower in MCDD fed mice than in those with simple steatosis due to choline 
deficiency alone. These findings emphasise the complexity of the relationship 
between hepatic inflammation and fibrosis, suggesting that factors additional to those 
promoting steatohepatitis may determine progression to hepatic fibrosis.  
 
In addition to steatohepatitis, the MCDD, but not the CDD, led to activation of 
hepatic stellate cells (HSCs), central players in the development of hepatic fibrosis. 
Furthermore, the MCDD increased both pro-inflammatory and pro-fibrotic cytokine 
gene expression, including Tnf, Il1b, and Tgfb1. Other key baseline differences 
between dietary models included the expression of the genes encoding the matrix 
metalloproteinases (MMPs), and their tissue inhibitors (TIMPs). The MCDD 
increased expression of Mmp 9, 12 and 13, and Timp1, although despite the latter 
there was no detectable increase in fibrosis by analysis of picosirius red staining. 
 
Picosirius red staining confirmed hepatic fibrosis in each dietary group treated with 
CCl4, compared with olive oil treated controls. However, despite the greater CCl4-
associated activation of hepatic stellate cells in MCDD than CDD mice, and 
regardless of the MCDD induced pro-inflammatory and pro-fibrotic phenotype, there 
was no increase in fibrosis in MCDD than CDD treated mice. Furthermore, despite 
generalised upregulation of MMPs in MCDD mice, they did not upregulate Mmp2 
expression as was seen in CDD mice following CCl4 injury.  
 
Current dogma suggests that chronic liver injury and therefore inflammation leads to 
hepatic fibrosis, with cytokines such as those upregulated by the MCDD, leading to 
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HSC activation and increased production of TIMPs. Hepatic stellate cells are central 
to the development of hepatic fibrosis, developing a myofibroblast-like phenotype in 
response to inflammation, and secreting the fibrillar collagens that contribute to the 
fibrotic extracellular matrix (ECM) (Atzori et al. 2009;Rockey et al. 1992). The 
HSCs can also produce MMPs/TIMPs, cytokines (eg TGFβ), and oxidative stress 
(Atzori et al. 2009).  
 
The increase in hepatic stellate cell activation was marked in MCDD mice. However, 
this was not translated into increased fibrosis, suggesting that factors distal to hepatic 
stellate cell activation in the complex fibrotic cascade are essential for translation 
into hepatic fibrosis. The increased extracellular matrix deposition in liver fibrosis 
can be considered an imbalance between matrix deposition and degradation, with 
MMPs and their inhibitors playing an essential role in this process. Although pro-
fibrogenic TIMP1 was upregulated in MCDD mice, the marked MMP response in 
may have hastened the resolution of any CCl4 induced scar in this group. Indeed, the 
lack of upregulation of Col1a2 suggests that collagen synthesis was occurring at 
similar rates in all groups, supporting the hypothesis that altered rates of degradation 
may be a key difference between these models. However, the dynamic nature of 
MMP and TIMP expression also means that we may have missed early differences 
three days after CCl4 injection, and may explain for example the differences between 
αSMA staining and gene expression (Hemmann et al. 2007). 
 
Clearly a key difference between the groups was the weight loss in the MCDD group. 
This was associated with low leptin levels in the MCDD but not the CDD group, and 
the weight loss in the MCDD group may therefore be acting to protect the liver from 
fibrosis. In keeping with this, obese, diabetic, hyperleptinaemic db/db mice fail to 
lose weight and develop increased hepatic fibrosis compared to ob/ob and db/m 
controls fed a MCDD. Leptin appears to be essential for the fibrogenic response to 
CCl4 (Leclercq et al. 2002). Another adipocytokine, adiponectin, may also be 
important in the progression to fibrosis, having previously been shown to be 
increased in the MCDD model (Okumura et al. 2006), and adiponectin can inhibit 
hepatic stellate cell activation (Adachi et al. 2008). 
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No rodent model of NAFLD fully recapitulates human disease. Nonetheless, MCDD 
has been extensively studied in rodents as it reliably produces a histological picture 
similar to human non-alcoholic steatohepatitis (NASH), and prolonged MCDD 
feeding can induce mild fibrosis (Mu et al. 2010;Sahai et al. 2004a). Previous studies 
have confirmed upregulation of pro-inflammatory and pro-fibrotic cytokines in 
MCDD mice (e.g. (Leclercq et al. 2004;Mu et al. 2010;Sahai et al. 2004b)). Similarly, 
increased TIMP1 and MMP expression has recently been demonstrated in the 
MCDD model (Mu et al. 2010). However, crucially, previous studies have not 
included controls with fatty liver. A CDD leads to steatosis alone and has been less 
well studied than MCDD in fatty liver research, although prolonged administration in 
rats leads to hepatic fibrosis (Mu et al. 2010;Sakaida et al. 1998). Intriguingly CDD 
improves insulin sensitivity in high fat fed mice, possibly due to altered intra-hepatic 
fatty acid handling (Raubenheimer et al. 2006). Whether these differences between 
CDD and MCDD mice influence susceptibility to hepatic fibrosis has not previously 
been studied.  
 
Carbon tetrachloride injury is probably the best characterised model of hepatic 
fibrogenesis. CCl4 is metabolised to toxic trichloromethyl (CCl3*) free radicals by 
cytochrome P450s (especially CYP2E1, 2B1 and CYP3A) (Clawson 1989), which 
reacts with oxygen to form trichloromethylperoxy radicals (CCl3OO*) causing lipid 
peroxidation and possibly reducing VLDL export (Boll et al. 2001;Weber et al. 
2003). Indeed, given the upregulation of CCl4 metabolising CYP2E1 in MCDD the 
model (Leclercq et al. 2000), and the proposed role of oxidative stress in the 
pathogenesis of the MCDD model (Oz et al. 2006), we had hypothesised a greater 
fibrotic reaction in the MCDD group. Reduced phosphatidlycholine synthesis in 
MCDD mice may partly explain this finding as CCl3* has been shown to bind 
phosphatidylcholine in particular (Boll et al. 2001). Interestingly, we did not see 
conversion of the CDD into MCDD phenotype, which might have been expected if a 
lack of hepatic methionine/glutathione dependent antioxidants was the only 
difference between MCDD and CDD fed rodents (Oz et al. 2006), supporting the 
hypothesis that factors other than oxidative stress explain the contrasting phenotypes 
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in these two models. In support of this, markers of oxidative stress do not increase 
until after eight weeks in MCDD fed mice, with mild fibrosis not occurring until this 
time (Sahai et al. 2004a;Yamaguchi et al. 2007) 
 
It is possible the duration of the experiment may have limited our ability to detect 
differences in fibrosis between groups. However, we were unable to study mice for 
longer than in the current experiment due to UK Home Office limitations with 
respect to weight loss, although four weeks of CCl4 treatment is usually sufficient to 
induce fibrosis (Constandinou et al. 2005). Lastly, it is possible that our method of 
quantifying fibrosis may have underestimated the degree of perivascular fibrosis in 
MCDD mice, as we avoided large blood vessels to avoid confounding effects of 
vascular type 1 collagen staining. Additional measures of hepatic fibrosis e.g. semi-
quantitative histological scoring or hepatic hydroxyproline content analysis may also 
have been helpful. 
 
In summary, we examined the susceptibility of two contrasting dietary models of 
NAFLD and demonstrated that in mice deficient in choline and/or methionine neither 
steatosis nor steatohepatitis increased susceptibility to CCl4 induced fibrosis. This 
was despite greater upregulation of pro-inflammatory and pro-fibrotic cytokines, and 
more marked hepatic stellate cell activation in MCDD mice. The significant 
upregulation of matrix turnover apparatus in the MCDD model may have limited the 
fibrogenic response by enhancing collagen degradation. In addition, the reduction in 
leptin levels was another key difference potentially limiting fibrosis in MCDD fed 
mice, supporting the hypothesis that the development of progressive liver disease is 
dependent on the associated metabolic milieu. Two inter-related metabolic factors 
that may be critical in modulating progression to liver disease include intrahepatic 
fatty acid and glucocorticoid metabolism. These factors may have important 
implications for human disease, potentially explaining the highly variable 
progression to fibrosis in NAFLD.  
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4 Chapter 4-Metabolic pathways promoting intrahepatic fatty acid 
accumulation in methionine and choline deficiency; implications for 




In Chapter 3 I confirmed that mice fed a methionine and choline deficient diet 
(MCDD), but not a choline deficient diet (CDD), developed a pro-inflammatory and 
pro-fibrotic phenotype associated with the development of steatohepatitis. The 
mechanisms underlying susceptibility to progressive liver disease in the MCDD 
model, and in NAFLD in general, remain incompletely defined. Importantly, it is not 
known whether specific changes in hepatic triglyceride handling leading to the 
accumulation of intracellular fatty acids predisposes to hepatocyte damage and the 
development of non-alcoholic steatohepatitis (NASH). However, the marked weight 
loss induced by the MCDD would suggest that changes in fatty acid metabolism may 
be central to the development of NASH in this model. 
 
Broadly speaking, the accumulation of hepatic triglyceride can be considered an 
imbalance between the supply of free fatty acids (FFAs), from both plasma and intra-
hepatic de novo lipogenesis (DNL), and their removal either by fatty acid oxidation 
or export in very low density lipoprotein (VLDL). Studies in humans suggest that 
both increased release of FFAs from extra hepatic tissues and increased DNL 
contribute to the accumulation of liver triglyceride in NAFLD (Donnelly et al. 
2005;Fabbrini et al. 2008;Fabbrini et al. 2009). Such abnormalities of fatty acid 
metabolism may play a role not only in the insulin resistance associated with 
NAFLD, but also in promoting hepatic inflammation. In addition to influencing rates 
of hepatic gluconeogenesis and VLDL export (Chen et al. 1999;Lewis et al. 1995), 
FFAs are inherently toxic to hepatocytes (Malhi et al. 2006), e.g. activating the 
proinflammatory cytokine nuclear transcription factor kappa β (Feldstein et al. 
2004;Itani et al. 2002), and upregulating mediators of apoptosis (Feldstein et al. 
2003). A toxic role for FFAs in the liver is supported by the observation that 
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inhibiting diacylglycerol acyltransferase 2, the final enzyme in the pathway 
esterifying fatty acids to triglycerides, promotes steatohepatitis and liver fibrosis in 
mice, despite reducing intrahepatic triglycerides (Yamaguchi et al. 2007). 
 
In humans practical limitations mean that only the broadest association can be made 
between hepatic triglyceride/fatty acid handling and NASH. In contrast the 
mechanisms underlying susceptibility to steatohepatitis and fibrosis mediated by 
fatty acids can be defined by studies in animal models with contrasting susceptibility 
to NASH. Feeding rodents diets deficient in choline and/or methionine reliably leads 
to the accumulation of intrahepatic triglyceride (Ghoshal and Farber 1993;Nakae 
1999), but there are contrasting consequences for liver inflammation. A MCDD 
causes steatohepatitis and hepatic insulin resistance (Leclercq et al. 2007;Rinella et al. 
2008;Rizki et al. 2006), albeit that peripheral insulin sensitivity is improved due to 
significant weight loss (Rinella and Green 2004). In contrast, a simple CDD leads to 
steatosis without significant inflammation, and is associated with improved hepatic 
and peripheral insulin sensitivity without weight loss following a high fat diet 
(Raubenheimer et al. 2006). These diets provide readily tractable models to define 
the differences in hepatic fatty acid metabolism that underlies susceptibility to NASH 
as opposed to simple steatosis.  
 
Impaired VLDL export was previously thought to be the dominant mechanism for 
the accumulation of liver fat in both CDD and MCDD models (Lombardi et al. 1968). 
More recent ex vivo studies have shown that VLDL export may not be decreased in 
CDD mice (Kulinski et al. 2004), while alterations in gene expression support the 
hypothesis that a primary increase in fatty acid esterification protects CDD mice 
against the toxic effects of intrahepatic fatty acids (Raubenheimer et al. 2006). 
Moreover, weight loss in MCDD but not CDD mice suggests that increased flux of 
potentially toxic FFAs from the periphery to the liver may only occur with MCDD. 
However, these inferences concerning fatty acid metabolism in MCDD and CDD 
mice are drawn indirectly from ex vivo measurements. In this Chapter I have 
characterized fatty acid metabolism in detail in vivo using stable isotope tracers in 
mice fed CDD and MCDD, and identified pathways which could explain contrasting 
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propensity to hepatocyte damage and steatohepatitis in these models; observations 
with implications for understanding the pathogenesis of human NASH. 
 
 




Stable-isotope labeled tracers were from Cambridge Isotopes (Andover, MA, USA) 
and all other chemicals from Sigma (Poole, UK) unless otherwise stated. Solvents 
were glass-distilled HPLC grade (Rathburn, Walkerburn, UK). Human albumin 
solution (20%w/v) was from the Scottish National Blood Transfusion Service 
(Lothian, UK). 
 
4.2.2 Animals and procedures 
  
All experiments were carried out under a UK Home Office animal license. 12 week 
old male C57BL/6J mice (Harlan, Bicester, UK) were maintained under controlled 
conditions of light and temperature. Following a 2 week period of acclimatization, 
mice were offered either control (choline and methionine supplemented) chow (CS), 
choline deficient diet (CDD) or methionine-choline deficient diet (MCDD) (Dyets 
Inc., Bethlehem, PA) for 2 weeks as per Section 2.2.  
 
4.2.3 Fatty acid flux studies 
  
To quantify FFA turnover by stable isotope dilution, 1,2,3,4-[13C]4-palmitate was 
infused intravenously (n= 12-15 mice/group) and tracer enrichment of the palmitate 
pool in liver, adipose tissue and plasma was measured by gas chromatography mass 
spectrometry (GCMS) (Baar et al. 2005) as described in Section 2.9.3.  
 
Jugular venous cannulae were inserted under general anaesthesia (intraperitoneal 
medetomidine and ketamine) on day 10 of dietary manipulations, and mice allowed 
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four days to recover prior to tracer infusions as described in detail in Section 2.11.1. 
[13C]4 palmitate was prepared by dissolving its potassium salt in saline and 
complexing with 20% w/v albumin solution at 40°C. In initial studies a stock 
solution was diluted so that infusion at 5µl/min provided 0.271µmoles/kg/min tracer  
(Baar et al. 2005;Jung et al. 1999). Following preliminary analysis, the concentration 
was later increased so that the infusion delivered 0.542µmoles/kg/min to increase 
tissue enrichment. Calculated kinetic results were similar in both groups so data were 
combined for statistical analysis. Following a four hour fast, the tracer infusion was 
commenced using a Harvard apparatus syringe pump (World Precision Instruments, 
Stevenage, UK) for 180minutes (Jung et al. 1999). Animals were sacrificed by 
decapitation within 60seconds of being disturbed and trunk blood collected on wet 
ice. Plasma was stored at -80oC. Liver and adipose depots were immediately 
harvested, weighed and snap frozen on dry ice. Palmitate and its tracer were 
quantified by GCMS and triglycerides (TG) by spectrophotometric assay as detailed 
below. 
 
4.2.3.1 Kinetic calculations 
Assuming steady state conditions after 180minutes of infusion (Baar et al. 2005), the 
rate of appearance (Ra) of palmitate in plasma was calculated using equation 1. 
 
Equation 1 
Ra (µmol/kg/min) = F/IE 
 
where F is the isotope infusion rate (µmol/kg/min) and IE is the isotopic enrichment 
(the tracer to tracee ratio [TTR]).  
 
An index of the contribution of circulating FFAs to TG pools in tissues and plasma 





Fraction of TG palmitate derived from plasma FFA =   
IE of [13C]4 -palmitate in TG palmitate/ IE of [
13C]4- palmitate in plasma 
 
The absolute contribution of circulating palmitate to tissue or plasma TGs was 
calculated by correcting for the TG pool size using equation 3.    
 
Equation 3 
Absolute palmitate uptake = fraction of TG palmitate derived from plasma x TG pool 
size 
 
where tissue and plasma TG pool sizes were calculated by multiplying TG 
concentration by tissue weight (assuming adipose tissue to be composed of pure TG 
of molecular weight 861 (Frayn 1983)), or estimated plasma volume (3.5% body 
weight (Huang et al. 2006)) respectively.  
 
4.2.4 De novo lipogenesis studies 
 
To assess DNL, in other groups of mice (n=8/group), [13C]2-acetate was added to 
diets for 5 days before sacrifice and incorporation of 13C into TG assessed in liver 
and plasma using mass isotopomer distribution analysis (MIDA) after analysis of 
TG-derived palmitate and its labeled isotopomers by GCMS (Baar et al. 
2005;Hellerstein and Neese 1999). Mice were housed individually and fed diets as 
above in a paste (225g powdered chow as above with 45ml water) packed into 50ml 
plastic tubes to facilitate weighing of food intake for the duration of the study. For 
the final 5 days, labeled [13C]2-acetate (4.5g) was added to the water before 
preparation of the paste. Tissues were collected as described above.  
 
4.2.4.1 Mass isotopomer distribution analysis 
GCMS was used to determine the pattern of incorporation of [13C]2-acetate into 
newly synthesized hepatic TG FFAs using the method of Chinkes et al (Chinkes et al. 
1996) as described in detail in Section 2.7.2.4. 
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4.2.5 Hepatic triglyceride export studies 
 
In further mice (n=7-8/group), following a 4 hour fast, hepatic VLDL export was 
assessed by measuring the rate of accumulation of TG (quantified by 
spectrophotometry) in plasma from serial tail nicks taken at 0, 30, 60, 120 and 
180minutes following administration of tyloxapol (Triton W1339) by tail vein 
injection (500mg/kg; 15% v/v in normal saline)(Li et al. 1997). Equation 4 converted 
the rate of appearance per plasma volume into whole body rate of appearance, and 
plasma volume was estimated as 3.5% of body weight (Huang et al. 2006). 
 
Equation 4 
TG export (mg/kg/hour) =  
[slope of line (mg/dl/min) x estimated plasma volume (dl)] / [weight (kg) x 60] 
 
4.2.6 Hepatic inflammation studies 
 
In an additional study (n=10/group), livers were fixed in 10%v/v formalin for 
immunohistochemical analysis after two weeks of dietary interventions, as above. In 
addition, fasting plasma samples from these mice were used for measurement of liver 
function tests and total plasma FFAs. 
 
4.2.7 Biochemical Assays 
 
4.2.7.1 Lipid extraction 
Plasma free fatty acids were extracted and derivatised using a modified method of 
Patterson et al (Patterson et al. 1999) as described in Section 2.9.1. 
 
To measure palmitate enrichment of plasma and hepatic TGs, lipids were extracted 
using a modified Folch technique (Folch et al. 1957) and the TG fraction separated 
by solid phase extraction (Burdge et al. 2000). TGs were then hydrolysed to their 
constituent FFAs and derivatised using acidified methanolic sulphuric acid (2% v/v) 
as described in Section 2.9.2. 
 148 
 
4.2.7.2 Gas chromatography mass spectrometry 
GC-MS conditions were as described in Section 2.9.3 and fatty acid methyl esters 
derived from plasma FFA and TG pools were analysed using selective ion 
monitoring of molecular ions with m/z 270, 272, 274 and 284, corresponding to 
[M+0], [M+2], and [M+4] isotopomers of methyl palmitate and the methyl 
heptadecanoate internal standard respectively. To avoid concentration dependent 
effects of methyl palmitate on ionization, each sample was analysed several times 
using a range of injection volumes as previously described (Patterson et al. 1998), 
and tracer to tracee ratios determined from a standard curve. 
 
4.2.7.3 Enzymatic assays 
Plasma and liver TGs were quantified enzymatically using a colorimetric assay 
(Infinity; ThermoTrace, Australia), as described in Section 2.10. Plasma FFAs were 
measured in duplicate using a commercial kit (Wako, Fuggerstrabe, Germany), and 
liver function tests, including alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST), measured using commercial colorimetric kits (Randox 
laboratories, Co. Antrim, UK) adapted for use on a Cobras centrifugal analyser 




Paraffin embedded sections of liver were stained using an anti-granulocyte antibody 
(108413 Rat anti-mouse GR1 antibody, Cambridge Biosciences, Cambridge, UK) as 
described in detail in Section 2.5.3.3.  
 
4.2.9 Statistical analysis 
 
Results are presented as mean ± standard error (SEM) and were compared by one 





4.3.1 Body composition and liver triglycerides 
 
The three groups of mice were the same weight initially. Consistent with previous 
studies (Rinella et al. 2008;Rizki et al. 2006) mice on MCDD lost weight (Figure 
4.1), with marked loss of both subcutaneous and epididymal fat (Table 4.1). CDD 
mice gained weight, but less than mice on control diet (Figure 4.1). Food intake 
(measured in the DNL study) was reduced on MCDD compared to both control diet 
and CDD (Table 4.1). However, mice were otherwise active and healthy, displaying 
no external signs of distress. 
 
Figure 4.1 Effect of choline ± methionine deficiency on body weight  
Data points represent mean ± SEM. N= 8-30/group depending on time point. Final weights 
were analysed by one away ANOVA with Tukey`s post hoc comparison test. CS, control diet; 













































Liver triglyceride pool size was variable, but similarly increased in both CDD and 
MCDD mice compared to controls after two weeks of dietary intervention (Table 
4.1).  
 
Table 4.1 Effect of choline ± methionine deficiency on liver weights and 
triglycerides, adipose depot weights and food intake 
Data are means ± SEM, analysed by one way ANOVA with Tukey`s post hoc tests where 
appropriate. *P<0.05, ***P<0.001 vs CS; †P<0.05, ††P<0.01, †††P<0.001 vs CDD. Data were 
collected in different experiments and combined here, hence varying numbers: $n= 21-










Liver weight        
(% body weight) 
4.0±0.1 4.7±0.1*** 3.8±0.1††† 
Liver TG pool 
(µmol/liver)$ 
24.37±2.4 45.94±3.9*** 43.30±3.5*** 
Adipose depot weights 
(% body weight) 
   
   Subcutaneous$ 1.5±0.2 1.3±0.1 0.7±0.1***/†† 
   Epididymal$ 1.6±0.1 1.4±0.1 0.4±0.0***/††† 
   Mesenteric§  0.3±0.1 0.4±0.1 0.1±0.0*/††† 
Food intake  
(g/kg body weight/day)§ 
127.9±4.5 130.8±2.8 104±2.7***/††† 
Liver function tests§    
   Bilirubin (µmol/l) 4.9 ± 0.8 4.5 ± 0.7 5.3 ± 0.6 
   ALT (U/L) 31 ± 3 48 ± 4 231 ± 79†/* 




4.3.2 Hepatic inflammation 
 
Steatohepatitis was confirmed in the MCDD mice at two weeks, with substantially 
increased plasma ALT (Table 4.1) and an inflammatory infiltrate in the liver on 
immunohistochemistry (Figure 4.2). In contrast, there was no elevation in plasma 
transaminases or liver inflammatory infiltrate in CDD mice. 
 
Figure 4.2 Effects of choline ± methionine deficiency on liver inflammatory cell 
infiltration 
Data are mean ± SEM for n= 10 per group. Two weeks of a methionine and choline deficient 
diet (MCDD) but not choline deficient diet (CDD) produced an increase in neutrophil 
staining. A) Average cell counts of anti GR1 positive staining cells per high power fields, 
*p<0.05. Exemplary GR1 positive staining cells in B) controls group (CS), C) CDD and D) 














































4.3.3 Fatty acid flux 
 
Despite the loss of peripheral fat depots in the MCDD group, the rate of appearance 
(Ra) of palmitate did not differ between the three groups (Table 4.2). In keeping with 
this, fasting FFAs were not statistically different: 670±62 vs 602±91 vs 887±220 
µmol/l for CS, CDD, and MCDD respectively. 
 
The contribution of FFAs to triglyceride pools was assessed in liver and plasma. 
Despite marked differences in the fractional contribution of plasma palmitate to liver 
triglycerides, there was no effect of diet on the absolute contribution of plasma 
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palmitate to the liver triglyceride-derived palmitate pool. However, the contribution 
of plasma palmitate to circulating triglyceride-palmitate was reduced in MCDD mice. 
 
Table 4.2 Effect of choline ± methionine deficiency on fatty acid flux measured 
by dilution of [
13
C]4 palmitate tracer 
Data are means ± SEM, analysed by one way ANOVA with Tukey`s post hoc tests where 
appropriate:  *P<0.05, **P<0.01, ***P<0.001 vs CS; †P<0.05 vs CDD.  N= 12-15/group. 







27.16±3.46 26.25±2.27 28.34±3.46 
Fractional 
contribution to liver 
TG pool (%) 
34.03±5.11 11.38±1.95*** 14.56±1.93*** 
Liver TG pool 
(µmol/liver) 
23.98±3.69 51.27±6.15** 40.52±4.58* 
Absolute 
contribution to liver 
TG pool 
(µmol/liver) 
6.88±1.12 5.10±0.87 5.83±0.93 
Fractional 
contribution to 
plasma TG pool (%) 
39.55±5.25 28.80±4.30 23.77±5.23 
Plasma TG pool size 
(µmoles)  
0.67±0.05 0.67±0.06 0.46±0.3*/† 
Absolute 
contribution to 
plasma TG pool 
(µmoles) 
0.26±0.04 0.19±0.04 0.11±0.03* 
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4.3.4 De novo lipogenesis 
 
MIDA of triglyceride palmitate following ingestion of [13C]2-acetate is summarized 
in Table 4.3. There were no differences in fractional synthesis rates, i.e. the 
percentage of newly synthesized fatty acids contributing to the triglyceride pool, 
between diets. However, taking into account the differing hepatic triglyceride pool 
sizes, there was a marked increase in absolute rates of hepatic DNL in MCDD mice, 
which was not detected in CDD mice. Despite increased hepatic DNL in MCDD 
mice, a smaller amount of newly synthesized fatty acids appeared in the plasma 
triglyceride pool.  
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Table 4.3 Effect of choline ± methionine deficiency on hepatic de novo 
lipogenesis and newly synthesised hepatic fatty acid export 
Absolute synthesis rates were calculated from mass isotopomer distribution analysis of 
triglyceride derived palmitate following dietary [13C]2-acetate labeling. The absolute 
synthesis rate of plasma TGs represents the hepatic export of newly synthesised fatty acids. 
Results are means ± SEM, analysed by one way ANOVA with Tukey’s post hoc tests where 
appropriate. *P<0.05, **P<0.01 vs CS. N=8/group, except plasma TG data, where n=5-
7/group 





Liver    
Acetyl CoA 
enrichment (%) 
7.6±0.6 8.9±0.5 7.2±0.3 
Liver TG pool 
(µmol/liver) 
25.0±2.3 38.2±4.0 48.5±5.0** 
M+2 Enrichment 0.104±0.009 0.121±0.008 0.132±0.007 




5.6±0.7 5.9±0.4 6.8±0.3 
Absolute synthesis 
rate (µmol/day) 
1.4±0.3 2.3±0.4 3.4±0.4** 
Plasma TG    
Acetyl CoA 
enrichment (%) 
7.6±0.5 8.9±0.4 7.4±0.4 




6.5±0.5 6.2±0.4 6.6±0.7 
Absolute synthesis 
rate (µmol/day) 
0.33±0.05 0.27±0.04 0.19±0.03* 
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4.3.5 Triglyceride export 
 
Intravenous tyloxapol induced a linear increase in plasma triglyceride levels, which 
was not altered in CDD mice but was markedly reduced in MCDD mice (Figure 4.3).  
 
Figure 4.3 Effect of choline ± methionine deficiency on plasma triglycerides 
(TG) following intravenous tyloxapol 
Hepatic TG export was reduced in the MCDD group only. Data are expressed as mean ± 
SEM. Rate of TG export (142±21 vs 122±15 vs 80±7mg/kg/hr for CS, CDD and MCDD 
respectively) was calculated from the linear portion of the graphs using Equation 6 and 
analysed by one away ANOVA with Tukey`s post hoc comparison test where appropriate. 







These data reveal marked differences in fatty acid metabolism in mice fed a 
methionine and choline-deficient diet (MCDD) versus a simple choline-deficient diet 
(CDD), which may promote the development of hepatocyte damage and 
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triglyceride accumulation. Measurement of plasma triglycerides after tyloxapol 
confirmed impaired hepatic triglyceride export in the MCDD mice only, with 
palmitate and acetate tracer administration demonstrating that export of both newly 
synthesized and plasma derived re-esterified FFAs is impaired. Reduced liver 
secretion of fatty acids (in VLDL) and hence supply to adipose tissue, rather than 
increased lipolysis and adipose release of fatty acids, may therefore contribute to loss 
of body fat in MCDD mice. In addition, hepatic de novo lipogenesis (DNL) is 
increased in MCDD mice, potentially exacerbating accumulation of fatty acids as 
well as triglycerides in hepatocytes. In contrast, in choline deficiency without 
methionine deficiency (CDD) there were no significant changes in liver triglyceride 
secretion, fatty acid turnover or DNL. No increased fatty acid esterification was 
measured in CDD mice by [13C]4 dilution, as previously hypothesized 
(Raubenheimer et al. 2006), although we cannot exclude that a co-existing 
intrahepatic fatty acid pool exists that is not successfully labeled in our tracer studies 
and contributes to triglyceride accrual. 
 
Methionine and choline are both key nutrients necessary for the synthesis of 
phosphatidyl choline and export of VLDL from the liver (Li and Vance 2008;Zeisel 
and Blusztajn 1994). It has been widely assumed that hepatic triglyceride 
accumulation in both CDD and MCDD is the result of impaired VLDL export 
(reviewed in (Kulinski et al. 2004)). Impaired VLDL export has recently been 
confirmed using tyloxapol in MCDD mice (Rinella et al. 2008). However, in CDD 
mice this explanation is based on an experiment which demonstrated reduced 
incorporation of radiolabeled palmitate tracer into plasma triglycerides and retention 
of radioactivity in the liver in rats acutely (15 hours) after introducing a CDD 
(Lombardi et al. 1968). These observations could be explained by increased dilution 
of tracer in the expanded triglyceride storage pool in liver from which VLDL is 
exported, or increased mitochondrial oxidation of palmitate and release of 
radioactivity. Here, we show that CDD mice studied after 2 weeks of dietary 
manipulation do not share an impairment of hepatic VLDL export with MCDD mice. 
Not only was triglyceride accumulation following tyloxapol normal in CDD mice, 
but incorporation of palmitate tracer into plasma triglycerides was intact following 
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tracer palmitate or acetate administration. This conclusion is supported by recent in 
vitro studies in murine liver cell lines (Kulinski et al. 2004).  
 
The difference in VLDL export between CDD and MCDD alone is unlikely to 
explain the contrasting risk of steatohepatitis. Both apolipoprotein B100 (apoB100) 
and the Mttp encoded microsomal triglyceride transfer protein are essential for 
hepatic triglyceride export, and deficiency of these proteins in both mice and humans 
leads to hepatic steatosis (Bjorkegren et al. 2002;Li et al. 1997;Raabe et al. 
1999;Schonfeld et al. 2003;Wetterau et al. 1992), but critically is not associated with 
the inflammation seen in the MCDD model. However, impaired VLDL export may 
sensitize the liver to additional toxic insults, as evidenced by an increase in 
lipopolysaccharide induced inflammation in mice with reduced hepatic Mttp 
expression (Charlton et al. 2002). Moreover, limited circumstantial evidence 
suggests that patients with steatohepatitis have impaired apoB-dependent triglyceride 
export (Tietge et al. 1999) and more frequent polymorphisms in the Mttp gene 
(Schonfeld et al. 2008). 
 
The impaired hepatic triglyceride export and steatosis found in the ApoB-38.9 mouse 
model of familial hypobetalipoproteinaemia is associated with suppression of de 
novo lipogenesis, perhaps reflecting an adaptive mechanism (Lin et al. 2002). Using 
deuterium as a tracer, DNL has previously been shown to be lower in C3H/HeOuJ 
mice fed a high sucrose, lipogenic MCDD than in mice fed a methionine/choline 
supplemented lipogenic diet; however, in keeping with our findings, absolute DNL 
rates were still markedly elevated on the lipogenic MCDD diet compared to standard 
chow fed controls (Rizki et al. 2006). DNL has not previously been investigated in 
CDD mice using in vivo tracer techniques. We found that DNL is markedly increased 
in MCDD mice but not in CDD mice, although this result should be interpreted with 
the caveat that the ASR calculation is dependent on the hepatic triglyceride pool size 
which, surprisingly, was not significantly increased in the CDD group in the de novo 
lipogenesis experiment (Table 4.3). The difference in DNL between CDD and 
MCDD mice was also not statistically significant. We opted to use a doubly labeled 
acetate tracer to improve accuracy of GCMS for MIDA as suggested by Chinkes et 
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al (Chinkes et al. 1996), although due to theoretical concerns over intrahepatic acetyl 
CoA gradients, the use of an acetate tracer may have slightly underestimated DNL 
(Bederman et al. 2004).  
 
It does not appear that alterations in fatty acid supply to the liver from peripheral 
tissues is important in the MCDD or CDD model. We studied mice after two weeks 
of dietary manipulation when the fatty liver phenotypes are established. Weight loss 
in the MCDD mice was rapid initially and slowing by two weeks (Figure 4.1). It is 
therefore possible that we have under-estimated any acute increase in peripheral fatty 
acid release. However, increased peripheral fat turnover does not appear necessary to 
maintain steatohepatitis. There is also debate as to whether the Ra of palmitate 
should be expressed relative to fat mass, fat free mass or total body weight (Koutsari 
and Jensen 2006). We expressed the Ra of palmitate per unit of body mass to best 
represent the total flux of fatty acids to the liver, although clearly the Ra of palmitate 
would be higher in the MCDD group if expressed relative to fat mass.  
 
We have not made in vivo measurements of hepatic fatty acid oxidation. These are 
difficult, particularly in mice. Even if we had collected expired carbon dioxide or 
conducted indirect calorimetry (Baar et al. 2005), this would not have been specific 
to hepatic mitochondrial oxidation. Whole body β-oxidation rates have been shown 
to be elevated in MCDD mice, with an associated increase in CPT1a activity and 
palmitate oxidation measured ex vivo (Rizki et al. 2006), although this was not 
sufficient to increase plasma β−hydroxybutyrate levels (Rinella et al. 2008) or to 
compensate for the increased hepatic fatty acid load secondary to impaired VLDL 
export and increased DNL. There is accruing evidence that fatty acid oxidation may 
be less efficient in the MCDD model (Romestaing et al. 2008), leading to increased 
microsomal and peroxisomal oxidation, generating reactive oxygen species and lipid 
peroxides thought to be important in the pathogenesis of inflammation and liver cell 
necrosis (Leclercq et al. 2000). Clearly the impact in the liver of increased FFA 
generation and impaired export, as we have described here, would be exacerbated by 
any relative failure of fatty acid oxidation (Ghoshal and Farber 1993). Another 
technical limitation is that repeated sampling is not possible in mice to confirm that 
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steady state of tracer enrichments has been achieved. This may be most relevant to 
the incorporation of labelled palmitate within triglyceride pools, although even if 
steady state has not been achieved then the index we used in equation 2 is likely to 
reliably reflect the rate of change. Finally, it would be ideal to conduct pair-feeding 
experiments to match weight loss in CDD and MCDD mice, although such is the 
severity of weight loss in MCDD mice this would be technically very challenging. 
 
In summary, using a number of methodologies, including in vivo tracer techniques, 
we have demonstrated important differences in fatty acid metabolism which 
associate with contrasting susceptibility to steatohepatitis in CDD and MCDD mice. 
We speculate that the combination of abnormalities in fatty acid metabolism in 
MCDD mice leads to accumulation of free fatty acids within the liver that is 
disproportionate to the accumulation of triglycerides and predisposes MCDD mice to 
complications. It will be important to establish if similar changes in fatty acid 
metabolism are predictive of steatohepatitis and liver damage in other circumstances, 





5 Chapter 5-Hepatic glucocorticoid metabolism in choline ± 
methionine deficient models of non-alcoholic fatty liver disease and 




In Chapter 3 I examined the susceptibility of two contrasting models of fatty liver to 
carbon tetrachloride (CCl4) induced hepatic fibrosis. I found that steatohepatitis 
induced by a methionine and choline deficient diet (MCDD) did not increase 
susceptibility to fibrosis compared to isolated steatosis induced by a methionine 
supplemented choline deficient diet (CDD). In this chapter I investigate whether 
changes in key enzymes regulating hepatic glucocorticoid levels, predicted to reduce 
hepatic glucocorticoid levels, contribute to the development of steatosis, NASH, or 
progression to liver fibrosis.   
 
There is accruing evidence that tissue-specific dysregulation of glucocorticoid 
metabolism contributes to the pathogenesis of the metabolic syndrome incorporating 
central obesity, type 2 diabetes, dyslipidaemia, and hypertension (Seckl and Walker 
2001;Tomlinson et al. 2004). Non-alcoholic fatty liver disease (NAFLD) is 
considered to be the hepatic manifestation of the metabolic syndrome (Marchesini et 
al. 2001), which may be of particular relevance as the liver plays a central role in 
glucocorticoid hormone metabolism (Stimson et al. 2009). Glucocorticoids have both 
wide-ranging metabolic (Andrews and Walker 1999) and immunomodulatory 
(Chapman et al. 2009) properties, and a reduction in local glucocorticoid levels, 
either via increased inactivation or impaired regeneration, could have significant 
consequences for both the development and progression of NAFLD from simple 
steatosis to steatohepatitis, fibrosis and/or cirrhosis e.g. through effects on 
intrahepatic fatty acid metabolism or pro-inflammatory/pro-fibrotic cytokine 
production (Gentile and Pagliassotti 2008;Syn et al. 2009;Yamaguchi et al. 2007). 
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Corticosterone, the principle glucocorticoid in rodents, can be generated from its 
inactive metabolite 11-dehydrocorticosterone by 11β-HSD1 in the liver, amplifying 
glucocorticoid levels and receptor activation within tissues (Seckl and Walker 
2001;Tomlinson et al. 2004). Conversely, glucocorticoids are inactivated by the 
hepatic A-ring reductases (5α-reductase type 1 and 5β-reductase) and 3α-
hydroxysteroid dehydrogenase (3α-HSD) (Tomlinson et al. 2004) (see Figure 1.4 in 
Chapter 1).   
 
Dysregulation of one or more of these enzymes, thereby altering local glucocorticoid 
levels, can influence the development of NAFLD (and insulin resistance) e.g. 
transgenic mice overexpressing 11β-HSD1, in either adipose tissue (Masuzaki et al. 
2001) or the liver (Paterson et al. 2004), have increased hepatic triglycerides. 
Conversely, in the majority of rodent models with fatty liver, hepatic glucocorticoid 
signalling is abnormal with suppressed 11β-HSD1 and increased A-ring reductase 
activity, predicted to lower intrahepatic glucocorticoid levels (Livingstone et al. 
2005;Livingstone et al. 2009a). It is unclear whether abnormalities of glucocorticoid 
metabolism also influence hepatic inflammation as few rodent models of NAFLD 
spontaneously develop steatohepatitis and human studies are problematic. The 
influence of dysregulation of glucocorticoid metabolism on the progression to 
hepatic fibrosis is also unknown.  
 
I have compared hepatic glucocorticoid metabolism in CDD and MCDD dietary 
models of steatosis and steatohepatitis respectively, including following induction of 
fibrosis with CCl4, to investigate the contribution of abnormalities of glucocorticoid 
signalling to progressive liver disease in NAFLD.  
 
5.2 RESEARCH DESIGN AND METHODS 
 
Animals and procedures  
 
All experiments were carried out under a UK Home Office animal license using 12 
week old male C57BL/6J mice (Harlan, Bicester, UK) maintained under controlled 
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conditions of light and temperature. Following a 2 week period of acclimatisation, 
mice (n=7/group) were offered either control (choline and methionine supplemented) 
chow (CS), choline deficient diet (CDD) or methionine-choline deficient diet 
(MCDD) (Dyets Inc., Bethlehem, PA) for 4 weeks and fibrosis induced with twice 
weekly intraperitoneal injections of 0.3µl/g CCl4 (1:3 v/v in olive oil). Controls were 
injected with olive oil alone. Mice were culled 3 days following the last CCl4 
injection and sections of liver snap frozen and stored at -80ºC prior to analysis.  
 
5.2.1 Messenger RNA (mRNA) extraction and quantification  
 
mRNA transcripts were quantified using real time PCR as described in Section 2.6, 
with primers and probes designed from the Roche UPL library (see Table 5.1). The 
abundance of transcript levels were normalised to mean values of internal control 
house keeping genes (GAPDH; Assay ID Mm99999915_gl, and cyclophilin A; 
Assay ID Mm02342429_g1, Applied Biosystems, Warrington, UK; TBP, Roche, 
Burgess Hill, UK). 
 





Sequence Direction UPL 
probe 
no. 
Hsd11b1  NM_008288.2 tctacaaatgaagagttcagaccag Forward 1 
(11β-HSD1)  gccccagtgacaatcacttt Reverse  
Srd5a1  NM_175283.3 gggaaactggatacaaaataccc Forward 41 
(5α-reductase1)  gcacgagctccccaaaata Reverse  
Akr1d1 NM_145364.2 gaaaagatagcagaagggaaggt Forward 103 
(5β-reductase)  gggacatgctctgtattccataa Reverse  
Akr1c6 NM_030611.3 tggggtgtccacctttaacc Forward 78 
(3α-HSD)  tccctgattgagataaggatgac Reverse  
Tbp NM_013684.3 ggcggtttggctaggttt Forward 107 
  gggttatcttcacacaccatga Reverse  
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5.2.2 In vitro enzyme activity assays   
 
In vivo, 11β-HSD1 acts as a keto-reductase to convert inactive 11-
dehydrocorticosterone to corticosterone. In contrast, in vitro, dehydrogenation 
predominates and the assay is therefore measured in this direction, ensuring an 
adequate supply of nicotinamide adenine dinucleotide phosphate (NADP+) cofactor. 
5β-Reductase converts both corticosterone and 11-dehydrocorticosterone to 5β 
metabolites, and its in vitro activity is assessed by a two step conversion of 
corticosterone to 5β-tetrahydrocorticosterone, also involving 3α-HSD, in which 5β-
reductase is the rate limiting step (Livingstone et al. 2000a). It is not possible to 
undertake an enzyme activity assay of 5α-reductase as is unstable in vitro (Eicheler 
et al. 1995), and the activity of 3αHSD was not determined as it is not rate limiting 
(Barat et al. 2007). 
 
100mg of liver was homogenised in 1ml of KREBS buffer in 2ml eppendorfs and 
centrifuged at 1000 x g for 10mins at 4ºC. The supernatant was then resuspended in 
KREBS buffer and the protein content determined as follows using a colourimetric 
assay. Protein standards were prepared from a 10mg/ml bovine serum albumin 
solution (Promega, Madison, WI, USA) diluted in KREBS buffer to give a series of 
concentrations ranging from 0-1.2mg/ml. Protein concentration was then determined 
using a Bio-Rad protein assay solution (Bio-Rad Laboratories GmbH, Munich, 
Germany) diluted 1 in 5 in distilled water. 10µl of the tissue homogenate or protein 
standard was added to 190µl of the diluted assay solution and samples run in 
duplicate in 96 well plates (BD Falcon, Becton Dickinson, Franklin Lakes, NJ, USA). 
After incubating for 30mins at room temperature, absorbance was measured at 
590nm on an Optimax microplate reader (Molecular Devices Ltd, Berkshire, UK) 
and the mean of each duplicate calculated, accepting a variability of <10%. The 
standard curve (prepared from the protein standard dilutions) was deemed acceptable 
if the R2 value was >0.99. Samples were frozen at -20ºC prior to the activity assay. 
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5.2.2.1 11β-HSD1 activity assay 
After thawing at room temperature, samples were diluted in KREBS buffer to 
normalise protein concentrations. Tissue homogenates (40µg/ml) were incubated in 
duplicate at 37ºC in KREBS buffer containing 0.2% w/v glucose, NADP (2mmol/l), 
1,2,6,7-[3H]4-corticosterone (10nmol/l), and unlabelled corticosterone (1.99µmol/l) 
in a final reaction volume of 500µl. Negative controls were also run without either 
corticosterone, or NADP, or protein. Protein concentrations and incubation periods 
were chosen to achieve first order kinetics. 
 
A 200µl aliquot of the reaction mixture was removed after 60mins incubation and the 
reaction halted and steroids extracted by the addition of 2ml ethyl acetate. After 
mixing, the organic phase was transferred into borosilicate glass reaction tubes and 
evaporated under oxygen free nitrogen at 60ºC. Samples were redissolved in 1ml of 
mobile phase (water, acetonitrile, and methanol; 65:15:25), transferred to clear shell 
HPLC vials (Supelco, Poole, Dorset, UK), and stored at -20ºC prior to high 
performance liquid chromatography (HPLC). 
 
Steroids were separated by HPLC comprising a Waters auto-injector, mobile-phase 
pump, C18 reverse phase Sunfire 5µm (150mm length, 4.6mm i.d.) column 
(Hertfordshire, UK), column heater, and radioactivity monitor linked to a 
scintillation fluid pump (Berthold, Leeds, UK). The mobile phase flow rate was 
1.5ml/min, and the scintillant (Gold multipurpose flow scintillation cocktail, 
Meridian, Surrey, UK) flow rate was 2ml/min. The β-emissions from the tritiated 
steroids cause the scintillation, producing photoemissions measured by the 
photodiode.  
 
The column heater was set to 40ºC and radioactive standards were injected at the 
start of every run to confirm the identity and retention time of the peaks. The 
retention times for 11-dehydrocorticosterone and corticosterone were approximately 
14mins and 19mins respectively. Chromeleon software version 6.5 (Dionex, Surrey, 
UK) controlled the system and was used to integrate the areas under the peaks. 11β-
HSD1 velocity was calculated from the conversion of 1,2,6,7-[3H]4-corticosterone to 
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1,2,6,7-[3H]4-11-dehydrocorticosterone using the formula: area under the peak 
(AUP) [3H]4-dehydrocorticosterone / (AUP [
3H]4-corticosterone + AUP [
3H]4-
dehydrocorticosterone). Results were reported as pmol/hour/mg protein (correcting 
for the total concentration of corticosterone in the reaction mixture).  
 
5.2.2.2 5β-Reductase activity assay 
This assay was carried out on the cytosolic fraction obtained after ultracentrifugation 
of the tissue homogenates prepared as described above. After centrifuging the 
homogenate at 1000 x g for 10mins at 4ºC, the supernatant was centrifuged at 14,000 
x g for 20mins. The cytosolic fraction was obtained by centrifugation of the resultant 
supernatant at 100,000 x g for 60mins (leaving a microsomal pellet), and the protein 
concentration was determined as before.  
 
Cytosolic samples were diluted in assay buffer (40mmol/l Na2HPO4, 320mmol/l 
sucrose, and 1mmol/l dithiothreitol, pH 7.5) to normalise protein concentrations to 
100µg in 180µl. A 250µl reaction mixture was prepared with the addition of 50µl co-
factor mix (containing 10mmol/l NADPH, 25mmol/l glucose-6-phosphate, and 
5units/ml glucose-6-phosphate dehydrogenase), plus 20µl substrate mix (containing 
1250nmol/l 1,2,6,7-[3H]4-corticosterone and 123.75µmol/l corticosterone). This gave 
final concentrations of 2mmol/l NADPH, 5mmol/l glucose-6-phopshate, 1unit/ml 
glucose-6-phosphate dehydrogenase, 100nmol/l 1,2,6,7-[3H]4-corticosterone and 
9.975µmol/l corticosterone. The assay was performed in glass reaction tubes and 
after briefly vortexing, samples were incubated at 37ºC for 16hours. Control samples 
were also run containing either no cytosol or no cofactor mix. The reaction was 
stopped by the addition of 2.5ml ethyl acetate and tubes vortexed. Samples were 
stored overnight at -20ºC.  
 
The halted reaction mixtures were centrifuged at 1000 x g for 5mins at 4ºC and the 
upper organic phase transferred to fresh glass tubes and dried down under oxygen 
free nitrogen at 60ºC. Samples were redissolved in 200µl of HPLC mobile phase 
(water, acetonitrile, and methanol; 65:15:25) and transferred to clear shell HPLC 
vials (Supelco, Poole, Dorset, UK). 
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Steroids were separated using the same HPLC system, column and mobile phase as 
above, heated to 35ºC, and quantified by on-line scintillation counting. The mobile 
phase was run at 1ml/min for a run time of 45mins. 1,2,6,7-[3H]4-corticosterone and 
1,2,6,7-[3H]4-5β-tetrahydrocorticosterone had retention times of ~25 and 36mins 
respectively. 5β-Reductase activity was assessed by conversion of 1,2,6,7-[3H]4-
corticosterone to 1,2,6,7-[3H]4-5β-tetrahydrocorticosterone. 
 
5.2.3 Statistical analysis 
 
Results are presented as mean ± standard error (SEM). Between group differences 
were compared by one way ANOVA, assuming equal variances, with Tukey’s post 
hoc multiple comparison test when appropriate. An overall effect of CCl4 treatment 
was determined by two way ANOVA and the effect in each dietary group assessed 
by Student`s t-test (or the non-parametric equivalent) using Graphpad Prism software 





5.3.1 Effect of choline ± methionine deficiency on glucocorticoid signalling 
 
There was no difference in abundance of transcripts of 11β-HSD1, 5α-reductase, 5β-
reductase, or 3α-HSD between CDD mice with simple steatosis and controls fed a 
supplemented diet (Figure 5.1). In contrast, MCDD mice had reduced 11β-HSD1 and 
5α-reductase 1 mRNA levels but no change in 3α-HSD or 5β-reductase transcript 
abundance. Results of enzyme activity assays were somewhat different: again, there 
was no abnormality in CDD mice, but MCDD mice exhibited no significant 
difference in 11β-HSD1 or 5β-reductase activities (Figure 5.2). 
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5.3.2 Effect of carbon tetrachloride on glucocorticoid metabolism in control 
mice fed a methionine and choline supplemented (CS) diet 
 
There was no change in 11β-HSD1 mRNA levels or activity in response to CCl4 in 
CS fed mice (Figures 5.1 and 5.2). Similarly, CCl4 did not influence mRNA levels of 
5α-reductase or 3α-HSD, and although there was an increase in abundance of 5β-
reductase transcripts, this was not confirmed by enzyme activity assay. 
 
5.3.3 Effect of carbon tetrachloride on glucocorticoid metabolism in methionine 
± choline deficiency  
 
CCl4 had no effect on mRNA levels of 11β-HSD1, 5α-reductase and 3α-HSD (Figure 
5.1) or 11β-HSD1 enzyme activity in CDD mice (Figure 5.2). Similarly, in MCDD 
mice, CCl4 had no influence on mRNA levels of 3α-HSD and 5α-reductase, with 5α-
reductase mRNA levels remaining suppressed. In contrast, 11β-HSD1 mRNA levels 
were no longer suppressed in CCl4 treated MCDD mice, although this was not 
confimed by enzyme activity assay (Figure 5.2). CCl4 increased 5β-reductase gene 
expression (Figure 5.1, P<0.01 by two way ANOVA), although again enzyme 
activity assays were not confirmatory (Figure 5.2), and indeed, 5β-reductase enzyme 







Figure 5.1 Hepatic gene expression studies 
Data are expressed as a ratio to the abundance of transcripts of control genes, as means ± 
SEM.. Differences between dietary groups were analysed by one way ANOVA with Tukey’s 
post hoc comparison test where appropriate. An overall effect of CCl4 was assessed using a 
two way ANOVA, with the effect in each dietary group assessed by Student’s t-test (or non-
























































































































































































































†P<0.01 for an effect of CCl4 by two way ANOVA.
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Figure 5.2 Hepatic enzyme velocities 
Hepatic A) 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and B) 5β-reductase 
velocity determined by HPLC in choline ± methionine deficiency and following carbon 
tetrachloride (CCl4) induced hepatic fibrosis. Differences between dietary groups were 
analysed by one way ANOVA with Tukey’s post hoc comparison test where appropriate. 
Effects of CCl4 treatment was analysed by Student’s t-test (or non-parametric equivalent if 


















































































These results suggest significant differences in hepatic glucocorticoid metabolism in 
livers with steatohepatitis secondary to a methionine and choline deficient diet 
(MCDD) compared to both steatotic livers (without inflammation), due to an isolated 
choline deficienct diet (CDD), and non-steatotic livers from mice fed a methionine 
and choline supplemented (CS) diet. Furthermore, despite similar hepatic triglyceride 
accumulation (as documented in Section 3.3.4), there were model specific 
differences in response to carbon tetrachloride (CCl4) suggesting that changes in 
hepatic glucocorticoid signalling may play an important role in modulating their 
contrasting susceptibility to fibrosis.  
 
The hepatic gene expression studies, summarised in Table 5.2, predict no change in 
hepatic glucocorticoid levels in the CDD model, whereas the reduced 11β-HSD1 
mRNA levels in the inflamed MCDD livers predict lower intrahepatic 
glucocorticoids in this model, potentially contributing to the pathogenesis of 
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steatohepatitis. However, these results need to be interpreted with some caution 
given the conflicting results of the 11β-HSD1 activity assay. Furthermore, any 
reduction in glucocorticoid levels in MCDD mice may be offset by reduced 
clearance by 5α-reductase.  
 
CCl4 injury increased 5β-reductase transcript levels in all three dietary groups, 
predicted to enhance glucocorticoid clearance. However, activity assays were not 
supportive of these findings. Indeed, 5β-reductase enzyme velocity was specifically 
reduced in MCDD mice treated with CCl4. In addition, sustained downregulation of 
5α-reductase and the relative lack of downregulation of 11β-HSD1 mRNA levels in 
CCl4 treated MCDD mice, would also suggest that a reduction in glucocortoid 
clearance, combined with a relative increase in glucocorticoid regeneration could 
have contributed to the reduction in fibrosis in these mice. However, enzyme activity 
assay findings were again conflicting.  
 
Table 5.2 Summary of effects of choline ± methionine deficiency and carbon 
tetrachloride on mRNA levels of gene regulating hepatic glucocorticoid levels  
 Baseline  Post CCl4   
 CDD MCDD CDD MCDD 
11β-HSD1 ↔ ↓ ↔ ↑ 
5α-Reductase ↔ ↓ ↔ ↔ 
5β-Reductase ↔ ↔ ↑ ↑ 
3α-HSD ↔ ↔ ↔ ↔ 
 
Given the opposing effects of 11β-HSD1 and 5α-reductase in MCDD mice and the 
discrepancies between the gene expression and enzyme activity results it is difficult 
to draw definitive conclusions from these results. Reasons for these differences in 
mRNA levels and measured enzyme velocities are unclear, but may relate to 
differential stability of mRNA transcripts and protein (Eicheler et al. 1995), or post-
tranlational modification of proteins (Oppermann et al. 1995). Nevertheless, the 
current observations provide encouragement that further investigation of 
glucocorticoid metabolism in NAFLD will be productive. 
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The liver is the principle site in the body for metabolism of glucocorticoids, 
principally by the A-ring reductases and 3α-HSD. In addition, 11β-HSD1 is highly 
expressed in the liver, acting in a tissue specific manner to amplify local 
glucocorticoid levels. Most (Drake et al. 2005;Liu et al. 2003;Livingstone et al. 
2009a;Livingstone et al. 2000a), but not all (Liu et al. 2005), studies of rodents with 
fatty liver, although crucially not with steatohepatitis, have found reduced hepatic 
11β-HSD1 activity. Furthermore, glucocorticoid inactivating A-ring reductase 
activity is also often increased, possibly in response to increased glucocorticoid 
regeneration within adipose tissue (Liu et al. 2003;Livingstone et al. 
2009a;Livingstone et al. 2000a). The lack of inflammation in these NAFLD models 
suggest that the changes in glucocorticoid metabolism are not the primary event 
inducing hepatic inflammation, but may represent a protective mechanism against the 
metabolic complications of obesity, whilst increasing susceptibility to factors 
promoting steatohepatitis.  
 
It is unclear what is driving changes in hepatic glucocorticoid metabolism in MCDD 
mice, in whom, unlike other models of NAFLD, weight loss rather than obesity is a 
key feature. 11β-HSD1 is regulated by numerous factors, including glucocorticoids, 
insulin, sex steroids, IGF-1, and cytokines (Seckl and Walker 2001), although some 
of these factors may have opposing effects e.g. TNFα and insulin (Handoko et al. 
2000), and have tissue specific effects e.g. cytokines don`t appear to upregulate 
hepatic 11β-HSD1 (Escher et al. 1997;Tomlinson et al. 2001). Weight loss is another 
potential regulator of 11β-HSD1, although recent evidence suggests this relates to 
dietary macronutrient content (Stimson et al. 2007), which was identical in our 
groups, whilst reduced leptin levels in MCDD mice are unlikely to be relevant 
(Livingstone et al. 2009a). Fatty acids may also be important, increasing adipose 
11β-HSD1 activity in vivo in humans (Wake et al. 2006), although effects in 
hepatocytes are unknown. In contrast, factors regulating the A-ring reductases are 
less well studied (Livingstone et al. 2009a), and the reduced expression of 5α-
reductase in the MCDD mice is unusual amongst models of NAFLD, the actions of 
which would oppose those of 11β-HSD1. In addition, the CDD model appears 
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unique in that there are no apparent changes in hepatic glucocorticoid metabolism, 
although this did not appear to provide any apparent benefit in reducing the 
development of liver fibrosis.  
 
The “two hit” hypothesis suggests that a toxic insult, e.g. oxidative stress secondary 
to fatty acid lipotoxicity, is required in addition to steatosis to promote the 
development of hepatic inflammation (Day and James 1998). There are few easily 
employed models of steatohepatitis in rodents (Anstee and Goldin 2006), hence we 
have used a MCDD in which abnormalities of hepatic fatty acid metabolism, 
impaired mitochondrial beta oxidation and increased reactive oxygen species may 
contribute to the development of steatohepatitis (Ip et al. 2003;Kashireddy and Rao 
2004;Larter et al. 2008a). However, these factors are not mutually exclusive and 
changes in intrahepatic glucocorticoid levels may modulate their potency e.g. 
glucocorticoids can reduce reactive oxygen species generation, increase hepatic 
antioxidant defences (Eken et al. 2006;Gil et al. 1997;Ozturk et al. 2006) and inhibit 
hepatocyte apoptosis, possibly via effects on NFκB signalling (Evans-Storms and 
Cidlowski 2000;Iida et al. 1998). It is also difficult to separate the metabolic from the 
anti-inflammatory effects of glucocorticoids, with glucocorticoid receptor blockade 
(using RU486) increasing CCl4 induced hepatic inflammation, whilst also reducing 
triglyceride accumulation (Swain et al. 1999). 
  
The effects of glucocorticoids on hepatic fibrosis have not previously been studied in 
a model of fatty liver, although they have been shown to limit hepatic fibrosis 
induced by bile duct ligation (Eken et al. 2006;Ozturk et al. 2006), a model known to 
influence hepatic glucocorticoid metabolism via bile acid induced inhibition of 5β-
reductase activity, an enzyme also important in cholesterol and bile acid metabolism 
(McNeilly et al. 2010). Glucocorticoids have a number of potential anti-fibrotic 
actions, including effects on hepatic stellate cells to reduce transforming growth 
factor-β secretion (Bolkenius et al. 2004) and type I collagen expression (Cutroneo 
and Sterling, Jr. 2004). Other possible anti-fibrotic mechanisms include reduced 
angiotensin 1 receptor expression in hepatoma cells (Wintersgill et al. 1995) and 
reduced expression of tissue inhibitor of matrix metalloproteinases (Oishi et al. 2002). 
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It is feasible that the predicted relative increase in hepatic glucocorticoid levels in 
CCl4 treated MCDD mice may have limited the rise in mRNA levels of TIMP2 seen 
in CS and CDD mice (see Section 3.3.6). 
 
Human studies are more problematic than rodent studies of NAFLD due to the 
heterogeneity of subjects, the chronicity of changes leading to steatohepatitis and/or 
fibrosis, and the need for invasive liver biopsy. In a recent study, currently only 
published in abstract form (Ahmed et al. 2010), patients with biopsy proven NAFLD 
had increased 5α-reductase and reduced 11β-HSD1 activity, thus seeming to limit 
hepatic glucocorticoid exposure. Interestingly, hepatic 11β-HSD1 activity was 
significantly increased in the subgroup with steatohepatitis. This is in contrast to the 
gene expression results in our MCDD mice, although this could relate to the stage of 
NAFLD pathogenesis, with the increase in 11β-HSD1 activity protecting against 
progression to fibrosis. However, another recent study of 75 patients found no 
association with 11β-HSD1 activity and steatohepatitis, whilst 5α and 5β-reductase 
activity was increased in patients with NAFLD, both with and without NASH, versus 
controls undergoing investigation for increased aminotransferases (Konopelska et al. 
2009). Other evidence for an important role of abnormalities of glucocorticoid 
metabolism in the pathogenesis of NAFLD comes from a study demonstrating 
increased hepatic glucocorticoid clearance and post dexamethasone suppression of 
cortisol levels correlating with the degree of hepatic inflammation and fibrosis in 
NAFLD, although metabolism of dexamethasone in NAFLD is a potential 
confounder (Targher et al. 2006). 
 
Our study clearly has a number of limitations, including the disparity between the 
gene expression and enzyme activity results which, in other studies have generally 
correlated well e.g. (Livingstone et al. 2009a;Livingstone et al. 2000b). We have not 
examined glucocorticoid metabolism in adipose tissue, which may be an important 
determinant of hepatic glucocorticoid signalling, nor have we measured expression 
of the gene encoding the glucocorticoid receptor. In addition we have not measured 
circulating plasma corticosterone levels, which are likely to be increased following 
the CCl4 insult (Swain et al. 1999).  
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In summary, we have undertaken preliminary studies to investigate glucocorticoid 
metabolism in two contrasting models of NAFLD, with and without steatohepatitis, 
and demonstrated changes in gene expression of a number of key enzymes regulating 
hepatic glucocorticoid levels, including in response to CCl4 injury. In particular, 
suppression of hepatic 11β-HSD1 was an important finding which may contribute to 
the development of steatohepatitis in the MCDD model, whilst upregulation of 11β-
HSD1 in response to a toxic fibrogenic insult may limit progression to hepatic 
fibrosis. Given the abnormalities of hepatic glucocorticoid metabolism in human 
obesity, and the potential therapeutic use of 11β-HSD1 in type 2 diabetes, these 
findings may have important implications for the development of progressive liver 
disease in humans. Indeed, I have proceeded to a clinical study investigating the role 
of glucocorticoid blockade and its influence on fatty acid metabolism in individuals 






6 Chapter 6 - Conclusions  
 
The increasing prevalence of obesity represents a major public health concern due to 
the associated morbidity and mortality. Not only does obesity lead to a multitude of 
chronic health problems including hypertension, dyslipidaemia, type 2 diabetes, 
obstructive sleep apnoea, and premature cardiovascular disease, but it is also 
associated with increased accumulation of fat within the liver or non-alcoholic fatty 
liver disease (NAFLD). In its simplest form, steatosis, NAFLD may be relatively 
benign and indeed may actually be a protective mechanism against the metabolic 
consequences of obesity. However, for reasons that are unclear, some individuals 
also develop hepatic inflammation known as non-alcoholic steatohepatitis (NASH), 
which can progress to liver fibrosis, and cirrhosis, with associated increases in 
morbidity and mortality. Indeed, the majority of patients previously labelled as 
having cryptogenic cirrhosis are likely to have NAFLD.  
 
We sought to investigate pathways influencing the development of progressive liver 
disease in NAFLD, hypothesising that abnormalities of fatty acid and glucocorticoid 
metabolism, promoting increased intrahepatic fatty acids and reduced intrahepatic 
glucocorticoids respectively, promote the development of steatohepatitis. Human 
studies of NAFLD are difficult to undertake due to the heterogeneity of patients, the 
difficulty in predicting those who will develop NASH and/or fibrosis, and the need to 
perform (ideally serial) liver biopsies, which have an associated morbidity and 
mortality. We therefore opted to study dietary models of NAFLD in rodents in which 
the risk of insulin resistance, steatohepatitis and fibrosis differs, namely the 
methionine and choline deficient diet (MCDD), and the isolated choline deficient 
diet (CDD). The MCDD is a commonly employed model of steatohepatitis, which 
can lead to mild fibrosis, whereas the CDD leads to steatosis alone and does not 
produce spontaneous fibrosis in mice. Previous studies have also shown these models 
to have unique properties with respect to hepatic insulin signalling, with hepatic 
insulin resistance despite marked weight loss in MCDD mice (Leclercq et al. 
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2007;Schattenberg et al. 2005), and protection from high fat diet induced insulin 
resistance in CDD mice (Raubenheimer et al. 2006).  
 
Table 6.1 summarises the findings of our studies which may underlie the contrasting 
susceptibility to steatohepatitis in the MCDD model. In Chapter 3, after firstly 
confirming that a MCDD alone induced significant steatohepatitis, we investigated 
the possible molecular mechanisms underlying the contrasting predisposition to 
NASH and hepatic insulin resistance in these two dietary models of NAFLD and 
investigated whether these differences also influenced susceptibility to hepatic 
fibrosis induced by carbon tetrachloride (CCl4). There were clear differences 
between CDD and MCDD fed mice, with marked upregulation of proinflammatory 
(e.g. TNFα, IL-1β) and profibrotic cytokine gene (e.g. TGFβ) expression only in the 
steatohepatitic MCDD livers. Consistent with a profibrotic phenotype there was also 
increased activation of activated hepatic stellate cells in the MCDD mice alone, with 
no significant change seen in CDD mice. However, CCl4 did not augment 
proinflammatory or profibrotic gene expression in either model of NAFLD, and 
despite the widespread changes in the MCDD livers, surprisingly there was no 
increased susceptibility to CCl4 induced hepatic fibrosis. Indeed, picosirius red 
staining appeared less pronounced in MCDD versus CDD livers, although it would 
have been optimal to have confirmed this with additional measures of hepatic 
fibrosis such as measures of hepatic hydroxproline concentration or histological 
scoring. .  
 
Dynamic changes in matrix metalloproteinase (MMP) and their tissue inhibitors 
(TIMPs) play a central role in determining the fibrotic content of extracellular matrix 
and there were significant differences in MMP and TIMP expression between CDD 
and MCDD mice. The marked upregulation of MMPs in the MCDD versus CDD 
mice may have influenced fibrogenesis in the MCDD model, with an increased 




Table 6.1 Summary of findings in choline ± methionine deficieny in C57Bl6 mice  
 CDD MCDD 
Liver TGs ↑ ↑ 
Liver inflammation ↔ ↑ 
Body weight ↔ ↓ 
Susceptibility to liver fibrosis ↔ ↔ 
Fatty acid metabolism   
     FFA turnover ↔ ↔ 
     De novo lipogenesis ↔ ↑ 
     Hepatic TG export ↔ ↓ 
     FFA oxidation ? ? 
Hepatic glucocorticoid metabolism 
(effects of CCl4 in parenthesis)* 
  
     11β-HSD1 ↔ (↔) ↓ (relative ↑) 
     5α-Reductase ↔ (↔) ↓ (↓) 
     5β-Reductase ↔ (↑) ↔ (↑) 
     3α-HSD ↔ (↔) ↔ (↔) 
*based on gene expression data 
 
Simplistically, NAFLD can be considered an imbalance between the supply of free 
fatty acids (FFA), from either plasma (via lipolysis or dietary sources) or hepatic de 
novo lipogenesis, and the disposal of FFAs through hepatic VLDL export or fatty 
acid oxidation. However, despite being an important fuel, fatty acids are inherently 
toxic to hepatocytes, and if the capacity for FFA disposal is overwhelmed then this 
may promote the development of NASH and/or fibrosis. Hence, we hypothesised that 
the contrasting liver disease phenotypes in MCDD and CDD mice associate with 
differences in intrahepatic fatty acid metabolism. 
 
To investigate this hypothesis, in Chapter 4 we undertook detailed metabolic studies, 
including the use of in vivo metabolic tracer techniques, in CDD and MCDD fed 
mice, as well as controls fed a supplemented diet. We demonstrated key differences 
in fatty acid metabolism which associated with the differing susceptibility to 
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steatohepatitis in MCDD and CDD fed mice. In particular, hepatic TG export was 
reduced in MCDD but not CDD mice, supporting recent ex vivo studies that VLDL 
export is unchanged in isolated choline deficiency, and contradicting a commonly 
reported belief that VLDL export is similarly reduced in both CDD and MCDD mice. 
In addition, our studies using mass isotopmer distribution analysis demonstrated an 
increase in de novo lipogenesis in MCDD mice alone. Neither model had an 
increased uptake of circulating FFAs. These results support the hypothesis that 
increased intrahepatic fatty acids promote steatohepatitis, in the MCDD model due to 
the combination of increased hepatic de novo lipogenesis and impaired VLDL export.  
 
The final hypothesis was to investigate whether altered glucocorticoid metabolism, 
promoting a reduction in intrahepatic glucocorticoid levels, associates with 
susceptibility to hepatic insulin resistance, inflammation and fibrosis in NAFLD. 
This may represent an important mechanism as glucocorticoids are likely to be 
important regulators of both the metabolic and inflammatory response in NAFLD. 
There is accruing evidence that tissue specific dysregulation of glucocorticoid 
metabolism contributes to the metabolic complications of obesity, including insulin 
resistance. In vivo the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-
HSD1) acts to amplify local glucocorticoid levels, predominantly in the liver and 
adipose tissue. However, its activity is dysregulated in human obesity, with down 
regulation of hepatic 11β-HSD1 activity, associated with increased clearance of 
glucocorticoids by inactivating A-ring reductases. These changes would be predicted 
to reduce intrahepatic glucocorticoid concentrations, which given the metabolic and 
immunomodulatory effects of glucocorticoids may be critical in the pathogenesis of 
NAFLD. 
 
We found changes suggestive of significant differences in glucocorticoid metabolism 
in the contrasting dietary models of NAFLD, although these need to be interpreted 
with caution as gene expression and enzyme activity assay results were not 
concordant. In association with steatohepatitis, 11β-HSD1 gene expression was 
reduced in the MCDD fed mice, whereas its expression was unchanged in CDD mice. 
Other rodent models incorporating obesity, insulin resistance and fatty liver (albeit 
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without steatohepatitis) have also generally found reduced hepatic 11β-HSD1 
expression, but glucocorticoid clearance by inactivating A-ring reductases is usually 
increased. This was not the case in MCDD mice in which 5α-reductase expression 
was also reduced, perhaps compensating for the reduction in intrahepatic 
glucocorticoid levels in the MCDD model. These contrasting findings make it 
difficult to accurately predict the true influence of the MCDD on hepatic 
glucocorticoid levels. 
 
That hepatic inflammation is not a feature of other rodent models of fatty liver in 
which 11β-HSD1 expression is reduced is important as it suggests that the predicted 
reduction in intrahepatic glucocorticoid levels may predispose to steatohepatitis, 
requiring the appropriate metabolic milieu or second hit to occur for inflammation to 
develop. Our results suggest the accumulation of intrahepatic fatty acids in the 
MCDD model, due to increased de novo lipogenesis, combined with impaired TG 
export, appear to be an important factor in contributing to this metabolic milieu 
predisposing to steatohepatitis and may have important implications for human 
obesity in which hepatic 11β-HSD1 activity is also reduced. Furthermore, it may be 
of particular importance if inhibitors of 11β-HSD1 are to be introduced as a 
treatment for trpe 2 diabetes. 
 
The lack of suppression of 11β-HSD1 in the CDD livers also appears to be unique 
amongst models of NAFLD, suggesting that peripheral glucocorticoid regeneration 
may not be increased in this weight neutral model of NAFLD. Preservation of 
intrahepatic glucocorticoid levels could protect CDD fed mice from the development 
of steatohepatitis, although any increase in glucocorticoid levels would be predicted 
to have adverse metabolic consequences and indeed may actually contribute to the 
development of fatty liver. In contrast, CDD mice have previously been found to be 
protected from the metabolic effects of a high fat diet (Raubenheimer et al. 2006), 
although a failure to suppress intrahepatic glucocorticoid levels would be predicted 
to do the opposite (Stimson et al. 2010). 
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In addition to influencing susceptibility to hepatic inflammation, changes in hepatic 
glucocorticoid metabolism in response to CCl4 may have significantly influenced the 
progression to hepatic fibrosis in CDD and MCDD mice. The MCDD model was 
unique in that 11β-HSD1 expression was upregulated in response to CCl4, possibly 
limiting the fibrogenic effect of CCl4 in these mice. However, this antifibrotic 
response may have detrimental metabolic effects on hepatic insulin resistance as 
recent human studies suggest that hepatic down regulation of 11β-HSD1 is lost in 
patients with type 2 diabetes, a population known to be at increased risk of NASH 
(Stimson et al. 2010).  
 
Overall, these findings suggest that the downregulation of hepatic 11β-HSD1 in 
association with fatty liver acts may act as a protective mechanism against the 
development of insulin resistance and glucocorticoid hormone excess. This may then 
increase susceptibility to hepatic inflammation when other metabolic factors come in 
to play, such as an overwhelming load of intrahepatic fatty acids. However, the 
ability to upregulate 11β-HSD1 in response to CCl4 in MCDD mice suggests this 
may be an important anti-fibrotic mechanism, although it is unclear whether this has 
any detrimental metabolic effect. Furthermore, the results need to be interpreted with 
caution given the disparity between the gene expression and the enzyme activity 
assay results. However, it is tempting to hypothesise that the reduced intrahepatic 
glucocorticoid levels are maladaptive, contributing to the reduced hepatic VLDL 
export, with any associated upregulation of fatty acid oxidation (Berthiaume et al. 
2007b) overwhelming already saturated mitochondrial β-oxidation in MCDD fed 
mice. 
 
The results of these experiments in rodents emphasise that further work is required to 
dissect the underlying mechanisms influencing progression of NAFLD to both 
steatohepatitis and fibrosis. These results have provided interesting preliminary data 
to support future studies, but the models were perhaps too disparate to draw 
definitive conclusions on the role of fatty acid and glucocorticoid metabolism on 
influencing progressive liver disease. To further test the hypothesis that 
abnormalities of fatty acid metabolism contribute to the progression of NAFLD 
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studies could be undertaken in humans with NASH and/or fibrosis to quantify 
hepatic de novo lipogenesis. VLDL export could also be quantified using metabolic 
tracer studies in humans, employing labelled acetate, or deuterium, as well as leucine 
tracers to calculate the contribution of de novo lipogenesis (Diraison et al. 2003).  
 
A number of additional studies could be undertaken to further investigate the role of 
glucocorticoid hormone metabolism in the development of NASH and hepatic 
fibrosis. In the first instance, profiling urinary glucocorticoid metabolites or 
undertaking additional enzyme activity assays in the CDD and MCDD models may 
provide further evidence for a role in abnormalities of glucocorticoid metabolism in 
the development of progressive liver disease. Other studies which may help to 
delineate the effects of glucocorticoids on the development of steatohepatitis and 
fibrosis would include employing the same diets and/or CCl4 injury in hepatic over-
expressors of 11β-HSD1 or adrenalectomised mice. Alternatively, 11β-HSD1 or 
tissue-specific glucocorticoid receptor knockout mice, or pharmacological 11β-
HSD1 inhibitors could be employed. However, in all these models it could be 
difficult to dissect which effects are secondary to the immunomodulatory versus the 
metabolic effects of glucocorticoids, the latter of which may require further 
metabolic tracer studies to be undertaken. Lastly, a long term prospective study of 
urinary steroid profiling in patients with NAFLD examining their subsequent risk of 
heptic inflammation and fibrosis would be desirable to investigate the above 
hypothesis. 
 
To conclude, we have shown in rodent models that abnormalities of hepatic fatty 
acid metabolism are associated with the development of non-alcoholic steatohepatitis. 
However, despite these inflammatory changes we did not show an increased 
susceptibility to hepatic fibrosis, suggesting that additional factors are necessary for 
inflammation to be translated into fibrosis. Lastly, our preliminary results suggest 
that hepatic glucocorticoid metabolism may be a key regulator of susceptibility to 
inflammation and the progression to liver fibrosis. These studies justify undertaking 
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